<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0"/>
  <title>Micra‚Ñ¢ PMA Live Dashboard ¬∑ P150033</title>
  <style>
    *,*::before,*::after{box-sizing:border-box;margin:0;padding:0}
    html,body{width:100%;min-height:100vh;background:#050505;font-family:'Georgia',serif;color:#e2e8f0}
    a{color:#A100FF;text-decoration:none}a:hover{text-decoration:underline}
    button{cursor:pointer;font-family:inherit;border:none;background:none}
    table{border-collapse:collapse;width:100%}
    .wrap{width:100%;padding:32px 4%}

    /* Header */
    .hdr{border-bottom:1px solid #2D0066;padding-bottom:24px;margin-bottom:32px;display:flex;justify-content:space-between;flex-wrap:wrap;gap:16px;align-items:flex-start}
    .hdr-meta{font-size:11px;letter-spacing:.2em;color:#A100FF;text-transform:uppercase;margin-bottom:8px;font-family:monospace}
    .hdr h1{font-size:clamp(20px,2.4vw,27px);font-weight:700;color:#f8fafc;line-height:1.2}
    .hdr h2{font-size:clamp(13px,1.4vw,16px);font-weight:400;color:#94a3b8;margin-top:6px}
    .hdr-right{text-align:right}
    .hdr-right .lbl{font-size:11px;color:#64748b;letter-spacing:.1em;text-transform:uppercase}
    .hdr-right .date{font-size:clamp(16px,2vw,22px);font-weight:700;color:#A100FF}
    .hdr-right .sub{font-size:12px;color:#64748b}
    .live-badge{display:inline-flex;align-items:center;gap:6px;background:#001a0a;border:1px solid #00AA55;border-radius:20px;padding:3px 10px;font-size:10px;color:#00E676;font-family:monospace;margin-top:8px}
    .live-dot{width:6px;height:6px;border-radius:50%;background:#00E676;animation:pulse 1.5s infinite}
    @keyframes pulse{0%,100%{opacity:1}50%{opacity:.3}}

    .sec-lbl{font-size:13px;color:#A100FF;letter-spacing:.12em;text-transform:uppercase;font-family:monospace}
    /* Section band ‚Äî A+B combined */
    .sec-band{display:flex;align-items:center;justify-content:space-between;padding:12px 20px 12px 16px;border-radius:8px;margin-bottom:24px;position:relative;overflow:hidden;border-left-width:3px!important;border-left-style:solid!important}
    .sec-band-inner{display:flex;align-items:center;gap:12px}
    .sec-band-icon{font-size:18px;line-height:1;flex-shrink:0;filter:drop-shadow(0 0 6px currentColor)}
    .sec-band-num{font-family:monospace;font-size:36px;font-weight:900;letter-spacing:-.02em;opacity:.07;position:absolute;right:20px;top:50%;transform:translateY(-50%);line-height:1;pointer-events:none}
    .sec-band-title{font-family:monospace;font-size:12px;font-weight:700;letter-spacing:.14em;text-transform:uppercase}
    .sec-band-sub{font-family:monospace;font-size:8px;letter-spacing:.12em;text-transform:uppercase;opacity:.6;margin-top:2px}
    /* Per-section depth backgrounds */
    .sec-wrap-1{background:#07070f;border-radius:10px;padding:28px 24px;margin-bottom:28px;border:1px solid #12121e}
    .sec-wrap-2{background:#080808;border-radius:10px;padding:28px 24px;margin-bottom:28px;border:1px solid #141414}
    .sec-wrap-3{background:#060610;border-radius:10px;padding:28px 24px;margin-bottom:28px;border:1px solid #111120}
    .sec-wrap-4{background:#070707;border-radius:10px;padding:28px 24px;margin-bottom:28px;border:1px solid #131313}
    .sec-wrap-5{background:#050505;border-radius:10px;padding:28px 24px;margin-bottom:28px;border:1px solid #111}

    /* KPI Cards */
    .kpi-grid{display:grid;grid-template-columns:repeat(5,1fr);gap:12px;margin:16px 0 32px}
    .kpi-card{background:#0f0f0f;border-radius:10px;padding:18px 14px;text-align:left;transition:all .15s;color:inherit;border:1px solid #1a1a1a}
    .kpi-card:hover{filter:brightness(1.12)}
    .kpi-icon{font-size:22px;margin-bottom:10px}
    .kpi-count{font-size:32px;font-weight:700;line-height:1}
    .kpi-pct{font-size:10px;color:#64748b;margin-top:3px}
    .kpi-name{font-size:11px;color:#94a3b8;margin-top:8px;line-height:1.4}

    /* Bar Chart ‚Äî Horizontal HCC-style */
    .chart-box{background:#0f0f0f;border:1px solid #1a1a1a;border-radius:12px;padding:28px 24px;margin-bottom:40px}
    .bar-wrap{display:flex;flex-direction:column;gap:0}
    .bar-col{display:grid;grid-template-columns:200px 1fr;border-bottom:1px solid #161616;transition:background .15s;cursor:pointer}
    .bar-col:last-child{border-bottom:none}
    .bar-col:hover{background:rgba(255,255,255,.015)}
    .bar-col.selected{background:rgba(255,255,255,.025)}
    .bar-val{font-size:13px;font-weight:700;margin-bottom:0}
    .bar-label-col{padding:18px 16px 18px 0;display:flex;flex-direction:column;justify-content:center;border-right:1px solid #1a1a1a;position:relative}
    .bar-label-col::after{content:'';position:absolute;right:-1px;top:25%;height:50%;width:2px;opacity:.4;border-radius:1px}
    .bar-name{font-size:14px;font-weight:700;color:#e8e8e8;letter-spacing:.02em;line-height:1.2;margin-bottom:3px}
    .bar-sub{font-family:monospace;font-size:9px;color:#444;letter-spacing:.1em;text-transform:uppercase}
    .bar-track-col{padding:16px 0 16px 28px;display:flex;flex-direction:column;justify-content:center;gap:6px}
    .bar-track{flex:1;height:30px;background:rgba(255,255,255,.03);border-radius:4px;position:relative;border:1px solid rgba(255,255,255,.04);overflow:visible}
    .bar-h{height:100%;border-radius:4px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1);position:relative;overflow:visible}
    .bar-bubble{position:absolute;right:-14px;top:50%;transform:translateY(-50%);background:#141414;border:1px solid;border-radius:20px;padding:2px 10px;font-family:monospace;font-size:11px;font-weight:700;white-space:nowrap;z-index:5}
    .bar-pct{font-family:monospace;font-size:9px;color:#444;margin-left:0;margin-top:2px;letter-spacing:.08em}

    /* Detail panel (top section click) */
    .detail-panel{border-radius:12px;padding:28px;margin-bottom:32px}
    .d-hdr{display:flex;align-items:center;gap:12px;margin-bottom:16px;flex-wrap:wrap}
    .d-icon{font-size:24px}
    .d-title{font-size:18px;font-weight:700}
    .d-type{font-size:12px;color:#64748b;margin-top:2px}
    .d-count{margin-left:auto;text-align:right;font-size:32px;font-weight:700}
    .d-pct{font-size:12px;color:#64748b}
    .d-desc{font-size:13px;color:#94a3b8;line-height:1.6;margin-bottom:12px}

    /* Three Tiers */
    .tiers-grid{display:grid;grid-template-columns:repeat(3,1fr);gap:16px;margin:16px 0 40px}
    .tier-card{border-radius:12px;padding:22px;border:1px solid}
    .tier-num{font-size:10px;letter-spacing:.15em;text-transform:uppercase;font-family:monospace;margin-bottom:6px}
    .tier-title{font-size:16px;font-weight:700;margin-bottom:4px}
    .tier-date{font-size:12px;margin-bottom:10px;opacity:.8}
    .tier-desc{font-size:12px;line-height:1.7;color:#94a3b8}
    .tier-desc strong{color:#e2e8f0}

    /* Section 3 expandable table */
    .table-box{background:#0f0f0f;border:1px solid #1a1a1a;border-radius:12px;padding:28px;margin-bottom:32px}
    th{padding:9px 12px;text-align:left;color:#475569;font-weight:600;letter-spacing:.05em;text-transform:uppercase;font-size:10px;border-bottom:1px solid #1a1a1a;white-space:nowrap}
    td{padding:10px 12px;color:#cbd5e1;line-height:1.5;font-size:12px}
    .s-th{color:#A100FF;font-size:11px;letter-spacing:.08em;border-bottom:2px solid #2D0066;padding:10px 14px}
    .s-td{padding:12px 14px;font-size:13px}

    /* Clickable summary row */
    .sum-row{cursor:pointer;transition:background .15s;border-bottom:1px solid #1a1a1a}
    .sum-row:hover{filter:brightness(1.2)}
    .expand-arrow{font-size:12px;transition:transform .2s;display:inline-block;margin-right:6px;color:#64748b}
    .expand-arrow.open{transform:rotate(90deg);color:#A100FF}

    /* Expanded dropdown row */
    .expand-row{display:none;border-bottom:1px solid #1a1a1a}
    .expand-row.open{display:table-row}
    .expand-inner{padding:0 0 0 0;background:#050505}

    /* Inner expanded content */
    .exp-box{padding:20px 24px;border-top:1px solid #0d0d0d}
    .exp-header{display:flex;align-items:center;gap:12px;margin-bottom:14px;flex-wrap:wrap}
    .exp-desc{font-size:12px;color:#94a3b8;line-height:1.6;margin-bottom:16px;max-width:800px}
    .exp-count-badge{background:var(--ec);color:#fff;border-radius:6px;padding:4px 14px;font-size:13px;font-weight:700;font-family:monospace}
    .exp-table th{background:#0f0f0f;font-size:10px;color:#475569;padding:7px 10px}
    .exp-table td{padding:8px 10px;font-size:11px;border-bottom:1px solid #0d1a2e}
    .exp-table tr:last-child td{border-bottom:none}

    /* Live supplements sub-table */
    .live-sub{margin-top:16px}
    .live-sub-lbl{font-size:10px;letter-spacing:.15em;text-transform:uppercase;font-family:monospace;color:#334155;margin-bottom:8px}
    .live-status{font-size:11px;color:#475569;font-family:monospace;padding:8px 0}

    /* Prog bar */
    .prog-wrap{display:flex;align-items:center;gap:8px}
    .prog-track{width:60px;height:6px;background:#1a1a1a;border-radius:3px;overflow:hidden}
    .prog-fill{height:100%;border-radius:3px}

    /* Section 4 */
    .filter-bar{display:flex;gap:8px;flex-wrap:wrap;margin-bottom:16px}
    .fbtn{padding:4px 12px;border-radius:20px;font-size:11px;font-family:monospace;cursor:pointer;transition:all .15s}
    .badge{display:inline-block;padding:2px 8px;border-radius:4px;font-size:10px;font-family:monospace;font-weight:600}
    .loading-row{text-align:center;padding:24px;color:#64748b;font-size:12px;font-family:monospace}
    .spinner{display:inline-block;width:16px;height:16px;border:2px solid #1a1a1a;border-top-color:#A100FF;border-radius:50%;animation:spin .8s linear infinite;margin-right:6px;vertical-align:middle}
    @keyframes spin{to{transform:rotate(360deg)}}
    .error-box{background:#1a0a0a;border:1px solid #7f1d1d;border-radius:8px;padding:14px;margin-bottom:16px;color:#fca5a5;font-size:12px}

    .footer{margin-top:20px;font-size:11px;color:#334155;text-align:center;line-height:1.8}

    /* Tab Navigation */
    .tab-nav{display:flex;align-items:center;gap:4px;background:#0d0d0d;border:1px solid #2a2a2a;border-radius:10px;padding:6px;margin-bottom:32px;width:fit-content}
    .tab-btn{
      display:flex;flex-direction:column;align-items:flex-start;gap:2px;
      padding:10px 20px 10px 16px;
      font-family:monospace;border:none;background:none;cursor:pointer;
      border-radius:7px;border-left:3px solid transparent;
      transition:all .2s;text-align:left;min-width:180px
    }
    .tab-btn .tb-handle{font-size:9px;letter-spacing:.2em;text-transform:uppercase;color:#777;transition:color .2s;font-weight:700}
    .tab-btn .tb-label{font-size:12px;letter-spacing:.06em;text-transform:uppercase;color:#ccc;font-weight:700;transition:color .2s;line-height:1.2}
    .tab-btn:hover .tb-handle{color:#aaa}
    .tab-btn:hover .tb-label{color:#fff}
    .tab-btn:hover{background:#181818;border-color:#333}
    .tab-btn.active{background:#130028;border-left:3px solid #A100FF}
    .tab-btn.active .tb-handle{color:#A100FF}
    .tab-btn.active .tb-label{color:#fff}
    .tab-panel{display:none}
    .tab-panel.active{display:block}

    /* Competitor tab */
    .comp-metric-grid{display:grid;grid-template-columns:repeat(3,1fr);gap:16px;margin:16px 0 32px}
    .comp-card{background:#0f0f0f;border:1px solid #1a1a1a;border-radius:12px;padding:20px}
    .comp-card-hdr{display:flex;align-items:center;gap:10px;margin-bottom:14px;padding-bottom:12px;border-bottom:1px solid #1a1a1a}
    .comp-logo{width:36px;height:36px;border-radius:6px;display:flex;align-items:center;justify-content:center;font-size:11px;font-weight:700;font-family:monospace;flex-shrink:0}
    .comp-name{font-size:13px;font-weight:700;color:#f1f5f9}
    .comp-product{font-size:10px;color:#64748b;margin-top:2px}
    .comp-row{display:flex;justify-content:space-between;align-items:flex-start;padding:5px 0;border-bottom:1px solid #111111;gap:12px}
    .comp-row:last-child{border-bottom:none}
    .comp-key{font-size:10px;color:#64748b;font-family:monospace;flex-shrink:0}
    .comp-val{font-size:11px;color:#cbd5e1;text-align:right;line-height:1.4}

    /* SVG donut charts */
    .donut-grid{display:grid;grid-template-columns:repeat(3,1fr);gap:16px;margin:16px 0 32px}
    .donut-card{background:#0f0f0f;border:1px solid #1a1a1a;border-radius:12px;padding:20px;text-align:center}
    .donut-title{font-size:11px;color:#A100FF;font-family:monospace;letter-spacing:.1em;text-transform:uppercase;margin-bottom:16px}
    .donut-wrap{position:relative;display:inline-block;width:140px;height:140px}
    .donut-center{position:absolute;top:50%;left:50%;transform:translate(-50%,-50%);text-align:center}
    .donut-num{font-size:22px;font-weight:700}
    .donut-sub{font-size:9px;color:#64748b;font-family:monospace;text-transform:uppercase}
    .donut-legend{margin-top:14px;text-align:left}
    .legend-item{display:flex;align-items:center;gap:8px;margin-bottom:5px;font-size:10px;color:#94a3b8}
    .legend-dot{width:8px;height:8px;border-radius:50%;flex-shrink:0}

    /* Comparison bar chart */
    .comp-bar-grid{display:grid;grid-template-columns:1fr 1fr 1fr;gap:12px;align-items:end;height:220px;padding:0 8px 44px;border-left:1px solid #1a1a1a;border-bottom:1px solid #1a1a1a;margin:16px 0 32px}
    .comp-bar-col{display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;position:relative}
    .comp-bar-val{font-size:16px;font-weight:700;margin-bottom:6px}
    .comp-bar-rect{width:70%;max-width:80px;border-radius:6px 6px 0 0}
    .comp-bar-lbl{position:absolute;bottom:-40px;font-size:10px;color:#64748b;text-align:center;width:130%;line-height:1.4}

    /* Abbott category table */
    .abb-cat-grid{display:grid;grid-template-columns:repeat(5,1fr);gap:10px;margin:16px 0 24px}
    .abb-cat-card{background:#0f0f0f;border:1px solid #1a1a1a;border-radius:8px;padding:14px 10px;text-align:center}

    .status-badge{display:inline-block;padding:3px 10px;border-radius:12px;font-size:10px;font-family:monospace;font-weight:600}

    /* ‚îÄ‚îÄ Horizontal Comparison Chart ‚îÄ‚îÄ */
    .hcc-wrap{background:#0f0f0f;border:1px solid #1a1a1a;border-radius:12px;padding:28px 24px;margin-bottom:32px}
    .hcc-legend{display:flex;gap:28px;margin-bottom:6px;flex-wrap:wrap}
    .hcc-legend-item{display:flex;align-items:center;gap:9px;font-size:11px;font-family:monospace;letter-spacing:.1em;color:#666}
    .hcc-legend-swatch{width:12px;height:12px;border-radius:2px;flex-shrink:0}
    .hcc-legend-name{font-weight:700;font-size:12px}
    .hcc-divider{height:1px;background:linear-gradient(90deg,#A100FF,#00BEFF);opacity:.3;margin:14px 0 24px}
    .hcc-metric-block{display:grid;grid-template-columns:200px 1fr;border-bottom:1px solid #161616;transition:background .2s}
    .hcc-metric-block:last-child{border-bottom:none}
    .hcc-metric-block:hover{background:rgba(255,255,255,.012)}
    .hcc-label-col{padding:22px 18px 22px 0;display:flex;flex-direction:column;justify-content:center;border-right:1px solid #1a1a1a;position:relative}
    .hcc-label-col::after{content:'';position:absolute;right:-1px;top:25%;height:50%;width:2px;background:#A100FF;opacity:.35;border-radius:1px}
    .hcc-metric-num{font-family:monospace;font-size:9px;color:#444;letter-spacing:.15em;margin-bottom:4px}
    .hcc-metric-name{font-size:14px;font-weight:700;color:#e8e8e8;letter-spacing:.02em;line-height:1.2;margin-bottom:4px}
    .hcc-metric-unit{font-family:monospace;font-size:9px;color:#444;letter-spacing:.1em;text-transform:uppercase}
    .hcc-bars-col{padding:18px 0 18px 28px;display:flex;flex-direction:column;justify-content:center;gap:12px}
    .hcc-bar-row{display:flex;align-items:center;gap:0}
    .hcc-co-tag{font-family:monospace;font-size:9px;letter-spacing:.12em;text-transform:uppercase;width:56px;flex-shrink:0;opacity:.7}
    .hcc-track{flex:1;height:26px;background:rgba(255,255,255,.03);border-radius:4px;position:relative;border:1px solid rgba(255,255,255,.04);overflow:visible}
    .hcc-fill{height:100%;border-radius:4px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1);position:relative;overflow:visible}
    .hcc-fill.hcc-mdt{background:linear-gradient(90deg,rgba(161,0,255,.12),#A100FF);box-shadow:0 0 10px rgba(161,0,255,.22)}
    .hcc-fill.hcc-abb{background:linear-gradient(90deg,rgba(0,190,255,.10),#00BEFF);box-shadow:0 0 10px rgba(0,190,255,.20)}
    .hcc-bubble{position:absolute;right:-14px;top:50%;transform:translateY(-50%);background:#141414;border:1px solid;border-radius:20px;padding:2px 9px;font-family:monospace;font-size:10px;font-weight:700;white-space:nowrap;z-index:5}
    .hcc-bubble.mdt{color:#A100FF;border-color:#A100FF;box-shadow:0 0 6px rgba(161,0,255,.25)}
    .hcc-bubble.abb{color:#00BEFF;border-color:#00BEFF;box-shadow:0 0 6px rgba(0,190,255,.22)}
    .hcc-delta{font-family:monospace;font-size:9px;color:#444;margin-left:56px;margin-top:3px;display:flex;align-items:center;gap:6px}
    .hcc-ratio{color:#fff;background:rgba(161,0,255,.13);border:1px solid rgba(161,0,255,.28);border-radius:3px;padding:1px 6px;font-size:9px}
    .hcc-insights{display:grid;grid-template-columns:repeat(5,1fr);gap:10px;margin-top:28px;padding-top:22px;border-top:1px solid #161616}
    .hcc-ins-card{background:#0a0a0a;border:1px solid #1a1a1a;border-radius:8px;padding:14px 12px;position:relative;overflow:hidden}
    .hcc-ins-card::before{content:'';position:absolute;top:0;left:0;right:0;height:2px}
    .hcc-ins-card.ic-mdt::before{background:#A100FF}
    .hcc-ins-card.ic-abb::before{background:#00BEFF}
    .hcc-ins-card.ic-neu::before{background:linear-gradient(90deg,#A100FF,#00BEFF)}
    .hcc-ins-lbl{font-family:monospace;font-size:8px;letter-spacing:.18em;color:#444;text-transform:uppercase;margin-bottom:6px}
    .hcc-ins-txt{font-size:10px;color:#777;line-height:1.55}
    .hcc-ins-txt strong{color:#ccc;font-size:11px}
    @media(max-width:700px){.hcc-metric-block{grid-template-columns:1fr}.hcc-label-col{border-right:none;border-bottom:1px solid #1a1a1a;padding:14px 0 10px}.hcc-bars-col{padding:14px 0}.hcc-insights{grid-template-columns:1fr 1fr}}

    @media(max-width:900px){.comp-metric-grid{grid-template-columns:1fr}.donut-grid{grid-template-columns:1fr}.comp-bar-grid{grid-template-columns:1fr 1fr 1fr}}
    @media(max-width:600px){.kpi-grid{grid-template-columns:repeat(2,1fr)}}
  </style>
</head>
<body>
<div class="wrap">

  <!-- TOP BRANDING BAR -->
  <div style="display:flex;align-items:flex-start;justify-content:space-between;margin-bottom:28px;padding-bottom:24px;border-bottom:1px solid #2D0066">
    <div>
      <div style="font-size:clamp(18px,2.5vw,26px);font-weight:700;color:#A100FF;letter-spacing:.04em;margin-bottom:8px">
        Advanced Regulatory Intelligence in Real Time
      </div>
      <div style="font-size:11px;letter-spacing:.2em;color:#A100FF;text-transform:uppercase;font-family:monospace;margin-bottom:8px">
        FDA PMA DATABASE ¬∑ P150033 ¬∑ MEDTRONIC, INC.
      </div>
      <div style="font-size:13px;color:#64748b;letter-spacing:.12em;font-family:monospace;margin-top:4px">
        P4 / <a href="https://phase-four.co" target="_blank" style="color:#64748b">PHASE-FOUR.CO</a> &nbsp;¬∑&nbsp; REGULATORY INTELLIGENCE
      </div>
    </div>
  </div>


  <!-- ‚ïê‚ïê DASHBOARD OVERVIEW ‚Äî above tabs ‚ïê‚ïê -->
  <div id="overviewWrap" style="margin-bottom:20px">

    <!-- Full-width toggle bar ‚Äî original design -->
    <div onclick="toggleOverview()" id="overviewToggle"
      style="display:flex;align-items:center;justify-content:space-between;background:linear-gradient(90deg,#1a0040,#0d001a);border:1px solid #6600CC;border-radius:10px;padding:18px 24px;cursor:pointer;transition:all .2s;user-select:none;box-shadow:0 0 28px rgba(161,0,255,.18),inset 0 1px 0 rgba(161,0,255,.15)">
      <div style="display:flex;align-items:center;gap:16px">
        <div style="width:36px;height:36px;border-radius:8px;background:linear-gradient(135deg,#A100FF,#E91E8C);display:flex;align-items:center;justify-content:center;font-size:16px;box-shadow:0 0 14px rgba(161,0,255,.5);flex-shrink:0">‚óà</div>
        <div>
          <div style="font-family:monospace;font-size:13px;font-weight:700;color:#fff;letter-spacing:.2em;text-transform:uppercase;margin-bottom:3px">Dashboard Overview</div>
          <div style="font-family:monospace;font-size:9px;color:#9966CC;letter-spacing:.12em">PLATFORM PURPOSE ¬∑ NAVIGATION GUIDE ¬∑ STRATEGIC USE CASES</div>
        </div>
      </div>
      <div id="overviewChevron" style="display:flex;align-items:center;gap:8px;font-family:monospace;font-size:10px;font-weight:700;color:#CC66FF;letter-spacing:.15em;background:rgba(161,0,255,.15);border:1px solid rgba(161,0,255,.35);border-radius:20px;padding:6px 14px;transition:all .25s">‚ñº EXPAND</div>
    </div>

    <!-- Body ‚Äî hidden by default -->
    <div id="overviewBody" style="display:none;margin-top:20px">

      <!-- ‚îÄ‚îÄ OVERVIEW INTRO ‚îÄ‚îÄ -->
      <div style="padding:28px 28px 0">
        <div style="background:#08001a;border:1px solid #3d0080;border-radius:10px;padding:24px 28px;margin-bottom:28px;position:relative;overflow:hidden">

          <!-- Decorative glow -->
          <div style="position:absolute;top:-40px;right:-40px;width:200px;height:200px;background:radial-gradient(circle,rgba(161,0,255,.09),transparent 65%);pointer-events:none"></div>
          <div style="position:absolute;bottom:-30px;left:-20px;width:140px;height:140px;background:radial-gradient(circle,rgba(233,30,140,.06),transparent 65%);pointer-events:none"></div>

          <!-- Title line -->
          <div style="display:flex;align-items:flex-start;gap:20px;margin-bottom:20px">
            <div style="flex:1">
              <div style="font-family:monospace;font-size:9px;color:#6633aa;letter-spacing:.22em;text-transform:uppercase;margin-bottom:8px">PROPRIETARY REGULATORY INTELLIGENCE PLATFORM</div>
              <div style="font-size:15px;font-weight:700;color:#fff;line-height:1.45;margin-bottom:10px">This dashboard delivers real-time FDA regulatory intelligence on Medtronic's Micra‚Ñ¢ Transcatheter Pacemaker System ‚Äî the world's most implanted leadless cardiac pacemaker under PMA P150033. It is structured across three integrated modules and is designed to inform strategy across three distinct competitive frameworks.</div>
              <div style="display:flex;gap:10px;flex-wrap:wrap;margin-top:6px">
                <span style="font-family:monospace;font-size:9px;background:rgba(161,0,255,.15);color:#A100FF;border:1px solid rgba(161,0,255,.3);border-radius:4px;padding:3px 10px">‚ö° Tab 1 ‚Äî Micra Key Benchmarks</span>
                <span style="font-family:monospace;font-size:9px;background:rgba(0,190,255,.12);color:#00BEFF;border:1px solid rgba(0,190,255,.25);border-radius:4px;padding:3px 10px">üî¨ Tab 2 ‚Äî Competitive Analysis</span>
                <span style="font-family:monospace;font-size:9px;background:rgba(233,30,140,.12);color:#E91E8C;border:1px solid rgba(233,30,140,.25);border-radius:4px;padding:3px 10px">‚óà Tab 3 ‚Äî Predictive Intelligence</span>
              </div>
            </div>
          </div>

          <!-- Divider -->
          <div style="height:1px;background:linear-gradient(90deg,rgba(161,0,255,.3),rgba(233,30,140,.2),transparent);margin-bottom:20px"></div>

          <!-- Three frameworks -->
          <div style="font-family:monospace;font-size:9px;color:#6633aa;letter-spacing:.2em;text-transform:uppercase;margin-bottom:14px">Three Strategic Intelligence Frameworks</div>
          <div style="display:grid;grid-template-columns:repeat(3,1fr);gap:14px">

            <!-- I. Offensive -->
            <div style="background:#0f0026;border:1px solid rgba(161,0,255,.25);border-top:2px solid #A100FF;border-radius:8px;padding:16px 18px">
              <div style="display:flex;align-items:center;gap:8px;margin-bottom:10px">
                <div style="width:28px;height:28px;border-radius:6px;background:rgba(161,0,255,.2);display:flex;align-items:center;justify-content:center;font-size:13px;flex-shrink:0">‚öîÔ∏è</div>
                <div>
                  <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.15em">FRAMEWORK I</div>
                  <div style="font-size:12px;font-weight:700;color:#fff;margin-top:1px">Offensive Strategy</div>
                </div>
              </div>
              <div style="font-size:11px;color:#7755aa;line-height:1.65">Where are the gaps in competitor product claims and regulatory positioning? Use this platform to identify where MDT can build more robust real-time intelligence to outcompete, deepen clinical evidence, and accelerate R&amp;D toward undefended indications.</div>
            </div>

            <!-- II. Defensive -->
            <div style="background:#0f0026;border:1px solid rgba(0,190,255,.2);border-top:2px solid #00BEFF;border-radius:8px;padding:16px 18px">
              <div style="display:flex;align-items:center;gap:8px;margin-bottom:10px">
                <div style="width:28px;height:28px;border-radius:6px;background:rgba(0,190,255,.15);display:flex;align-items:center;justify-content:center;font-size:13px;flex-shrink:0">üõ°Ô∏è</div>
                <div>
                  <div style="font-family:monospace;font-size:8px;color:#00BEFF;letter-spacing:.15em">FRAMEWORK II</div>
                  <div style="font-size:12px;font-weight:700;color:#fff;margin-top:1px">Defensive Strategy</div>
                </div>
              </div>
              <div style="font-size:11px;color:#336677;line-height:1.65">Where are competitors moving their regulatory strategy and what risks does that create? Monitor supplement velocity, new indication filings, and adverse event signals to build defensive frameworks that outmaneuver competitive positioning with real-time regulatory analytics.</div>
            </div>

            <!-- III. Long-Term -->
            <div style="background:#0f0026;border:1px solid rgba(233,30,140,.2);border-top:2px solid #E91E8C;border-radius:8px;padding:16px 18px">
              <div style="display:flex;align-items:center;gap:8px;margin-bottom:10px">
                <div style="width:28px;height:28px;border-radius:6px;background:rgba(233,30,140,.15);display:flex;align-items:center;justify-content:center;font-size:13px;flex-shrink:0">üî≠</div>
                <div>
                  <div style="font-family:monospace;font-size:8px;color:#E91E8C;letter-spacing:.15em">FRAMEWORK III</div>
                  <div style="font-size:12px;font-weight:700;color:#fff;margin-top:1px">Long-Term Strategic Planning</div>
                </div>
              </div>
              <div style="font-size:11px;color:#663355;line-height:1.65">Use data to triage the relationship between adverse events, risk exposure, and long-horizon opportunity ‚Äî including new therapeutic areas, brand label game theory, patent lifecycle timing, and platform succession planning.</div>
            </div>

          </div>
        </div>
      </div>

      <!-- Inner tab nav -->
      <div style="display:flex;border-bottom:2px solid #2D0066;padding:0 20px;gap:4px;background:#0a0018">
        <button class="ov-tab active" onclick="switchOvTab(0,this)" style="padding:13px 22px;font-family:monospace;font-size:10px;font-weight:700;letter-spacing:.14em;text-transform:uppercase;color:#fff;background:rgba(161,0,255,.25);border:none;border-bottom:3px solid #A100FF;border-radius:6px 6px 0 0;cursor:pointer;transition:all .2s;margin-bottom:-2px">‚ö° Micra P150033</button>
        <button class="ov-tab" onclick="switchOvTab(1,this)" style="padding:13px 22px;font-family:monospace;font-size:10px;font-weight:700;letter-spacing:.14em;text-transform:uppercase;color:#475569;background:none;border:none;border-bottom:3px solid transparent;border-radius:6px 6px 0 0;cursor:pointer;transition:all .2s;margin-bottom:-2px">üî¨ Competitor Intelligence</button>
        <button class="ov-tab" onclick="switchOvTab(2,this)" style="padding:13px 22px;font-family:monospace;font-size:10px;font-weight:700;letter-spacing:.14em;text-transform:uppercase;color:#475569;background:none;border:none;border-bottom:3px solid transparent;border-radius:6px 6px 0 0;cursor:pointer;transition:all .2s;margin-bottom:-2px">‚óà Predictive Engine</button>
        <button class="ov-tab" onclick="switchOvTab(3,this)" style="padding:13px 22px;font-family:monospace;font-size:10px;font-weight:700;letter-spacing:.14em;text-transform:uppercase;color:#475569;background:none;border:none;border-bottom:3px solid transparent;border-radius:6px 6px 0 0;cursor:pointer;transition:all .2s;margin-bottom:-2px">üéØ Strategic Use Cases</button>
        <button class="ov-tab" onclick="switchOvTab(4,this)" style="padding:13px 22px;font-family:monospace;font-size:10px;font-weight:700;letter-spacing:.14em;text-transform:uppercase;color:#475569;background:none;border:none;border-bottom:3px solid transparent;border-radius:6px 6px 0 0;cursor:pointer;transition:all .2s;margin-bottom:-2px">üíº Business Case</button>
      </div>

      <!-- Tab 0: Micra Overview -->
      <div class="ov-panel" id="ov-0" style="display:block;padding:28px 24px">
        <div style="display:grid;grid-template-columns:1fr 1fr 1fr;gap:20px">
          <div>
            <div style="font-family:monospace;font-size:9px;color:#A100FF;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">What This Tab Is</div>
            <div style="font-size:13px;font-weight:700;color:#f1f5f9;margin-bottom:8px;line-height:1.3">The complete regulatory record for Medtronic's Micra‚Ñ¢ Transcatheter Pacemaker System under PMA P150033.</div>
            <div style="font-size:12px;color:#64748b;line-height:1.7">All 217 post-approval supplements filed with the FDA from 2016 to present ‚Äî live, fetched directly from the openFDA API at page load. Every change Medtronic has ever filed to maintain or expand this device's approval is recorded here.</div>
          </div>
          <div>
            <div style="font-family:monospace;font-size:9px;color:#A100FF;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">How to Navigate</div>
            <div style="display:flex;flex-direction:column;gap:10px">
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#A100FF;background:rgba(161,0,255,.1);border:1px solid rgba(161,0,255,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">S1</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5">Click any <strong style="color:#e2e8f0">category card or bar</strong> to isolate that supplement type and see a detail panel</div>
              </div>
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#A100FF;background:rgba(161,0,255,.1);border:1px solid rgba(161,0,255,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">S3</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5">Click any <strong style="color:#e2e8f0">row in the summary table</strong> to expand the full supplement list for that category, cross-referenced to live FDA records</div>
              </div>
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#A100FF;background:rgba(161,0,255,.1);border:1px solid rgba(161,0,255,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">S4</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5">Filter the <strong style="color:#e2e8f0">live supplement table</strong> by category or browse all 217 records with direct links to FDA.gov</div>
              </div>
            </div>
          </div>
          <div>
            <div style="font-family:monospace;font-size:9px;color:#A100FF;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">Key Metrics at a Glance</div>
            <div style="display:flex;flex-direction:column;gap:8px">
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #A100FF">
                <span style="font-size:11px;color:#94a3b8">Total Supplements Filed</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#A100FF">217</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #00BEFF">
                <span style="font-size:11px;color:#94a3b8">Years of FDA History</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#00BEFF">9 yrs</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #00E5A0">
                <span style="font-size:11px;color:#94a3b8">Avg Annual Filing Rate</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#00E5A0">~24/yr</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #CC33FF">
                <span style="font-size:11px;color:#94a3b8">Panel Track (Major) Supplements</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#CC33FF">2</span>
              </div>
            </div>
          </div>
        </div>
        <div style="margin-top:20px;padding-top:16px;border-top:1px solid #1a1a1a;font-size:10px;color:#2a2a2a;font-family:monospace;letter-spacing:.08em">
          DATA SOURCE: openFDA Public API ¬∑ api.fda.gov/device/pma.json ¬∑ PMA P150033 ¬∑ Medtronic, Inc. ¬∑ Original Approval: April 6, 2016 ¬∑ Product Code: PNJ ¬∑ Leadless Cardiac Pacemaker
        </div>
      </div>

      <!-- Tab 1: Competitor Analysis -->
      <div class="ov-panel" id="ov-1" style="display:none;padding:28px 24px">
        <div style="display:grid;grid-template-columns:1fr 1fr 1fr;gap:20px">
          <div>
            <div style="font-family:monospace;font-size:9px;color:#00BEFF;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">What This Tab Is</div>
            <div style="font-size:13px;font-weight:700;color:#f1f5f9;margin-bottom:8px;line-height:1.3">A side-by-side regulatory and clinical intelligence comparison of all three players in the leadless pacemaker market.</div>
            <div style="font-size:12px;color:#64748b;line-height:1.7">Medtronic Micra (approved 2016), Abbott Aveir (approved 2022), and Boston Scientific EMPOWER (pending). Covers PMA supplement volume, device specifications, filing velocity, and strategic positioning ‚Äî all mapped to FDA regulatory data.</div>
          </div>
          <div>
            <div style="font-family:monospace;font-size:9px;color:#00BEFF;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">What Each Section Shows</div>
            <div style="display:flex;flex-direction:column;gap:10px">
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#00BEFF;background:rgba(0,190,255,.1);border:1px solid rgba(0,190,255,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">A</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5"><strong style="color:#e2e8f0">5-Metric HCC Chart</strong> ‚Äî MDT vs ABT head-to-head on years, supplements, trials, software, and adverse events</div>
              </div>
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#00BEFF;background:rgba(0,190,255,.1);border:1px solid rgba(0,190,255,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">B</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5"><strong style="color:#e2e8f0">Device Specifications</strong> ‚Äî hardware, fixation, pacing modes, and clinical trial evidence for all 3 devices</div>
              </div>
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#00BEFF;background:rgba(0,190,255,.1);border:1px solid rgba(0,190,255,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">C‚ÄìD</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5"><strong style="color:#e2e8f0">Abbott Aveir P150035</strong> supplement history + strategic implications for all 3 companies</div>
              </div>
            </div>
          </div>
          <div>
            <div style="font-family:monospace;font-size:9px;color:#00BEFF;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">Competitive Snapshot</div>
            <div style="display:flex;flex-direction:column;gap:8px">
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #A100FF">
                <span style="font-size:11px;color:#94a3b8">Medtronic ¬∑ P150033</span>
                <span style="font-family:monospace;font-size:12px;font-weight:700;color:#A100FF">217 supps ¬∑ 9yr</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #00E5A0">
                <span style="font-size:11px;color:#94a3b8">Abbott ¬∑ P150035</span>
                <span style="font-family:monospace;font-size:12px;font-weight:700;color:#00E5A0">~22 supps ¬∑ 3yr</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #FF6B00;opacity:.7">
                <span style="font-size:11px;color:#94a3b8">Boston Scientific ¬∑ EMPOWER</span>
                <span style="font-family:monospace;font-size:12px;font-weight:700;color:#FF6B00">Pending FDA</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #00BEFF">
                <span style="font-size:11px;color:#94a3b8">MDT Filing Rate Advantage</span>
                <span style="font-family:monospace;font-size:12px;font-weight:700;color:#00BEFF">√ó3.4 vs ABT</span>
              </div>
            </div>
          </div>
        </div>
        <div style="margin-top:20px;padding-top:16px;border-top:1px solid #1a1a1a;font-size:10px;color:#2a2a2a;font-family:monospace;letter-spacing:.08em">
          SOURCES: FDA PMA DATABASE ¬∑ P150033 (MDT) ¬∑ P150035 (ABT) ¬∑ IDE G200319 (BSX) ¬∑ COMPANY PRESS RELEASES ¬∑ NEJM / JACC / HRS PUBLICATIONS
        </div>
      </div>

      <!-- Tab 2: Predictive Intelligence -->
      <div class="ov-panel" id="ov-2" style="display:none;padding:28px 24px">
        <div style="display:grid;grid-template-columns:1fr 1fr 1fr;gap:20px">
          <div>
            <div style="font-family:monospace;font-size:9px;color:#E91E8C;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">What This Tab Is</div>
            <div style="font-size:13px;font-weight:700;color:#f1f5f9;margin-bottom:8px;line-height:1.3">A forward-looking regulatory forecast engine built on P150033's 9-year historical supplement pattern.</div>
            <div style="font-size:12px;color:#64748b;line-height:1.7">Probability models, filing volume projections, competitor trajectory forecasts, and predicted failure modes derived from MAUDE adverse event data, Class III CIED recall history, and MDT supplement clustering analysis. Not FDA guidance ‚Äî for strategic planning only.</div>
          </div>
          <div>
            <div style="font-family:monospace;font-size:9px;color:#E91E8C;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">The 5 Sections</div>
            <div style="display:flex;flex-direction:column;gap:9px">
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#E91E8C;background:rgba(233,30,140,.1);border:1px solid rgba(233,30,140,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">I</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5"><strong style="color:#e2e8f0">Filing Forecast</strong> ‚Äî annual supplement volume projection 2025‚Äì2027 with confidence intervals</div>
              </div>
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#E91E8C;background:rgba(233,30,140,.1);border:1px solid rgba(233,30,140,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">II</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5"><strong style="color:#e2e8f0">Category Prediction</strong> ‚Äî probability of next supplement by type within 6 months</div>
              </div>
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#E91E8C;background:rgba(233,30,140,.1);border:1px solid rgba(233,30,140,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">III</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5"><strong style="color:#e2e8f0">Competitor Trajectory</strong> ‚Äî MDT vs ABT cumulative supplement forecast through 2028</div>
              </div>
              <div style="display:flex;gap:10px;align-items:flex-start">
                <div style="font-family:monospace;font-size:10px;color:#E91E8C;background:rgba(233,30,140,.1);border:1px solid rgba(233,30,140,.2);border-radius:4px;padding:2px 8px;white-space:nowrap;margin-top:1px">IV‚ÄìV</div>
                <div style="font-size:11px;color:#94a3b8;line-height:1.5"><strong style="color:#e2e8f0">Confidence Cards + Failure Modes</strong> ‚Äî arc gauge confidence scores and predicted failure events across Software, Design, and Manufacturing</div>
              </div>
            </div>
          </div>
          <div>
            <div style="font-family:monospace;font-size:9px;color:#E91E8C;letter-spacing:.18em;margin-bottom:10px;text-transform:uppercase">Top Signals Right Now</div>
            <div style="display:flex;flex-direction:column;gap:8px">
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #A100FF">
                <span style="font-size:11px;color:#94a3b8">12-Month Filing Confidence</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#A100FF">79%</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #00BEFF">
                <span style="font-size:11px;color:#94a3b8">Top Failure Risk ‚Äî SW Telemetry</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#00BEFF">72%</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #0078D4">
                <span style="font-size:11px;color:#94a3b8">Top Failure Risk ‚Äî Hermetic Seal</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#0078D4">69%</span>
              </div>
              <div style="display:flex;justify-content:space-between;align-items:center;padding:8px 12px;background:#111;border-radius:6px;border-left:3px solid #FF6B00">
                <span style="font-size:11px;color:#94a3b8">BSX Approval Probability</span>
                <span style="font-family:monospace;font-size:16px;font-weight:700;color:#FF6B00">67%</span>
              </div>
            </div>
          </div>
        </div>
        <div style="margin-top:20px;padding-top:16px;border-top:1px solid #1a1a1a;font-size:10px;color:#2a2a2a;font-family:monospace;letter-spacing:.08em">
          MODEL BASIS: MAUDE ADVERSE EVENT DATABASE ¬∑ P150033 SUPPLEMENT CLUSTERING ¬∑ CLASS III CIED RECALL HISTORY ¬∑ NOT FDA GUIDANCE ¬∑ FOR STRATEGIC PLANNING ONLY
        </div>
      </div>


      <!-- Tab 3: Strategic Use Cases -->
      <div class="ov-panel" id="ov-3" style="display:none;padding:28px 24px">

        <!-- Intro -->
        <div style="margin-bottom:28px;padding-bottom:20px;border-bottom:1px solid #1e004a">
          <div style="font-size:14px;font-weight:700;color:#fff;margin-bottom:6px;line-height:1.4">How to Apply This Intelligence to Business &amp; Regulatory Strategy</div>
          <div style="font-size:12px;color:#7755aa;line-height:1.7;max-width:900px">This platform is built to do more than display data ‚Äî it is designed to inform decision-making across five critical strategic domains. Each use case below maps directly to the data available in Tabs 1‚Äì3 and explains the specific insight, the action it enables, and where in the dashboard to find it.</div>
        </div>

        <!-- 5 use case cards in a 2+3 grid -->
        <div style="display:grid;grid-template-columns:1fr 1fr;gap:16px;margin-bottom:16px">

          <!-- UC1: Regulatory Strategy & Planning -->
          <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:4px solid #A100FF;border-radius:10px;padding:22px;position:relative;overflow:hidden">
            <div style="position:absolute;top:-10px;right:-10px;width:80px;height:80px;background:radial-gradient(circle,rgba(161,0,255,.08),transparent 70%);pointer-events:none"></div>
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:14px">
              <div style="width:38px;height:38px;border-radius:8px;background:rgba(161,0,255,.2);border:1px solid rgba(161,0,255,.4);display:flex;align-items:center;justify-content:center;font-size:18px;flex-shrink:0">üìã</div>
              <div>
                <div style="font-family:monospace;font-size:9px;color:#A100FF;letter-spacing:.18em;margin-bottom:3px">USE CASE 01</div>
                <div style="font-size:13px;font-weight:700;color:#fff">Regulatory Strategy &amp; Planning</div>
              </div>
            </div>
            <div style="font-size:12px;color:#94a3b8;line-height:1.75;margin-bottom:14px">The 217-supplement historical record in Tab 1 reveals the full cadence, cost, and classification of every post-approval commitment Medtronic has made. Use this to anticipate your own regulatory burden during product development ‚Äî map expected supplement types, estimate FDA review timelines, and identify which changes will require Panel Track vs 30-day notice. Section V of Tab 3 predicts the next likely filings with failure-mode reasoning, enabling proactive regulatory planning rather than reactive submission.</div>
            <div style="display:flex;flex-wrap:wrap;gap:6px">
              <span style="font-family:monospace;font-size:8px;background:rgba(161,0,255,.1);color:#A100FF;border:1px solid rgba(161,0,255,.25);border-radius:3px;padding:2px 8px">Tab 1 ¬∑ Section 3</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(161,0,255,.1);color:#A100FF;border:1px solid rgba(161,0,255,.25);border-radius:3px;padding:2px 8px">Tab 3 ¬∑ Section V Failure Modes</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(161,0,255,.1);color:#A100FF;border:1px solid rgba(161,0,255,.25);border-radius:3px;padding:2px 8px">Tab 3 ¬∑ Section I Forecast</span>
            </div>
          </div>

          <!-- UC2: Label Expansion -->
          <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:4px solid #E91E8C;border-radius:10px;padding:22px;position:relative;overflow:hidden">
            <div style="position:absolute;top:-10px;right:-10px;width:80px;height:80px;background:radial-gradient(circle,rgba(233,30,140,.08),transparent 70%);pointer-events:none"></div>
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:14px">
              <div style="width:38px;height:38px;border-radius:8px;background:rgba(233,30,140,.2);border:1px solid rgba(233,30,140,.4);display:flex;align-items:center;justify-content:center;font-size:18px;flex-shrink:0">üìà</div>
              <div>
                <div style="font-family:monospace;font-size:9px;color:#E91E8C;letter-spacing:.18em;margin-bottom:3px">USE CASE 02</div>
                <div style="font-size:13px;font-weight:700;color:#fff">Label Expansion Strategy</div>
              </div>
            </div>
            <div style="font-size:12px;color:#94a3b8;line-height:1.75;margin-bottom:14px">Medtronic's label evolution from VVI single-chamber in 2016 to VDD AV synchrony in 2020 to dual-chamber indication in 2023 is a master class in sequential label expansion. Tab 1 Section 2 maps the Regulatory Hierarchy Tier structure ‚Äî use this to understand the clinical evidence threshold required to unlock each new patient population. The two Panel Track supplements (Micra AV + AV2) represent the biggest market expansions. Tab 3 Section II and the 53% Panel Track confidence signal where MDT's next label boundary will shift ‚Äî and where competitors have room to pre-empt.</div>
            <div style="display:flex;flex-wrap:wrap;gap:6px">
              <span style="font-family:monospace;font-size:8px;background:rgba(233,30,140,.1);color:#E91E8C;border:1px solid rgba(233,30,140,.25);border-radius:3px;padding:2px 8px">Tab 1 ¬∑ Section 2 Hierarchy</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(233,30,140,.1);color:#E91E8C;border:1px solid rgba(233,30,140,.25);border-radius:3px;padding:2px 8px">Tab 3 ¬∑ IV Panel Track 53%</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(233,30,140,.1);color:#E91E8C;border:1px solid rgba(233,30,140,.25);border-radius:3px;padding:2px 8px">Tab 1 ¬∑ Labeling Category</span>
            </div>
          </div>

        </div>

        <div style="display:grid;grid-template-columns:1fr 1fr 1fr;gap:16px">

          <!-- UC3: Market Penetration -->
          <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:4px solid #00BEFF;border-radius:10px;padding:22px;position:relative;overflow:hidden">
            <div style="position:absolute;top:-10px;right:-10px;width:80px;height:80px;background:radial-gradient(circle,rgba(0,190,255,.07),transparent 70%);pointer-events:none"></div>
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:14px">
              <div style="width:38px;height:38px;border-radius:8px;background:rgba(0,190,255,.2);border:1px solid rgba(0,190,255,.4);display:flex;align-items:center;justify-content:center;font-size:18px;flex-shrink:0">üåê</div>
              <div>
                <div style="font-family:monospace;font-size:9px;color:#00BEFF;letter-spacing:.18em;margin-bottom:3px">USE CASE 03</div>
                <div style="font-size:13px;font-weight:700;color:#fff">Market Penetration</div>
              </div>
            </div>
            <div style="font-size:12px;color:#94a3b8;line-height:1.75;margin-bottom:14px">MDT's 250K+ cumulative implants vs Abbott's ~40K reflects a 6-year first-mover advantage now being compressed. Tab 2's supplement filing rate comparison (~24/yr MDT vs ~7/yr ABT) signals that MDT is actively defending market position through iterative product improvement while Abbott invests in platform differentiation. Use the adverse event ratios and clinical trial count (8 vs 3) to benchmark evidence requirements for account penetration in high-scrutiny hospital systems and IDNs.</div>
            <div style="display:flex;flex-wrap:wrap;gap:6px">
              <span style="font-family:monospace;font-size:8px;background:rgba(0,190,255,.1);color:#00BEFF;border:1px solid rgba(0,190,255,.25);border-radius:3px;padding:2px 8px">Tab 2 ¬∑ Metric A</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(0,190,255,.1);color:#00BEFF;border:1px solid rgba(0,190,255,.25);border-radius:3px;padding:2px 8px">Tab 2 ¬∑ Device Specs</span>
            </div>
          </div>

          <!-- UC4: Competitor Gap & White Space -->
          <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:4px solid #00E5A0;border-radius:10px;padding:22px;position:relative;overflow:hidden">
            <div style="position:absolute;top:-10px;right:-10px;width:80px;height:80px;background:radial-gradient(circle,rgba(0,229,160,.07),transparent 70%);pointer-events:none"></div>
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:14px">
              <div style="width:38px;height:38px;border-radius:8px;background:rgba(0,229,160,.2);border:1px solid rgba(0,229,160,.4);display:flex;align-items:center;justify-content:center;font-size:18px;flex-shrink:0">üéØ</div>
              <div>
                <div style="font-family:monospace;font-size:9px;color:#00E5A0;letter-spacing:.18em;margin-bottom:3px">USE CASE 04</div>
                <div style="font-size:13px;font-weight:700;color:#fff">Competitor Gap &amp; White Space</div>
              </div>
            </div>
            <div style="font-size:12px;color:#94a3b8;line-height:1.75;margin-bottom:14px">The supplement category breakdown reveals where each company is and is not investing. MDT's 39% manufacturing concentration signals supply chain maturity ‚Äî ABT's higher design proportion signals an early-stage platform still in flux. BSX's pending EMPOWER introduces a white space MDT and ABT have not addressed: ATP + defibrillation integration. Tab 3 Section III competitor trajectory projects when ABT supplement velocity will approach MDT's ‚Äî use this window to identify where a third entrant or new indication could gain disproportionate share before the gap closes.</div>
            <div style="display:flex;flex-wrap:wrap;gap:6px">
              <span style="font-family:monospace;font-size:8px;background:rgba(0,229,160,.1);color:#00E5A0;border:1px solid rgba(0,229,160,.25);border-radius:3px;padding:2px 8px">Tab 2 ¬∑ Section C Abbott</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(0,229,160,.1);color:#00E5A0;border:1px solid rgba(0,229,160,.25);border-radius:3px;padding:2px 8px">Tab 3 ¬∑ Section III Trajectory</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(0,229,160,.1);color:#00E5A0;border:1px solid rgba(0,229,160,.25);border-radius:3px;padding:2px 8px">Tab 2 ¬∑ Section D Strategic</span>
            </div>
          </div>

          <!-- UC5: New Product Development -->
          <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:4px solid #FF6B00;border-radius:10px;padding:22px;position:relative;overflow:hidden">
            <div style="position:absolute;top:-10px;right:-10px;width:80px;height:80px;background:radial-gradient(circle,rgba(255,107,0,.07),transparent 70%);pointer-events:none"></div>
            <div style="display:flex;align-items:center;gap:12px;margin-bottom:14px">
              <div style="width:38px;height:38px;border-radius:8px;background:rgba(255,107,0,.2);border:1px solid rgba(255,107,0,.4);display:flex;align-items:center;justify-content:center;font-size:18px;flex-shrink:0">üî¨</div>
              <div>
                <div style="font-family:monospace;font-size:9px;color:#FF6B00;letter-spacing:.18em;margin-bottom:3px">USE CASE 05</div>
                <div style="font-size:13px;font-weight:700;color:#fff">New Product Development</div>
              </div>
            </div>
            <div style="font-size:12px;color:#94a3b8;line-height:1.75;margin-bottom:14px">Tab 3 Section V is the most direct NPD input in this platform. The 13 predicted failure modes across Software, Design, and Manufacturing are precisely the problems the next generation of leadless pacemakers needs to solve: tine dislodgement at yr 5‚Äì7, battery depletion in high-burden patients, hermetic seal integrity, and algorithm drift under AF load. These are clinically and regulatorily validated gaps ‚Äî each backed by MAUDE data and supplement clustering evidence ‚Äî that define the performance envelope a next-gen device must exceed to differentiate and win panel review.</div>
            <div style="display:flex;flex-wrap:wrap;gap:6px">
              <span style="font-family:monospace;font-size:8px;background:rgba(255,107,0,.1);color:#FF6B00;border:1px solid rgba(255,107,0,.25);border-radius:3px;padding:2px 8px">Tab 3 ¬∑ Section V Failure Modes</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(255,107,0,.1);color:#FF6B00;border:1px solid rgba(255,107,0,.25);border-radius:3px;padding:2px 8px">Tab 1 ¬∑ Design Category</span>
              <span style="font-family:monospace;font-size:8px;background:rgba(255,107,0,.1);color:#FF6B00;border:1px solid rgba(255,107,0,.25);border-radius:3px;padding:2px 8px">Tab 2 ¬∑ Section D Implications</span>
            </div>
          </div>

        </div>

        <!-- Methodology footnote -->
        <div style="margin-top:24px;padding:14px 18px;background:#050505;border:1px solid #1a0040;border-radius:8px;display:flex;align-items:flex-start;gap:12px">
          <div style="font-size:16px;flex-shrink:0;margin-top:1px">‚ö†Ô∏è</div>
          <div style="font-size:10px;color:#334155;font-family:monospace;letter-spacing:.06em;line-height:1.7">STRATEGIC USE DISCLAIMER: Data derived from public FDA PMA database (openFDA API), MAUDE adverse event database, published peer-reviewed clinical trials, and P150033/P150035 regulatory history. Predictive models are based on historical supplement clustering patterns and class III CIED recall data ‚Äî they do not constitute FDA guidance and should not be used as a substitute for independent regulatory counsel. For strategic planning and competitive intelligence purposes only. ¬∑ P4 / PHASE-FOUR.CO</div>
        </div>

      </div>

      <!-- Tab 4: Business Case -->
      <div class="ov-panel" id="ov-4" style="display:none;padding:28px 24px">

        <div style="margin-bottom:24px">
          <div style="font-family:monospace;font-size:8px;color:#888;letter-spacing:.2em;text-transform:uppercase;margin-bottom:6px">Regulatory Intelligence Platform ¬∑ Value Realization Framework</div>
          <div style="font-size:15px;font-weight:700;color:#fff;margin-bottom:4px">Business Case ‚Äî Leading & Lagging Indicator Model</div>
          <div style="font-size:11px;color:#555;line-height:1.6">Each use case below shows 3 leading indicators (inputs you control) that drive lagging outcomes (revenue, risk, speed). Baseline = manual/legacy process. Target = platform-enabled state. Improvement modeled on comparable regulatory intelligence deployments.</div>
        </div>

        <div style="display:grid;grid-template-columns:1fr 1fr;gap:16px">

          <!-- ‚îÄ‚îÄ OFFENSIVE ‚îÄ‚îÄ -->
          <div style="background:#08001a;border:1px solid #2a0055;border-radius:10px;overflow:hidden">
            <div style="background:linear-gradient(90deg,#A100FF,#6600CC);padding:12px 18px;display:flex;align-items:center;gap:10px">
              <span style="font-size:16px">‚ö°</span>
              <div>
                <div style="font-family:monospace;font-size:10px;font-weight:900;color:#fff;letter-spacing:.18em;text-transform:uppercase">Offensive</div>
                <div style="font-family:monospace;font-size:8px;color:rgba(255,255,255,.6);letter-spacing:.12em">Revenue Growth & Market Speed</div>
              </div>
            </div>
            <div style="padding:18px;display:flex;flex-direction:column;gap:16px">

              <!-- Metric 1 -->
              <div>
                <div style="display:flex;justify-content:space-between;align-items:baseline;margin-bottom:6px">
                  <div>
                    <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.14em;text-transform:uppercase;margin-bottom:2px">Leading ‚Üí Lagging</div>
                    <div style="font-size:11px;font-weight:700;color:#e2e8f0">Time to New Label Revenue</div>
                  </div>
                  <div style="font-family:monospace;font-size:13px;font-weight:900;color:#00E5A0;background:rgba(0,229,160,.1);border:1px solid rgba(0,229,160,.3);border-radius:4px;padding:2px 8px">‚àí33%</div>
                </div>
                <div style="position:relative;height:8px;background:#1a1a2e;border-radius:4px;overflow:hidden;margin-bottom:4px">
                  <div style="position:absolute;left:0;top:0;bottom:0;width:100%;background:#1e1e3a;border-radius:4px"></div>
                  <div style="position:absolute;left:0;top:0;bottom:0;width:67%;background:linear-gradient(90deg,#A100FF,#CC33FF);border-radius:4px;box-shadow:0 0 8px rgba(161,0,255,.5)"></div>
                </div>
                <div style="display:flex;justify-content:space-between">
                  <span style="font-family:monospace;font-size:8px;color:#444">Baseline: 18 months avg</span>
                  <span style="font-family:monospace;font-size:8px;color:#00E5A0">Target: 12 months</span>
                </div>
                <div style="font-size:10px;color:#444;margin-top:5px;line-height:1.5">Leading: Supplement cluster detection speed ¬∑ Real-time FDA tracking ¬∑ Competitor label gap analysis</div>
              </div>

              <!-- Metric 2 -->
              <div>
                <div style="display:flex;justify-content:space-between;align-items:baseline;margin-bottom:6px">
                  <div>
                    <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.14em;text-transform:uppercase;margin-bottom:2px">Leading ‚Üí Lagging</div>
                    <div style="font-size:11px;font-weight:700;color:#e2e8f0">Competitive Label Gap Identification</div>
                  </div>
                  <div style="font-family:monospace;font-size:13px;font-weight:900;color:#00E5A0;background:rgba(0,229,160,.1);border:1px solid rgba(0,229,160,.3);border-radius:4px;padding:2px 8px">‚àí58%</div>
                </div>
                <div style="position:relative;height:8px;background:#1a1a2e;border-radius:4px;overflow:hidden;margin-bottom:4px">
                  <div style="position:absolute;left:0;top:0;bottom:0;width:100%;background:#1e1e3a;border-radius:4px"></div>
                  <div style="position:absolute;left:0;top:0;bottom:0;width:42%;background:linear-gradient(90deg,#A100FF,#CC33FF);border-radius:4px;box-shadow:0 0 8px rgba(161,0,255,.5)"></div>
                </div>
                <div style="display:flex;justify-content:space-between">
                  <span style="font-family:monospace;font-size:8px;color:#444">Baseline: 6‚Äì8 weeks manual</span>
                  <span style="font-family:monospace;font-size:8px;color:#00E5A0">Target: &lt;2 weeks</span>
                </div>
                <div style="font-size:10px;color:#444;margin-top:5px;line-height:1.5">Leading: P150035 supplement velocity monitoring ¬∑ Indication expansion pattern recognition ¬∑ Panel Track prediction accuracy</div>
              </div>

              <!-- Metric 3 -->
              <div>
                <div style="display:flex;justify-content:space-between;align-items:baseline;margin-bottom:6px">
                  <div>
                    <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.14em;text-transform:uppercase;margin-bottom:2px">Leading ‚Üí Lagging</div>
                    <div style="font-size:11px;font-weight:700;color:#e2e8f0">Regulatory Filing Velocity (Supplements/Yr)</div>
                  </div>
                  <div style="font-family:monospace;font-size:13px;font-weight:900;color:#00E5A0;background:rgba(0,229,160,.1);border:1px solid rgba(0,229,160,.3);border-radius:4px;padding:2px 8px">+22%</div>
                </div>
                <div style="position:relative;height:8px;background:#1a1a2e;border-radius:4px;overflow:hidden;margin-bottom:4px">
                  <div style="position:absolute;left:0;top:0;bottom:0;width:100%;background:#1e1e3a;border-radius:4px"></div>
                  <div style="position:absolute;left:0;top:0;bottom:0;width:82%;background:linear-gradient(90deg,#A100FF,#CC33FF);border-radius:4px;box-shadow:0 0 8px rgba(161,0,255,.5)"></div>
                </div>
                <div style="display:flex;justify-content:space-between">
                  <span style="font-family:monospace;font-size:8px;color:#444">Baseline: ~18 supplements/yr</span>
                  <span style="font-family:monospace;font-size:8px;color:#00E5A0">Target: ~22 supplements/yr</span>
                </div>
                <div style="font-size:10px;color:#444;margin-top:5px;line-height:1.5">Leading: Supplement type clustering intelligence ¬∑ Category mix optimization ¬∑ Historical cadence benchmarking vs MDT</div>
              </div>

            </div>
          </div>

          <!-- ‚îÄ‚îÄ DEFENSIVE ‚îÄ‚îÄ -->
          <div style="background:#00100a;border:1px solid #003322;border-radius:10px;overflow:hidden">
            <div style="background:linear-gradient(90deg,#E91E8C,#A100FF);padding:12px 18px;display:flex;align-items:center;gap:10px">
              <span style="font-size:16px">üõ°Ô∏è</span>
              <div>
                <div style="font-family:monospace;font-size:10px;font-weight:900;color:#fff;letter-spacing:.18em;text-transform:uppercase">Defensive</div>
                <div style="font-family:monospace;font-size:8px;color:rgba(255,255,255,.6);letter-spacing:.12em">Risk Reduction & Compliance Speed</div>
              </div>
            </div>
            <div style="padding:18px;display:flex;flex-direction:column;gap:16px">

              <!-- Metric 1 -->
              <div>
                <div style="display:flex;justify-content:space-between;align-items:baseline;margin-bottom:6px">
                  <div>
                    <div style="font-family:monospace;font-size:8px;color:#E91E8C;letter-spacing:.14em;text-transform:uppercase;margin-bottom:2px">Leading ‚Üí Lagging</div>
                    <div style="font-size:11px;font-weight:700;color:#e2e8f0">MAUDE Failure Mode Detection Time</div>
                  </div>
                  <div style="font-family:monospace;font-size:13px;font-weight:900;color:#00BEFF;background:rgba(0,190,255,.1);border:1px solid rgba(0,190,255,.3);border-radius:4px;padding:2px 8px">‚àí47%</div>
                </div>
                <div style="position:relative;height:8px;background:#0a1a10;border-radius:4px;overflow:hidden;margin-bottom:4px">
                  <div style="position:absolute;left:0;top:0;bottom:0;width:100%;background:#0d1f14;border-radius:4px"></div>
                  <div style="position:absolute;left:0;top:0;bottom:0;width:53%;background:linear-gradient(90deg,#E91E8C,#FF6B6B);border-radius:4px;box-shadow:0 0 8px rgba(233,30,140,.5)"></div>
                </div>
                <div style="display:flex;justify-content:space-between">
                  <span style="font-family:monospace;font-size:8px;color:#444">Baseline: 72‚Äì96 hrs avg</span>
                  <span style="font-family:monospace;font-size:8px;color:#00BEFF">Target: &lt;38 hrs</span>
                </div>
                <div style="font-size:10px;color:#444;margin-top:5px;line-height:1.5">Leading: Real-time MAUDE signal monitoring ¬∑ Supplement-to-recall correlation modeling ¬∑ SW complaint cluster detection</div>
              </div>

              <!-- Metric 2 -->
              <div>
                <div style="display:flex;justify-content:space-between;align-items:baseline;margin-bottom:6px">
                  <div>
                    <div style="font-family:monospace;font-size:8px;color:#E91E8C;letter-spacing:.14em;text-transform:uppercase;margin-bottom:2px">Leading ‚Üí Lagging</div>
                    <div style="font-size:11px;font-weight:700;color:#e2e8f0">Regulatory Risk Score Accuracy</div>
                  </div>
                  <div style="font-family:monospace;font-size:13px;font-weight:900;color:#00BEFF;background:rgba(0,190,255,.1);border:1px solid rgba(0,190,255,.3);border-radius:4px;padding:2px 8px">+41%</div>
                </div>
                <div style="position:relative;height:8px;background:#0a1a10;border-radius:4px;overflow:hidden;margin-bottom:4px">
                  <div style="position:absolute;left:0;top:0;bottom:0;width:100%;background:#0d1f14;border-radius:4px"></div>
                  <div style="position:absolute;left:0;top:0;bottom:0;width:76%;background:linear-gradient(90deg,#E91E8C,#FF6B6B);border-radius:4px;box-shadow:0 0 8px rgba(233,30,140,.5)"></div>
                </div>
                <div style="display:flex;justify-content:space-between">
                  <span style="font-family:monospace;font-size:8px;color:#444">Baseline: 54% prediction accuracy</span>
                  <span style="font-family:monospace;font-size:8px;color:#00BEFF">Target: 76% accuracy</span>
                </div>
                <div style="font-size:10px;color:#444;margin-top:5px;line-height:1.5">Leading: Supplement type pattern clustering ¬∑ Class III CIED recall base rate modeling ¬∑ Historical 180-Day denial rate benchmarking</div>
              </div>

              <!-- Metric 3 -->
              <div>
                <div style="display:flex;justify-content:space-between;align-items:baseline;margin-bottom:6px">
                  <div>
                    <div style="font-family:monospace;font-size:8px;color:#E91E8C;letter-spacing:.14em;text-transform:uppercase;margin-bottom:2px">Leading ‚Üí Lagging</div>
                    <div style="font-size:11px;font-weight:700;color:#e2e8f0">Supplement Rejection / RTA Rate Reduction</div>
                  </div>
                  <div style="font-family:monospace;font-size:13px;font-weight:900;color:#00BEFF;background:rgba(0,190,255,.1);border:1px solid rgba(0,190,255,.3);border-radius:4px;padding:2px 8px">‚àí29%</div>
                </div>
                <div style="position:relative;height:8px;background:#0a1a10;border-radius:4px;overflow:hidden;margin-bottom:4px">
                  <div style="position:absolute;left:0;top:0;bottom:0;width:100%;background:#0d1f14;border-radius:4px"></div>
                  <div style="position:absolute;left:0;top:0;bottom:0;width:71%;background:linear-gradient(90deg,#E91E8C,#FF6B6B);border-radius:4px;box-shadow:0 0 8px rgba(233,30,140,.5)"></div>
                </div>
                <div style="display:flex;justify-content:space-between">
                  <span style="font-family:monospace;font-size:8px;color:#444">Baseline: ~14% RTA rate</span>
                  <span style="font-family:monospace;font-size:8px;color:#00BEFF">Target: ~10% RTA rate</span>
                </div>
                <div style="font-size:10px;color:#444;margin-top:5px;line-height:1.5">Leading: Peer supplement acceptance rate benchmarking ¬∑ Submission completeness scoring ¬∑ FDA reviewer pattern intelligence</div>
              </div>

            </div>
          </div>

        </div>

        <!-- Summary ROI strip -->
        <div style="margin-top:20px;background:#080808;border:1px solid #1a1a1a;border-radius:8px;padding:16px 20px;display:grid;grid-template-columns:repeat(4,1fr);gap:0">
          <div style="text-align:center;border-right:1px solid #1a1a1a;padding:8px">
            <div style="font-family:monospace;font-size:20px;font-weight:900;color:#A100FF">‚àí33%</div>
            <div style="font-family:monospace;font-size:8px;color:#333;letter-spacing:.12em;margin-top:3px">TIME TO LABEL REVENUE</div>
          </div>
          <div style="text-align:center;border-right:1px solid #1a1a1a;padding:8px">
            <div style="font-family:monospace;font-size:20px;font-weight:900;color:#E91E8C">‚àí47%</div>
            <div style="font-family:monospace;font-size:8px;color:#333;letter-spacing:.12em;margin-top:3px">FAILURE DETECTION TIME</div>
          </div>
          <div style="text-align:center;border-right:1px solid #1a1a1a;padding:8px">
            <div style="font-family:monospace;font-size:20px;font-weight:900;color:#00BEFF">+41%</div>
            <div style="font-family:monospace;font-size:8px;color:#333;letter-spacing:.12em;margin-top:3px">RISK PREDICTION ACCURACY</div>
          </div>
          <div style="text-align:center;padding:8px">
            <div style="font-family:monospace;font-size:20px;font-weight:900;color:#00E5A0">+22%</div>
            <div style="font-family:monospace;font-size:8px;color:#333;letter-spacing:.12em;margin-top:3px">FILING VELOCITY</div>
          </div>
        </div>

        <div style="margin-top:12px;font-family:monospace;font-size:8px;color:#2a2a2a;letter-spacing:.08em;line-height:1.6">METHODOLOGY: Improvement estimates derived from regulatory intelligence deployment benchmarks across Class III CIED manufacturers. Leading indicators modeled as input variables; lagging outcomes represent 12‚Äì24 month post-deployment performance deltas vs manual/legacy baseline. Not a guarantee of results. For strategic planning only ¬∑ P4 / PHASE-FOUR.CO</div>

      </div>
        </div><!-- /overviewBody -->
  </div><!-- /overviewWrap -->
  <!-- TAB NAVIGATION -->
  <div style="display:flex;align-items:center;gap:16px;margin-bottom:32px">
    <div class="tab-nav" style="margin-bottom:0">
      <button class="tab-btn active" onclick="switchTab('micra', this)">
        <span class="tb-handle">‚ö° Tab 1</span>
        <span class="tb-label">Micra P150033</span>
      </button>
      <button class="tab-btn" onclick="switchTab('competitor', this)">
        <span class="tb-handle">üî¨ Tab 2</span>
        <span class="tb-label">Competitor Analysis</span>
      </button>
      <button class="tab-btn" onclick="switchTab('predict', this)">
        <span class="tb-handle">‚óà Tab 3</span>
        <span class="tb-label">Predictive Intelligence</span>
      </button>
    </div>
    <!-- Click affordance ‚Äî points LEFT back at last tab -->
    <div style="display:flex;flex-direction:column;align-items:center;gap:4px;animation:tabPulse 2.5s ease-in-out infinite">
      <span style="font-family:monospace;font-size:8px;color:#aaaaaa;letter-spacing:.18em;text-transform:uppercase;white-space:nowrap">Select Me</span>
      <svg width="52" height="14" viewBox="0 0 52 14" fill="none" xmlns="http://www.w3.org/2000/svg">
        <path d="M50 7 H8 M14 2 L8 7 L14 12" stroke="#aaaaaa" stroke-width="1.8" stroke-linecap="round" stroke-linejoin="round"/>
      </svg>
    </div>
  </div>
  <style>
    @keyframes tabPulse {
      0%,100%{opacity:.45;transform:translateX(0)}
      50%{opacity:1;transform:translateX(-5px)}
    }
  </style>

  <!-- ‚ïê‚ïê TAB 1: MICRA DASHBOARD ‚ïê‚ïê -->
  <div class="tab-panel active" id="tab-micra">

  <!-- HEADER -->
  <div class="hdr">
    <div>
      <div class="hdr-meta">FDA PMA DATABASE ¬∑ P150033 ¬∑ MEDTRONIC, INC.</div>
      <h1>Micra‚Ñ¢ Transcatheter Pacemaker System</h1>
      <h2>PMA Supplement Classification ¬∑ 217 Approved Supplements (2016‚Äì2025)</h2>
      <div class="live-badge"><span class="live-dot"></span>LIVE DATA ¬∑ openFDA API</div>
    </div>
    <div class="hdr-right" style="text-align:right">
      <div class="lbl">Original PMA Approval</div>
      <div class="date">April 6, 2016</div>
      <div class="sub">Leadless Pacemaker ¬∑ Product Code PNJ</div>
      <div style="margin-top:10px;padding-top:10px;border-top:1px solid #1a1a1a">
        <div style="display:flex;align-items:center;gap:5px;margin-bottom:4px">
          <span style="width:5px;height:5px;border-radius:50%;background:#A100FF;display:inline-block;animation:pulse 1.5s infinite"></span>
          <span style="font-family:monospace;font-size:8px;color:#9966CC;letter-spacing:.14em;text-transform:uppercase">Last PMA Update</span>
        </div>
        <div id="pmaDate" style="font-family:monospace;font-size:11px;font-weight:700;color:#fff;letter-spacing:.08em">--.--.--</div>
        <div id="pmaTime" style="font-family:monospace;font-size:9px;color:#CC99FF;letter-spacing:.1em">--:--:-- HRS</div>
      </div>
    </div>
  </div>


  <!-- ‚ïê‚ïê DASHBOARD OVERVIEW ‚Äî top of Tab 1, lightweight expander ‚ïê‚ïê -->

  <!-- SECTION 1 -->
  <div class="sec-wrap-1">
    <div class="sec-band" style="border-left-color:#A100FF;background:rgba(161,0,255,.06);border:1px solid rgba(161,0,255,.12)">
      <div class="sec-band-inner">
        <div style="width:10px;height:38px;background:#A100FF;border-radius:3px;flex-shrink:0;box-shadow:0 0 10px #A100FF88"></div>
        <div>
          <div style="line-height:1.2">
              <div style="font-family:monospace;font-size:11px;font-weight:900;color:#ffffff;letter-spacing:.25em;text-transform:uppercase;font-size:13px">SECTION 1</div>
              <div style="font-family:monospace;font-size:13px;font-weight:600;color:#A100FF;letter-spacing:.08em;text-transform:uppercase;margin-top:4px;text-shadow:0 0 10px #A100FF44">Supplement Classification Overview</div>
            </div>
          <div class="sec-band-sub" style="color:#A100FF">217 Approved Supplements ¬∑ 5 Categories ¬∑ Live openFDA</div>
        </div>
      </div>
      <div class="sec-band-num" style="color:#A100FF">01</div>
    </div>
    <div style="position:absolute;left:0;top:0;bottom:0;width:3px;background:#A100FF;border-radius:3px 0 0 3px"></div>
    <div class="kpi-grid" id="kpiGrid"></div>
    <div class="chart-box" style="margin-top:20px">
      <div class="sec-lbl" id="chartLabel" style="margin-bottom:20px">SUPPLEMENT VOLUME BY CATEGORY ‚Äî TOTAL: 217</div>
      <div class="bar-wrap" id="barChart"></div>
    </div>
    <div id="detailPanel"></div>
  </div>


  <div class="sec-wrap-2">
    <div class="sec-band" style="border-left-color:#00BEFF;background:rgba(0,190,255,.05);border:1px solid rgba(0,190,255,.12)">
      <div class="sec-band-inner">
        <div style="width:10px;height:38px;background:#00BEFF;border-radius:3px;flex-shrink:0;box-shadow:0 0 10px #00BEFF88"></div>
        <div>
          <div style="line-height:1.2">
              <div style="font-family:monospace;font-size:11px;font-weight:900;color:#ffffff;letter-spacing:.25em;text-transform:uppercase;font-size:13px">SECTION 2</div>
              <div style="font-family:monospace;font-size:13px;font-weight:600;color:#00BEFF;letter-spacing:.08em;text-transform:uppercase;margin-top:4px;text-shadow:0 0 10px #00BEFF44">PMA Regulatory Hierarchy ‚Äî P150033</div>
            </div>
          <div class="sec-band-sub" style="color:#00BEFF">3 Tier Framework ¬∑ Original PMA ¬∑ Panel Track ¬∑ Post-Approval Supplements</div>
        </div>
      </div>
      <div class="sec-band-num" style="color:#00BEFF">02</div>
    </div>
  <div class="tiers-grid">
    <div class="tier-card" style="background:#0f0f0f;border-color:#2D0066">
      <div class="tier-num" style="color:#A100FF">Tier 1 ¬∑ Original PMA Approval</div>
      <div class="tier-title" style="color:#f8fafc">Micra VR (MC1VR01)</div>
      <div class="tier-date" style="color:#A100FF">April 6, 2016</div>
      <div class="tier-desc">First FDA-approved leadless transcatheter pacemaker. Single-chamber VVI(R) pacing implanted directly into the right ventricle via femoral vein. Expedited review granted.<br><br>
        <strong>Indicated for:</strong> High-grade AV block with AF, sinus node dysfunction, or where atrial lead placement is not feasible.<br><br>
        <strong>Clinical basis:</strong> MICRA-I trial (726 patients).</div>
    </div>
    <div class="tier-card" style="background:#0a0019;border-color:#5c0099">
      <div class="tier-num" style="color:#CC33FF">Tier 2 ¬∑ Panel Track Supplements</div>
      <div class="tier-title" style="color:#f8fafc">Major New Device Models</div>
      <div class="tier-date" style="color:#CC33FF">2020 ¬∑ 2023</div>
      <div class="tier-desc">Require full Advisory Committee review ‚Äî essentially new devices filed under the same PMA.<br><br>
        <strong>S061 ¬∑ Jan 2020:</strong> Micra AV (MC1AVR1) ‚Äî world's first accelerometer-based AV synchrony leadless pacemaker. New VDD indication for AV block (MARVEL 2 trial).<br><br>
        <strong>S152 ¬∑ May 2023:</strong> Micra AV2 (MC2AVR1) &amp; VR2 ‚Äî 2nd gen with 40% extended battery, redesigned circuit board.</div>
    </div>
    <div class="tier-card" style="background:#000f09;border-color:#003322">
      <div class="tier-num" style="color:#00E676">Tier 3 ¬∑ PMA Supplements (S001‚ÄìS219+)</div>
      <div class="tier-title" style="color:#f8fafc">Incremental Post-Approval Changes</div>
      <div class="tier-date" style="color:#00E676">2016 ‚Äì Present ¬∑ Live from FDA</div>
      <div class="tier-desc">All changes to the approved device filed as numbered supplements under 4 regulatory pathways:<br><br>
        <strong>30-Day Notice / Real-Time:</strong> Low-risk manufacturing &amp; process changes<br>
        <strong>180-Day:</strong> Software, labeling, and accessory changes<br>
        <strong>Special:</strong> Specific targeted changes<br>
        <strong>Panel Track:</strong> Major changes ‚Äî new indications or hardware platforms</div>
    </div>
  </div>

  </div><!-- /sec-wrap-1 -->

  </div><!-- /sec-wrap-2 -->

  <div class="sec-wrap-3">
    <div class="sec-band" style="border-left-color:#00E5A0;background:rgba(0,229,160,.05);border:1px solid rgba(0,229,160,.12)">
      <div class="sec-band-inner">
        <div style="width:10px;height:38px;background:#00E5A0;border-radius:3px;flex-shrink:0;box-shadow:0 0 10px #00E5A088"></div>
        <div>
          <div style="line-height:1.2">
              <div style="font-family:monospace;font-size:11px;font-weight:900;color:#ffffff;letter-spacing:.25em;text-transform:uppercase;font-size:13px">SECTION 3</div>
              <div style="font-family:monospace;font-size:13px;font-weight:600;color:#00E5A0;letter-spacing:.08em;text-transform:uppercase;margin-top:4px;text-shadow:0 0 10px #00E5A044">Category Summary ‚Äî Click Any Row to Expand</div>
            </div>
          <div class="sec-band-sub" style="color:#00E5A0">5 Categories ¬∑ Supplement Type Breakdown ¬∑ Expandable Detail</div>
        </div>
      </div>
      <div class="sec-band-num" style="color:#00E5A0">03</div>
    </div>
  <div class="sec-lbl" style="display:none"> ‚Äî <span style="color:#94a3b8;font-size:11px;letter-spacing:.05em">Click Any Row to Expand Full Supplement Details</span></div>
  <div class="table-box" style="margin-top:16px">
    <table id="summaryTable">
      <thead>
        <tr>
          <th class="s-th"></th>
          <th class="s-th">#</th>
          <th class="s-th">Category</th>
          <th class="s-th">Supplement Type</th>
          <th class="s-th">Count</th>
          <th class="s-th">% of 217</th>
          <th class="s-th">Clinical Significance</th>
          <th class="s-th">Regulatory Burden</th>
        </tr>
      </thead>
      <tbody id="summaryBody"></tbody>
    </table>
  </div>

  </div><!-- /sec-wrap-3 -->

  <div class="sec-wrap-4">
    <div class="sec-band" style="border-left-color:#FF6B00;background:rgba(255,107,0,.05);border:1px solid rgba(255,107,0,.12)">
      <div class="sec-band-inner">
        <div style="width:10px;height:38px;background:#FF6B00;border-radius:3px;flex-shrink:0;box-shadow:0 0 10px #FF6B0088"></div>
        <div>
          <div style="line-height:1.2">
              <div style="font-family:monospace;font-size:11px;font-weight:900;color:#ffffff;letter-spacing:.25em;text-transform:uppercase;font-size:13px">SECTION 4</div>
              <div style="font-family:monospace;font-size:13px;font-weight:600;color:#FF6B00;letter-spacing:.08em;text-transform:uppercase;margin-top:4px;text-shadow:0 0 10px #FF6B0044">All Approved Supplements ‚Äî Live from openFDA</div>
            </div>
          <div class="sec-band-sub" style="color:#FF6B00">Real-time Data ¬∑ openFDA Public API ¬∑ Filterable by Category</div>
        </div>
      </div>
      <div class="sec-band-num" style="color:#FF6B00">04</div>
    </div>
    <div class="sec-lbl" id="suppLabel" style="display:none">SECTION 4 ¬∑ All Approved Supplements ‚Äî Live from openFDA</div>
  <div id="errorMsg" class="error-box" style="display:none"></div>
  <div class="table-box" style="margin-top:16px">
    <div class="filter-bar" id="filterBtns"></div>
    <div style="overflow-x:auto">
      <table>
        <thead><tr id="suppHead"></tr></thead>
        <tbody id="suppBody"><tr><td colspan="5" class="loading-row"><span class="spinner"></span>Loading live supplements from openFDA‚Ä¶</td></tr></tbody>
      </table>
    </div>
  </div>

  </div><!-- /sec-wrap-4 -->

  <div class="footer">
    Sections 1‚Äì3: Classification based on FDA PMA supplement type patterns for Class III CIEDs ¬∑ Counts from P150033 regulatory history analysis<br>
    Section 4: Live data ¬∑ openFDA Public API ¬∑ api.fda.gov/device/pma.json ¬∑ Fetched at page load<br>
    <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p150033" target="_blank">accessdata.fda.gov ‚Äî Full P150033 Record</a> ¬∑ Last FDA update: 02/09/2026
  </div>

  <!-- ‚ïê‚ïê SECTION 5: REGULATORY MILESTONE TIMELINE ‚ïê‚ïê -->
  <div class="sec-wrap-5" style="margin-top:28px">
    <div class="sec-band" style="border-left-color:#E91E8C;background:rgba(233,30,140,.05);border:1px solid rgba(233,30,140,.1)">
      <div class="sec-band-inner">
        <div style="width:10px;height:38px;background:#E91E8C;border-radius:3px;flex-shrink:0;box-shadow:0 0 10px #E91E8C88"></div>
        <div>
          <div style="line-height:1.2">
              <div style="font-family:monospace;font-size:11px;font-weight:900;color:#ffffff;letter-spacing:.25em;text-transform:uppercase;font-size:13px">SECTION 5</div>
              <div style="font-family:monospace;font-size:13px;font-weight:600;color:#E91E8C;letter-spacing:.08em;text-transform:uppercase;margin-top:4px;text-shadow:0 0 10px #E91E8C44">Regulatory Milestone Timeline ‚Äî P150033 ¬∑ 2016‚ÄìPresent</div>
            </div>
          <div class="sec-band-sub" style="color:#E91E8C">Key FDA Approval Events ¬∑ Panel Track Supplements ¬∑ Label Expansions ¬∑ Device Generations</div>
        </div>
      </div>
      <div class="sec-band-num" style="color:#E91E8C">05</div>
    </div>

    <div style="background:#030303;border:1px solid #111;border-radius:10px;padding:32px 32px 28px">

      <!-- SVG wave ‚Äî minimalist, taller, animated -->
      <div style="position:relative">
        <svg id="timelineSvg" width="100%" viewBox="0 0 1000 432" preserveAspectRatio="xMidYMid meet" style="display:block;max-height:540px">
          <defs>
            <linearGradient id="waveGrad" x1="0" y1="0" x2="1" y2="0">
              <stop offset="0%"   stop-color="#A100FF"/>
              <stop offset="60%"  stop-color="#CC33FF"/>
              <stop offset="100%" stop-color="#E91E8C"/>
            </linearGradient>
            <linearGradient id="fillGrad" x1="0" y1="0" x2="0" y2="1">
              <stop offset="0%"   stop-color="#A100FF" stop-opacity="0.15"/>
              <stop offset="100%" stop-color="#A100FF" stop-opacity="0"/>
            </linearGradient>
            <filter id="glow">
              <feGaussianBlur stdDeviation="3.5" result="blur"/>
              <feMerge><feMergeNode in="blur"/><feMergeNode in="SourceGraphic"/></feMerge>
            </filter>
            <!-- Animated draw mask -->
            <mask id="drawMask">
              <rect id="drawRect" x="0" y="0" width="0" height="432" fill="white"/>
            </mask>
          </defs>

          <!-- Baseline -->
          <line x1="60" y1="275" x2="940" y2="275" stroke="#1e1e1e" stroke-width="1"/>
          <!-- tick marks -->
          <line x1="100" y1="272" x2="100" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="310" y1="272" x2="310" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="490" y1="272" x2="490" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="680" y1="272" x2="680" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="860" y1="272" x2="860" y2="280" stroke="#2a2a2a" stroke-width="1"/>

          <!-- Fill + Line ‚Äî masked for draw animation -->
          <g mask="url(#drawMask)">
            <path d="M100,258 C180,250 245,235 310,228 C375,221 430,206 490,192 C548,179 608,158 680,140 C738,126 795,118 860,112 L860,275 L100,275 Z" fill="url(#fillGrad)"/>
            <path d="M100,258 C180,250 245,235 310,228 C375,221 430,206 490,192 C548,179 608,158 680,140 C738,126 795,118 860,112"
                  fill="none" stroke="url(#waveGrad)" stroke-width="2.5" stroke-linecap="round" filter="url(#glow)"/>
          </g>

          <!-- ‚îÄ‚îÄ Milestone 1: 2016 S001 ‚îÄ‚îÄ -->
          <line x1="100" y1="228" x2="100" y2="258" stroke="#A100FF" stroke-width="1" stroke-opacity=".45"/>
          <circle cx="100" cy="258" r="5.5" fill="#050505" stroke="#A100FF" stroke-width="1.5"/>
          <circle cx="100" cy="258" r="2.2" fill="#A100FF"/>
          <rect x="70" y="208" width="38" height="16" rx="8" fill="#0d0d0d" stroke="#A100FF" stroke-width="1" stroke-opacity=".55"/>
          <text x="89" y="219.5" text-anchor="middle" fill="#A100FF" font-size="8" font-weight="600" font-family="monospace">S001</text>

          <!-- ‚îÄ‚îÄ Milestone 2: 2018 ~50 ‚îÄ‚îÄ -->
          <line x1="310" y1="208" x2="310" y2="228" stroke="#CC33FF" stroke-width="1" stroke-opacity=".45"/>
          <circle cx="310" cy="228" r="5.5" fill="#050505" stroke="#CC33FF" stroke-width="1.5"/>
          <circle cx="310" cy="228" r="2.2" fill="#CC33FF"/>
          <rect x="280" y="190" width="38" height="16" rx="8" fill="#0d0d0d" stroke="#CC33FF" stroke-width="1" stroke-opacity=".55"/>
          <text x="299" y="201.5" text-anchor="middle" fill="#CC33FF" font-size="8" font-weight="600" font-family="monospace">~50</text>

          <!-- ‚îÄ‚îÄ Milestone 3: 2020 S061 MAJOR ‚îÄ‚îÄ -->
          <line x1="490" y1="155" x2="490" y2="192" stroke="#A100FF" stroke-width="1.5" stroke-opacity=".7"/>
          <circle cx="490" cy="192" r="11" fill="none" stroke="#A100FF" stroke-width="1" stroke-opacity=".25"/>
          <circle cx="490" cy="192" r="7"  fill="#A100FF" stroke="#fff" stroke-width="1.5"/>
          <circle cx="490" cy="192" r="3"  fill="#fff"/>
          <rect x="459" y="134" width="38" height="16" rx="8" fill="#A100FF"/>
          <text x="478" y="145.5" text-anchor="middle" fill="#fff" font-size="8" font-weight="700" font-family="monospace">S061</text>

          <!-- ‚îÄ‚îÄ Milestone 4: 2023 S152 MAJOR ‚îÄ‚îÄ -->
          <line x1="680" y1="100" x2="680" y2="140" stroke="#E91E8C" stroke-width="1.5" stroke-opacity=".7"/>
          <circle cx="680" cy="140" r="11" fill="none" stroke="#E91E8C" stroke-width="1" stroke-opacity=".25"/>
          <circle cx="680" cy="140" r="7"  fill="#E91E8C" stroke="#fff" stroke-width="1.5"/>
          <circle cx="680" cy="140" r="3"  fill="#fff"/>
          <rect x="650" y="80" width="38" height="16" rx="8" fill="#E91E8C"/>
          <text x="669" y="91.5" text-anchor="middle" fill="#fff" font-size="8" font-weight="700" font-family="monospace">S152</text>

          <!-- ‚îÄ‚îÄ Milestone 5: 2025 217+ ‚îÄ‚îÄ -->
          <line x1="860" y1="92" x2="860" y2="112" stroke="#E91E8C" stroke-width="1" stroke-opacity=".45"/>
          <circle cx="860" cy="112" r="5.5" fill="#050505" stroke="#E91E8C" stroke-width="1.5"/>
          <circle cx="860" cy="112" r="2.2" fill="#E91E8C"/>
          <rect x="829" y="72" width="40" height="16" rx="8" fill="#0d0d0d" stroke="#E91E8C" stroke-width="1" stroke-opacity=".55"/>
          <text x="849" y="83.5" text-anchor="middle" fill="#E91E8C" font-size="8" font-weight="600" font-family="monospace">217+</text>

          <!-- Year labels -->
          <text x="100" y="300" text-anchor="middle" fill="#A100FF" font-size="13" font-weight="700" font-family="monospace" letter-spacing=".1em">2016</text>
          <text x="310" y="300" text-anchor="middle" fill="#9955CC" font-size="12" font-family="monospace" letter-spacing=".08em" opacity=".7">2018</text>
          <text x="490" y="302" text-anchor="middle" fill="#A100FF" font-size="15" font-weight="700" font-family="monospace" letter-spacing=".1em">2020</text>
          <text x="680" y="302" text-anchor="middle" fill="#E91E8C" font-size="15" font-weight="700" font-family="monospace" letter-spacing=".1em">2023</text>
          <text x="860" y="300" text-anchor="middle" fill="#E91E8C" font-size="12" font-family="monospace" letter-spacing=".08em" opacity=".7">2025</text>
        </svg>

        <script>
          // Animate the draw-mask on first view
          (function(){
            var triggered = false;
            function drawTimeline() {
              if (triggered) return;
              triggered = true;
              var r = document.getElementById('drawRect');
              if (!r) return;
              r.setAttribute('width','0');
              var start = null, dur = 2000;
              function step(ts) {
                if (!start) start = ts;
                var p = Math.min((ts - start) / dur, 1);
                var eased = p < 0.5 ? 2*p*p : -1+(4-2*p)*p;
                r.setAttribute('width', (eased * 1000).toFixed(1));
                if (p < 1) requestAnimationFrame(step);
              }
              requestAnimationFrame(step);
            }
            window._drawTimeline = drawTimeline;
            // IntersectionObserver ‚Äî fires when chart scrolls into view
            var svg = document.getElementById('timelineSvg');
            if (svg && 'IntersectionObserver' in window) {
              var obs = new IntersectionObserver(function(entries) {
                entries.forEach(function(e) {
                  if (e.isIntersecting) { drawTimeline(); obs.disconnect(); }
                });
              }, { threshold: 0.25 });
              obs.observe(svg);
            } else {
              setTimeout(drawTimeline, 400);
            }
          })();
        </script>
      </div>

      <!-- Milestone cards ‚Äî minimalist, expandable -->
      <style>
        .ms-card { border-radius:8px; overflow:hidden; transition:border-color .2s; }
        .ms-header { display:flex; align-items:center; justify-content:space-between; padding:14px 16px; cursor:pointer; user-select:none; }
        .ms-header:hover .ms-chevron { opacity:1; }
        .ms-chevron { font-family:monospace; font-size:9px; letter-spacing:.1em; opacity:.4; transition:opacity .2s,transform .25s; }
        .ms-body { display:none; padding:0 16px 16px; border-top:1px solid rgba(255,255,255,.04); }
        .ms-body.open { display:block; }
        .ms-tag { font-family:monospace; font-size:8px; border-radius:3px; padding:2px 7px; display:inline-block; }
      </style>

      <div style="display:grid;grid-template-columns:repeat(5,1fr);gap:10px;margin-top:24px">

        <!-- M1: 2016 -->
        <div class="ms-card" style="background:#0d0d0d;border:1px solid #222;border-top:2px solid #A100FF">
          <div class="ms-header" onclick="toggleMs('ms1',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.15em;margin-bottom:6px">APR 6, 2016</div>
              <div style="font-size:13px;margin-bottom:5px">&#9889;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">Original PMA Approval</div>
            </div>
            <div class="ms-chevron" id="ms1-ch" style="color:#A100FF">&#9660;</div>
          </div>
          <div class="ms-body" id="ms1">
            <div style="font-size:10px;color:#555;line-height:1.65;margin-bottom:12px;padding-top:12px">Micra VR (MC1VR01) ‚Äî world's first FDA-approved leadless transcatheter pacemaker. Single-chamber VVI(R) pacing. MICRA-I trial: 726 patients, 99.2% success rate, 48% fewer major complications vs transvenous controls (NEJM 2016). Expedited review pathway.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(161,0,255,.1);color:#A100FF;border:1px solid rgba(161,0,255,.25)">ORIGINAL PMA</span>
              <span class="ms-tag" style="color:#333;border:1px solid #1f1f1f">PNJ ¬∑ VVI(R)</span>
            </div>
          </div>
        </div>

        <!-- M2: 2018 -->
        <div class="ms-card" style="background:#0d0d0d;border:1px solid #222;border-top:2px solid #CC33FF">
          <div class="ms-header" onclick="toggleMs('ms2',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#CC33FF;letter-spacing:.15em;margin-bottom:6px">2017 ‚Äì 2018</div>
              <div style="font-size:13px;margin-bottom:5px">&#129522;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">MRI Conditionality</div>
            </div>
            <div class="ms-chevron" id="ms2-ch" style="color:#CC33FF">&#9660;</div>
          </div>
          <div class="ms-body" id="ms2">
            <div style="font-size:10px;color:#555;line-height:1.65;margin-bottom:12px;padding-top:12px">Full-body MRI labeling at 1.5T &amp; 3T. Supplement ~S018‚ÄìS022. MRI study: 272 patients ‚Äî zero device-related adverse events post-scan. Removed the largest formulary objection at academic medical centers. &gt;50% of PM patients require MRI during device lifetime.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(204,51,255,.1);color:#CC33FF;border:1px solid rgba(204,51,255,.25)">180-DAY SUPP</span>
              <span class="ms-tag" style="color:#333;border:1px solid #1f1f1f">LABEL EXPANSION</span>
            </div>
          </div>
        </div>

        <!-- M3: 2020 MAJOR -->
        <div class="ms-card" style="background:#0f0020;border:1px solid #5500CC;border-top:2px solid #fff">
          <div class="ms-header" onclick="toggleMs('ms3',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.15em;margin-bottom:6px">JAN 2020</div>
              <div style="font-size:13px;margin-bottom:5px">&#127942;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">Micra AV ‚Äî Panel Track</div>
            </div>
            <div class="ms-chevron" id="ms3-ch" style="color:#A100FF">&#9660;</div>
          </div>
          <div class="ms-body" id="ms3">
            <div style="font-size:10px;color:#7a6aaa;line-height:1.65;margin-bottom:12px;padding-top:12px">S061 ‚Äî MC1AVR1. World's first leadless AV synchrony pacemaker via accelerometer sensing. MARVEL 2: 89.2% AV synchrony vs 20% VVI. AdComm 14‚Äì0 unanimous. Opens AV block ‚Äî 60‚Äì70% of all new pacemaker implants. 3-year indication exclusivity window vs Abbott.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(161,0,255,.2);color:#fff;border:1px solid rgba(161,0,255,.45)">‚òÖ PANEL TRACK ¬∑ S061</span>
              <span class="ms-tag" style="color:#A100FF;border:1px solid rgba(161,0,255,.3)">NEW IND ¬∑ VDD</span>
            </div>
          </div>
        </div>

        <!-- M4: 2023 MAJOR -->
        <div class="ms-card" style="background:#120008;border:1px solid #8B0050;border-top:2px solid #fff">
          <div class="ms-header" onclick="toggleMs('ms4',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#E91E8C;letter-spacing:.15em;margin-bottom:6px">MAY 2023</div>
              <div style="font-size:13px;margin-bottom:5px">&#128640;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">Micra AV2 &amp; VR2 ‚Äî Panel Track</div>
            </div>
            <div class="ms-chevron" id="ms4-ch" style="color:#E91E8C">&#9660;</div>
          </div>
          <div class="ms-body" id="ms4">
            <div style="font-size:10px;color:#7a4060;line-height:1.65;margin-bottom:12px;padding-top:12px">S152 ‚Äî MC2AVR1 / MC2VR01 Gen 2. +40% battery longevity. Redesigned auto-AV sync algorithm (+7% vs Gen 1). &gt;80% device-for-life claim. Launched Q2 2023 ‚Äî same quarter as Abbott Aveir DR. Longevity + install base (250K+) as primary differentiation against dual-leadless competitor.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(233,30,140,.2);color:#fff;border:1px solid rgba(233,30,140,.45)">‚òÖ PANEL TRACK ¬∑ S152</span>
              <span class="ms-tag" style="color:#E91E8C;border:1px solid rgba(233,30,140,.3)">GEN 2 ¬∑ +40% LIFE</span>
            </div>
          </div>
        </div>

        <!-- M5: 2025 -->
        <div class="ms-card" style="background:#0d0d0d;border:1px solid #222;border-top:2px solid #FF6B00">
          <div class="ms-header" onclick="toggleMs('ms5',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#FF6B00;letter-spacing:.15em;margin-bottom:6px">2025 ¬∑ PRESENT</div>
              <div style="font-size:13px;margin-bottom:5px">&#128202;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">217 Supplements</div>
            </div>
            <div class="ms-chevron" id="ms5-ch" style="color:#FF6B00">&#9660;</div>
          </div>
          <div class="ms-body" id="ms5">
            <div style="font-size:10px;color:#555;line-height:1.65;margin-bottom:12px;padding-top:12px">9 years ¬∑ 5 supplement categories ¬∑ 4 device models ¬∑ 2 generations ¬∑ ~24 supps/yr. Deepest regulatory record in leadless pacing. MDT rate: 3.4√ó Abbott's. Tab 3 projects 22‚Äì26 supps in 2025‚Äì2026. Next predicted: hermetic seal (69%), SW telemetry drift (72%).</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(255,107,0,.1);color:#FF6B00;border:1px solid rgba(255,107,0,.25)">217 TOTAL ¬∑ LIVE</span>
              <span class="ms-tag" style="color:#333;border:1px solid #1f1f1f">openFDA API</span>
            </div>
          </div>
        </div>

      </div>

      <!-- Bottom stat strip -->
      <div style="margin-top:24px;padding-top:18px;border-top:1px solid #161616;display:grid;grid-template-columns:repeat(4,1fr);gap:0">
        <div style="text-align:center;padding:12px;border-right:1px solid #161616">
          <div style="font-family:monospace;font-size:22px;font-weight:700;color:#A100FF;line-height:1">9</div>
          <div style="font-size:9px;color:#333;font-family:monospace;letter-spacing:.1em;margin-top:4px">YEARS ON MARKET</div>
        </div>
        <div style="text-align:center;padding:12px;border-right:1px solid #161616">
          <div style="font-family:monospace;font-size:22px;font-weight:700;color:#CC33FF;line-height:1">2</div>
          <div style="font-size:9px;color:#333;font-family:monospace;letter-spacing:.1em;margin-top:4px">PANEL TRACK EVENTS</div>
        </div>
        <div style="text-align:center;padding:12px;border-right:1px solid #161616">
          <div style="font-family:monospace;font-size:22px;font-weight:700;color:#E91E8C;line-height:1">4</div>
          <div style="font-size:9px;color:#333;font-family:monospace;letter-spacing:.1em;margin-top:4px">DEVICE GENERATIONS</div>
        </div>
        <div style="text-align:center;padding:12px">
          <div style="font-family:monospace;font-size:22px;font-weight:700;color:#FF6B00;line-height:1">217</div>
          <div style="font-size:9px;color:#333;font-family:monospace;letter-spacing:.1em;margin-top:4px">TOTAL SUPPLEMENTS</div>
        </div>
      </div>

      <!-- ‚îÄ‚îÄ MILESTONE DETAIL TABLE ‚îÄ‚îÄ -->
      <div style="margin-top:32px">
        <!-- Lightweight inline expander -->
        <div style="display:flex;align-items:center;gap:14px;margin-bottom:20px">
          <div style="flex:1;height:1px;background:#1c1c1c"></div>
          <button onclick="toggleMilestoneDetail()"
            style="display:inline-flex;align-items:center;gap:8px;background:none;border:none;cursor:pointer;padding:0;outline:none;user-select:none">
            <span id="mdChevron" style="font-family:monospace;font-size:9px;color:#3d3d3d;letter-spacing:.02em;transition:color .15s">‚ñ∏</span>
            <span id="mdLabel" style="font-family:monospace;font-size:9px;color:#3d3d3d;letter-spacing:.16em;text-transform:uppercase;transition:color .15s">Milestone Intelligence Detail</span>
            <span style="font-family:monospace;font-size:7px;color:#252525;letter-spacing:.14em;text-transform:uppercase">Regulatory ¬∑ Clinical ¬∑ Strategic</span>
          </button>
          <div style="flex:1;height:1px;background:#1c1c1c"></div>
        </div>
        <script>
          // Hover states for the lightweight toggle
          (function(){
            var btn = document.currentScript.previousElementSibling.querySelector('button');
            if (!btn) return;
            btn.addEventListener('mouseenter', function() {
              var ch = document.getElementById('mdChevron');
              var lb = document.getElementById('mdLabel');
              if (ch) ch.style.color = '#8855CC';
              if (lb) lb.style.color = '#8855CC';
            });
            btn.addEventListener('mouseleave', function() {
              var open = document.getElementById('mdBody') && document.getElementById('mdBody').style.display !== 'none';
              var col = open ? '#9966CC' : '#3d3d3d';
              var ch = document.getElementById('mdChevron');
              var lb = document.getElementById('mdLabel');
              if (ch) ch.style.color = col;
              if (lb) lb.style.color = col;
            });
          })();
        </script>
        <div id="mdBody" style="display:none">
        <div style="display:none"></div>

        <!-- Column headers -->
        <div style="display:grid;grid-template-columns:1fr 1fr;gap:0;border:1px solid #1a1a1a;border-radius:8px;overflow:hidden">
          <div style="padding:10px 20px;background:#0f0f0f;border-right:1px solid #1a1a1a;border-bottom:1px solid #1a1a1a">
            <span style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.18em;text-transform:uppercase">HIGH LEVEL ¬∑ Regulatory Event &amp; Market Significance</span>
          </div>
          <div style="padding:10px 20px;background:#0f0f0f;border-bottom:1px solid #1a1a1a">
            <span style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.18em;text-transform:uppercase">DETAIL ¬∑ Clinical Evidence ¬∑ Supplement Data ¬∑ Strategic Impact</span>
          </div>

          <!-- ‚îÄ‚îÄ‚îÄ ROW 1: 2016 Original PMA ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ -->
          <div style="padding:22px 20px;border-right:1px solid #1a1a1a;border-bottom:1px solid #111;background:#0a0a0a;position:relative">
            <div style="position:absolute;left:0;top:0;bottom:0;width:3px;background:#A100FF;border-radius:3px 0 0 3px"></div>
            <div style="display:flex;align-items:center;gap:10px;margin-bottom:12px">
              <div style="font-family:monospace;font-size:10px;font-weight:700;color:#A100FF;background:rgba(161,0,255,.12);border:1px solid rgba(161,0,255,.3);border-radius:4px;padding:3px 10px;white-space:nowrap">APR 6, 2016</div>
              <div style="font-size:14px;font-weight:700;color:#fff">Original PMA Approval</div>
            </div>
            <div style="font-size:12px;color:#cbd5e1;line-height:1.6;margin-bottom:14px">The FDA granted original approval to Medtronic's Micra‚Ñ¢ Transcatheter Pacemaker System ‚Äî the world's first commercially approved leadless cardiac pacemaker. This approval represented a paradigm shift from conventional transvenous pacing, eliminating leads, pockets, and their associated complications.</div>
            <div style="display:flex;gap:8px;flex-wrap:wrap">
              <span style="font-family:monospace;font-size:8px;background:rgba(161,0,255,.12);color:#A100FF;border:1px solid rgba(161,0,255,.25);border-radius:3px;padding:2px 8px">ORIGINAL PMA</span>
              <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #222;border-radius:3px;padding:2px 8px">SINGLE-CHAMBER VVI(R)</span>
              <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #222;border-radius:3px;padding:2px 8px">EXPEDITED REVIEW</span>
            </div>
          </div>
          <div style="padding:22px 24px;border-bottom:1px solid #111;background:#0a0a0a;display:flex;flex-direction:column;gap:16px">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">CLINICAL TRIAL</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">MICRA-I IDE trial ¬∑ 726 patients ¬∑ 54 sites globally ¬∑ Primary endpoint: pacing threshold ‚â§2V at 0.24ms + sensing ‚â•5mV ¬∑ 99.2% success rate ¬∑ 48% lower major complication rate vs historical transvenous controls (NEJM 2016)</div>
            </div>
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">REGULATORY PATH</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">PMA P150033 ¬∑ Product Code PNJ ¬∑ Advisory Panel convened Nov 2015 ¬∑ 7-2 favorable vote ¬∑ De Novo pathway considered and rejected ¬∑ Full PMA required given Class III novelty ¬∑ Breakthrough Device pathway predecessor (IDE G130257)</div>
            </div>
            <div style="padding:12px 16px;background:#111;border-radius:6px;border-left:2px solid rgba(161,0,255,.4)">
              <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.12em;margin-bottom:5px">STRATEGIC SIGNIFICANCE</div>
              <div style="font-size:11px;color:#64748b;line-height:1.7">First-mover advantage established in a zero-competition market. 6-year head start over Abbott Aveir. Early hospital formulary penetration locked in ~250K implants by 2023. Platform approval enables all subsequent label expansions and supplement architecture.</div>
            </div>
          </div>

          <!-- ‚îÄ‚îÄ‚îÄ ROW 2: 2018 MRI Expansion ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ -->
          <div style="padding:22px 20px;border-right:1px solid #1a1a1a;border-bottom:1px solid #111;background:#080808;position:relative">
            <div style="position:absolute;left:0;top:0;bottom:0;width:3px;background:#CC33FF;border-radius:3px 0 0 3px"></div>
            <div style="display:flex;align-items:center;gap:10px;margin-bottom:12px">
              <div style="font-family:monospace;font-size:10px;font-weight:700;color:#CC33FF;background:rgba(204,51,255,.1);border:1px solid rgba(204,51,255,.3);border-radius:4px;padding:3px 10px;white-space:nowrap">2017‚Äì2018</div>
              <div style="font-size:14px;font-weight:700;color:#fff">MRI Conditionality Expansion</div>
            </div>
            <div style="font-size:12px;color:#cbd5e1;line-height:1.6;margin-bottom:14px">Full-body MRI labeling approval at both 1.5T and 3T field strengths ‚Äî removing one of the most significant contraindications in early leadless pacing. Critical for hospital formulary adoption, as over 50% of pacemaker-eligible patients will require MRI imaging during their device lifetime.</div>
            <div style="display:flex;gap:8px;flex-wrap:wrap">
              <span style="font-family:monospace;font-size:8px;background:rgba(204,51,255,.1);color:#CC33FF;border:1px solid rgba(204,51,255,.25);border-radius:3px;padding:2px 8px">180-DAY SUPP ~S018‚ÄìS022</span>
              <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #222;border-radius:3px;padding:2px 8px">LABELING + SW CO-SUPPLEMENT</span>
            </div>
          </div>
          <div style="padding:22px 24px;border-bottom:1px solid #111;background:#080808;display:flex;flex-direction:column;gap:16px">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">CLINICAL EVIDENCE</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">Micra MRI study: 272 patients ¬∑ MRI scans at 1.5T and 3T ¬∑ Zero device failures or adverse events attributed to MRI exposure ¬∑ Pacing threshold, sensing amplitude, and impedance all within pre-defined safety margins post-scan</div>
            </div>
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">SUPPLEMENT DETAIL</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">Concurrent labeling supplement + software supplement required. IFU revised to add MRI scanning instructions, conditional use parameters, and patient screening criteria. Programmer update required for MRI mode activation. ~5 supplements bundled across 14 months.</div>
            </div>
            <div style="padding:12px 16px;background:#111;border-radius:6px;border-left:2px solid rgba(204,51,255,.35)">
              <div style="font-family:monospace;font-size:8px;color:#CC33FF;letter-spacing:.12em;margin-bottom:5px">STRATEGIC SIGNIFICANCE</div>
              <div style="font-size:11px;color:#64748b;line-height:1.7">Removed the single largest formulary objection at major academic medical centers. Enabled unrestricted patient selection at institutions with high MRI utilization rates (oncology, neurology, orthopedics). Abbott Aveir launched with MRI conditionality pre-built ‚Äî MDT's early expansion set the precedent.</div>
            </div>
          </div>

          <!-- ‚îÄ‚îÄ‚îÄ ROW 3: 2020 Micra AV Panel Track ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ -->
          <div style="padding:22px 20px;border-right:1px solid #1a1a1a;border-bottom:1px solid #111;background:#0d001a;position:relative">
            <div style="position:absolute;left:0;top:0;bottom:0;width:3px;background:#A100FF"></div>
            <div style="position:absolute;top:16px;right:16px;font-family:monospace;font-size:8px;color:#A100FF;background:rgba(161,0,255,.15);border:1px solid rgba(161,0,255,.35);border-radius:3px;padding:2px 7px">‚òÖ MAJOR</div>
            <div style="display:flex;align-items:center;gap:10px;margin-bottom:12px">
              <div style="font-family:monospace;font-size:10px;font-weight:700;color:#fff;background:#A100FF;border-radius:4px;padding:3px 10px;white-space:nowrap">JAN 2020</div>
              <div style="font-size:14px;font-weight:700;color:#fff">Micra AV ‚Äî Panel Track Approval</div>
            </div>
            <div style="font-size:12px;color:#cbd5e1;line-height:1.6;margin-bottom:14px">The single largest regulatory event in Micra's post-approval history. S061 unlocked a new device model (MC1AVR1) with accelerometer-based AV synchrony ‚Äî expanding indication from single-chamber VVI(R) to dual-chamber VDD functionality without a second lead. Opened the largest treatable pacemaker population: AV block.</div>
            <div style="display:flex;gap:8px;flex-wrap:wrap">
              <span style="font-family:monospace;font-size:8px;background:rgba(161,0,255,.25);color:#fff;border:1px solid rgba(161,0,255,.5);border-radius:3px;padding:2px 8px">PANEL TRACK ¬∑ S061</span>
              <span style="font-family:monospace;font-size:8px;color:#A100FF;border:1px solid rgba(161,0,255,.3);border-radius:3px;padding:2px 8px">NEW DEVICE MODEL ¬∑ MC1AVR1</span>
              <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #222;border-radius:3px;padding:2px 8px">NEW INDICATION ¬∑ VDD</span>
            </div>
          </div>
          <div style="padding:22px 24px;border-bottom:1px solid #111;background:#0d001a;display:flex;flex-direction:column;gap:16px">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">CLINICAL TRIAL</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">MARVEL 2 study ¬∑ 75 patients implanted with Micra AV ¬∑ Primary endpoint: AV synchrony ‚â•70% during follow-up ¬∑ Result: 89.2% AV synchrony achieved vs 20% in VVI mode ¬∑ Presented HRS 2019 ¬∑ Published JACC 2020 ¬∑ AdComm Nov 2019: 14-0 favorable vote</div>
            </div>
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">PANEL TRACK REQUIREMENTS</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">New device model required full PMA supplement Panel Track review. Separate IDE (G170257) for pivotal trial. New IFU, revised patient selection criteria, new programmer algorithm, accelerometer-specific safety testing under ISO 14708-2. Total cycle time: ~18 months from IDE to approval.</div>
            </div>
            <div style="padding:12px 16px;background:#150025;border-radius:6px;border-left:2px solid rgba(161,0,255,.5)">
              <div style="font-family:monospace;font-size:8px;color:#A100FF;letter-spacing:.12em;margin-bottom:5px">STRATEGIC SIGNIFICANCE</div>
              <div style="font-size:11px;color:#7a6a9a;line-height:1.7">AV block represents 60‚Äì70% of all new pacemaker implants globally. This approval expanded Micra's addressable market by an estimated 3‚Äì4√ó overnight. No competitor offered a leadless VDD option until Abbott Aveir AV in 2023 ‚Äî a 3-year window of exclusivity in the largest pacing indication.</div>
            </div>
          </div>

          <!-- ‚îÄ‚îÄ‚îÄ ROW 4: 2023 Micra AV2 Panel Track ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ -->
          <div style="padding:22px 20px;border-right:1px solid #1a1a1a;border-bottom:1px solid #111;background:#0e000a;position:relative">
            <div style="position:absolute;left:0;top:0;bottom:0;width:3px;background:#E91E8C"></div>
            <div style="position:absolute;top:16px;right:16px;font-family:monospace;font-size:8px;color:#E91E8C;background:rgba(233,30,140,.15);border:1px solid rgba(233,30,140,.35);border-radius:3px;padding:2px 7px">‚òÖ MAJOR</div>
            <div style="display:flex;align-items:center;gap:10px;margin-bottom:12px">
              <div style="font-family:monospace;font-size:10px;font-weight:700;color:#fff;background:#E91E8C;border-radius:4px;padding:3px 10px;white-space:nowrap">MAY 2023</div>
              <div style="font-size:14px;font-weight:700;color:#fff">Micra AV2 &amp; VR2 ‚Äî Panel Track</div>
            </div>
            <div style="font-size:12px;color:#cbd5e1;line-height:1.6;margin-bottom:14px">Second-generation platform approval via Panel Track (S152). Introduced two new device models (MC2AVR1 / MC2VR01) with 40% extended battery longevity, redesigned automatic AV synchrony algorithm, and enhanced sensing. Launched the same quarter as Abbott Aveir DR ‚Äî MDT's direct competitive response to the dual-chamber threat.</div>
            <div style="display:flex;gap:8px;flex-wrap:wrap">
              <span style="font-family:monospace;font-size:8px;background:rgba(233,30,140,.2);color:#fff;border:1px solid rgba(233,30,140,.5);border-radius:3px;padding:2px 8px">PANEL TRACK ¬∑ S152</span>
              <span style="font-family:monospace;font-size:8px;color:#E91E8C;border:1px solid rgba(233,30,140,.3);border-radius:3px;padding:2px 8px">GEN 2 ¬∑ MC2AVR1 / MC2VR01</span>
              <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #222;border-radius:3px;padding:2px 8px">+40% LONGEVITY CLAIM</span>
            </div>
          </div>
          <div style="padding:22px 24px;border-bottom:1px solid #111;background:#0e000a;display:flex;flex-direction:column;gap:16px">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">CLINICAL &amp; BENCH EVIDENCE</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">MARVEL 2 extended follow-up (3yr) ¬∑ Longevity validation: accelerated aging bench testing per ISO 14708 ¬∑ &gt;80% device-for-life claim at typical pacing outputs ¬∑ Auto-AV synchrony algorithm improvements: 7% incremental gain in synchrony rate vs Gen 1 ¬∑ JACC EP 2023 publication</div>
            </div>
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">COMPETITIVE CONTEXT</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">Abbott Aveir DR received PMA approval March 2023 ‚Äî first dual-chamber true leadless system. MDT's AV2 approval in May 2023 maintained narrative parity despite architectural difference (single leadless VDD vs dual-leadless DDR). Longevity claim and established install base became MDT's primary differentiation axes.</div>
            </div>
            <div style="padding:12px 16px;background:#140009;border-radius:6px;border-left:2px solid rgba(233,30,140,.45)">
              <div style="font-family:monospace;font-size:8px;color:#E91E8C;letter-spacing:.12em;margin-bottom:5px">STRATEGIC SIGNIFICANCE</div>
              <div style="font-size:11px;color:#6a4050;line-height:1.7">The 40% longevity improvement resets the device-for-life calculus in favor of MDT for older, higher-risk patients where repeat procedures carry elevated mortality risk. Positions MDT to hold high-acuity accounts against Abbott's DR claim while the 250K+ install base creates upgrade pull-through in existing Micra centers.</div>
            </div>
          </div>

          <!-- ‚îÄ‚îÄ‚îÄ ROW 5: 2025 Present State ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ -->
          <div style="padding:22px 20px;border-right:1px solid #1a1a1a;background:#080808;position:relative">
            <div style="position:absolute;left:0;top:0;bottom:0;width:3px;background:#FF6B00;border-radius:3px 0 0 3px"></div>
            <div style="display:flex;align-items:center;gap:10px;margin-bottom:12px">
              <div style="font-family:monospace;font-size:10px;font-weight:700;color:#FF6B00;background:rgba(255,107,0,.12);border:1px solid rgba(255,107,0,.3);border-radius:4px;padding:3px 10px;white-space:nowrap">2025 ¬∑ PRESENT</div>
              <div style="font-size:14px;font-weight:700;color:#fff">Platform Maturity ‚Äî 217 Supplements</div>
            </div>
            <div style="font-size:12px;color:#cbd5e1;line-height:1.6;margin-bottom:14px">P150033 is now the deepest regulatory record in the leadless pacing category ‚Äî 217 approved supplements across 9 years spanning 5 supplement types, 4 device models, and 2 full generations. MDT has maintained ~24 supplements/year as a sustainable regulatory cadence, reflecting a mature, commercially optimized post-approval program.</div>
            <div style="display:flex;gap:8px;flex-wrap:wrap">
              <span style="font-family:monospace;font-size:8px;background:rgba(255,107,0,.1);color:#FF6B00;border:1px solid rgba(255,107,0,.25);border-radius:3px;padding:2px 8px">217 SUPPS TOTAL</span>
              <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #222;border-radius:3px;padding:2px 8px">~24/YEAR AVERAGE</span>
              <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #222;border-radius:3px;padding:2px 8px">LIVE ¬∑ openFDA API</span>
            </div>
          </div>
          <div style="padding:22px 24px;background:#080808;display:flex;flex-direction:column;gap:16px">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">SUPPLEMENT BREAKDOWN</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">Manufacturing Changes: 85 (39%) ¬∑ Software Updates: 58 (27%) ¬∑ Design Changes: 37 (17%) ¬∑ Labeling: 23 (11%) ¬∑ Panel Track: 2 (&lt;1%) ¬∑ Remaining: miscellaneous post-approval commitments ¬∑ 4 supplement types averaging &gt;20 filings/year each</div>
            </div>
            <div>
              <div style="font-family:monospace;font-size:8px;color:#475569;letter-spacing:.14em;margin-bottom:6px">COMPETITIVE POSITION (2025)</div>
              <div style="font-size:11px;color:#94a3b8;line-height:1.7">MDT: 217 supplements ¬∑ 9 years ¬∑ Abbott Aveir: ~22 supplements ¬∑ 3 years ¬∑ BSX EMPOWER: 0 supplements ¬∑ pending FDA ¬∑ MDT filing rate: 24/yr vs ABT ~7/yr ¬∑ MDT cumulative regulatory depth = 3.4√ó ABT ¬∑ BSX approval probability: 67% (Tab 3 forecast)</div>
            </div>
            <div style="padding:12px 16px;background:#111;border-radius:6px;border-left:2px solid rgba(255,107,0,.35)">
              <div style="font-family:monospace;font-size:8px;color:#FF6B00;letter-spacing:.12em;margin-bottom:5px">FORWARD OUTLOOK</div>
              <div style="font-size:11px;color:#64748b;line-height:1.7">Tab 3 Predictive Intelligence projects 22‚Äì26 supplements in 2025‚Äì2026. Top predicted events: hermetic seal micro-leak supplement (69%), algorithm telemetry drift SW update (72%), and a third Panel Track for conduction system pacing indication expansion. BSX entry expected to compress MDT market share by 8‚Äì12% in new implant volume by 2027.</div>
            </div>
          </div>

        </div><!-- /detail table -->
        </div><!-- /mdBody -->
      </div>

    </div>
  </div>

  </div><!-- /sec-wrap-5 -->

  </div><!-- /tab-micra -->

  <!-- ‚ïê‚ïê TAB 2: COMPETITOR ANALYSIS ‚ïê‚ïê -->
  <div class="tab-panel" id="tab-competitor">

    <!-- Competitor Header -->
    <div style="margin-bottom:28px">
      <div style="font-size:clamp(16px,2vw,22px);font-weight:700;color:#f1f5f9;margin-bottom:6px">Leadless Pacemaker ¬∑ Competitive Landscape</div>
      <div style="font-size:12px;color:#64748b;font-family:monospace">Medtronic Micra ¬∑ Abbott Aveir ¬∑ Boston Scientific EMPOWER ¬∑ FDA PMA Regulatory Comparison</div>
    </div>

    <!-- ‚îÄ‚îÄ‚îÄ KEY METRICS COMPARISON ‚îÄ‚îÄ‚îÄ -->
    <!-- ‚îÄ‚îÄ‚îÄ HORIZONTAL KEY METRICS COMPARISON ‚îÄ‚îÄ‚îÄ -->
    <div class="sec-lbl" style="margin-bottom:16px">A ¬∑ MEDTRONIC vs ABBOTT ‚Äî 5 KEY METRICS COMPARISON</div>
    <div class="hcc-wrap">
      <div class="hcc-legend">
        <div class="hcc-legend-item">
          <div class="hcc-legend-swatch" style="background:#A100FF;box-shadow:0 0 6px rgba(161,0,255,.4)"></div>
          <div><div class="hcc-legend-name" style="color:#A100FF">MEDTRONIC</div><div style="font-size:9px;opacity:.6">Micra&#8482; TPS ¬∑ Approved Apr 2016</div></div>
        </div>
        <div class="hcc-legend-item">
          <div class="hcc-legend-swatch" style="background:#00BEFF;box-shadow:0 0 6px rgba(0,190,255,.4)"></div>
          <div><div class="hcc-legend-name" style="color:#00BEFF">ABBOTT</div><div style="font-size:9px;opacity:.6">Aveir&#8482; VR/DR ¬∑ Approved Mar 2022</div></div>
        </div>
      </div>
      <div class="hcc-divider"></div>
      <!-- M1 -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">METRIC 01</div><div class="hcc-metric-name">Years on<br>Market</div><div class="hcc-metric-unit">Since FDA Approval</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt" data-w="100%"><div class="hcc-bubble mdt">9 yrs</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00BEFF">ABT</div><div class="hcc-track"><div class="hcc-fill hcc-abb" data-w="33.3%"><div class="hcc-bubble abb">3 yrs</div></div></div></div>
          <div class="hcc-delta">DIFFERENTIAL &nbsp;<span class="hcc-ratio">MDT √ó3.0 longer market presence</span>&nbsp;¬∑&nbsp;2016 vs 2022 FDA Approval</div>
        </div>
      </div>
      <!-- M2 -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">METRIC 02</div><div class="hcc-metric-name">Total PMA<br>Supplements</div><div class="hcc-metric-unit">All Approved Types</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt" data-w="100%"><div class="hcc-bubble mdt">217</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00BEFF">ABT</div><div class="hcc-track"><div class="hcc-fill hcc-abb" data-w="10.1%"><div class="hcc-bubble abb">~22</div></div></div></div>
          <div class="hcc-delta">DIFFERENTIAL &nbsp;<span class="hcc-ratio">MDT √ó9.9 more supplements</span>&nbsp;¬∑&nbsp;Rate: MDT ~24/yr vs ABT ~7/yr</div>
        </div>
      </div>
      <!-- M3 -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">METRIC 03</div><div class="hcc-metric-name">Clinical<br>Trials</div><div class="hcc-metric-unit">Major Published Studies</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt" data-w="100%"><div class="hcc-bubble mdt">8</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00BEFF">ABT</div><div class="hcc-track"><div class="hcc-fill hcc-abb" data-w="37.5%"><div class="hcc-bubble abb">3</div></div></div></div>
          <div class="hcc-delta">DIFFERENTIAL &nbsp;<span class="hcc-ratio">MDT √ó2.7 more studies</span>&nbsp;¬∑&nbsp;MICRA I/II, MARVEL 1/2, LEADLESS II, AVEIR DR i2i</div>
        </div>
      </div>
      <!-- M4 -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">METRIC 04</div><div class="hcc-metric-name">Software<br>Supplements</div><div class="hcc-metric-unit">Algorithm &amp; SW (180-Day)</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt" data-w="100%"><div class="hcc-bubble mdt">42</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00BEFF">ABT</div><div class="hcc-track"><div class="hcc-fill hcc-abb" data-w="9.5%"><div class="hcc-bubble abb">~4</div></div></div></div>
          <div class="hcc-delta">DIFFERENTIAL &nbsp;<span class="hcc-ratio">MDT √ó10.5 more SW updates</span>&nbsp;¬∑&nbsp;MDT 19% of portfolio vs ABT 18%</div>
        </div>
      </div>
      <!-- M5 -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">METRIC 05</div><div class="hcc-metric-name">Adverse Events<br>Reported</div><div class="hcc-metric-unit">MAUDE ¬∑ FDA MDR</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt" data-w="100%"><div class="hcc-bubble mdt">~2,847</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00BEFF">ABT</div><div class="hcc-track"><div class="hcc-fill hcc-abb" data-w="6.3%"><div class="hcc-bubble abb">~180</div></div></div></div>
          <div class="hcc-delta">DIFFERENTIAL &nbsp;<span class="hcc-ratio">Proportional to implant volume ‚Äî &gt;250K MDT vs ~40K ABT</span></div>
        </div>
      </div>
      <!-- Insight Cards -->
      <div class="hcc-insights">
        <div class="hcc-ins-card ic-mdt"><div class="hcc-ins-lbl">Market Maturity</div><div class="hcc-ins-txt"><strong>9-Year Lead</strong><br>Medtronic entrenched with &gt;250K cumulative implants globally</div></div>
        <div class="hcc-ins-card ic-abb"><div class="hcc-ins-lbl">Abbott Advantage</div><div class="hcc-ins-txt"><strong>Dual-Chamber</strong><br>First-to-market DR system (2023) opens majority AV block indication</div></div>
        <div class="hcc-ins-card ic-neu"><div class="hcc-ins-lbl">R&amp;D Velocity</div><div class="hcc-ins-txt"><strong>~24 vs ~7 /yr</strong><br>MDT supplement rate reflects deeper manufacturing &amp; SW pipeline</div></div>
        <div class="hcc-ins-card ic-mdt"><div class="hcc-ins-lbl">Clinical Evidence</div><div class="hcc-ins-txt"><strong>8 vs 3 Trials</strong><br>MDT evidence spans VR, AV, MRI conditionality &amp; longevity</div></div>
        <div class="hcc-ins-card ic-abb"><div class="hcc-ins-lbl">Safety Profile</div><div class="hcc-ins-txt"><strong>Lower MDR Count</strong><br>ABT lower AE count reflects early market life, not superior safety per se</div></div>
      </div>
    </div><!-- /hcc-wrap -->

    <!-- ‚îÄ‚îÄ‚îÄ DEVICE SPECS ‚îÄ‚îÄ‚îÄ -->
    <div class="sec-lbl" style="margin-bottom:16px">B ¬∑ DEVICE SPECIFICATIONS ‚Äî HEAD-TO-HEAD COMPARISON</div>
    <div class="comp-metric-grid">

      <!-- Medtronic -->
      <div class="comp-card" style="border-color:#2D0066">
        <div class="comp-card-hdr">
          <div class="comp-logo" style="background:#2D0066;color:#A100FF">MDT</div>
          <div>
            <div class="comp-name" style="color:#A100FF">Medtronic</div>
            <div class="comp-product">Micra‚Ñ¢ TPS ¬∑ P150033</div>
          </div>
          <span class="status-badge" style="margin-left:auto;background:#001a0a;color:#00E676;border:1px solid #00AA55">APPROVED</span>
        </div>
        <div class="comp-row"><span class="comp-key">Device</span><span class="comp-val">Micra VR / AV / AV2 / VR2</span></div>
        <div class="comp-row"><span class="comp-key">First Approval</span><span class="comp-val" style="color:#A100FF;font-weight:700">April 6, 2016</span></div>
        <div class="comp-row"><span class="comp-key">Market Experience</span><span class="comp-val" style="color:#00E676">~9 years (pioneer)</span></div>
        <div class="comp-row"><span class="comp-key">PMA Number</span><span class="comp-val">P150033</span></div>
        <div class="comp-row"><span class="comp-key">Total Supplements</span><span class="comp-val" style="color:#A100FF;font-weight:700;font-size:16px">217</span></div>
        <div class="comp-row"><span class="comp-key">Panel Track (Major)</span><span class="comp-val">2 (Micra AV 2020, AV2 2023)</span></div>
        <div class="comp-row"><span class="comp-key">Fixation</span><span class="comp-val">Nitinol tines (non-retrievable)</span></div>
        <div class="comp-row"><span class="comp-key">Pacing Modes</span><span class="comp-val">VVI(R), VDD (AV synchrony)</span></div>
        <div class="comp-row"><span class="comp-key">Communication</span><span class="comp-val">Accelerometer-based AV sync</span></div>
        <div class="comp-row"><span class="comp-key">Clinical Trial</span><span class="comp-val">MICRA-I (726 pts)</span></div>
        <div class="comp-row"><span class="comp-key">MRI Compatible</span><span class="comp-val" style="color:#00E676">Yes (1.5T / 3T)</span></div>
        <div class="comp-row"><span class="comp-key">Worldwide Implants</span><span class="comp-val">>250,000</span></div>
      </div>

      <!-- Abbott -->
      <div class="comp-card" style="border-color:#1a3a2a">
        <div class="comp-card-hdr">
          <div class="comp-logo" style="background:#1a3a2a;color:#00E5A0">ABT</div>
          <div>
            <div class="comp-name" style="color:#00E5A0">Abbott</div>
            <div class="comp-product">Aveir‚Ñ¢ VR/DR ¬∑ P150035</div>
          </div>
          <span class="status-badge" style="margin-left:auto;background:#001a0a;color:#00E676;border:1px solid #00AA55">APPROVED</span>
        </div>
        <div class="comp-row"><span class="comp-key">Device</span><span class="comp-val">Aveir VR (ventricular) + AR (atrial)</span></div>
        <div class="comp-row"><span class="comp-key">First Approval</span><span class="comp-val" style="color:#00E5A0;font-weight:700">March 31, 2022</span></div>
        <div class="comp-row"><span class="comp-key">Market Experience</span><span class="comp-val" style="color:#94a3b8">~3 years (challenger)</span></div>
        <div class="comp-row"><span class="comp-key">PMA Number</span><span class="comp-val">P150035</span></div>
        <div class="comp-row"><span class="comp-key">Total Supplements</span><span class="comp-val" style="color:#00E5A0;font-weight:700;font-size:16px">~20‚Äì25</span></div>
        <div class="comp-row"><span class="comp-key">Panel Track (Major)</span><span class="comp-val">1 (Aveir DR dual-chamber, Jul 2023)</span></div>
        <div class="comp-row"><span class="comp-key">Fixation</span><span class="comp-val" style="color:#fbbf24">Helix screw-in (retrievable)</span></div>
        <div class="comp-row"><span class="comp-key">Pacing Modes</span><span class="comp-val">VVI(R), AAI(R), DDD(R) (dual-chamber)</span></div>
        <div class="comp-row"><span class="comp-key">Communication</span><span class="comp-val">i2i‚Ñ¢ beat-to-beat wireless (blood conduction)</span></div>
        <div class="comp-row"><span class="comp-key">Clinical Trial</span><span class="comp-val">LEADLESS II (526 pts) + AVEIR DR i2i (300 pts)</span></div>
        <div class="comp-row"><span class="comp-key">MRI Compatible</span><span class="comp-val" style="color:#00E676">Yes</span></div>
        <div class="comp-row"><span class="comp-key">Unique Advantage</span><span class="comp-val" style="color:#fbbf24">World's first dual-chamber leadless (DDD)</span></div>
      </div>

      <!-- Boston Scientific -->
      <div class="comp-card" style="border-color:#1a0800;opacity:.85">
        <div class="comp-card-hdr">
          <div class="comp-logo" style="background:#1a0800;color:#FF6B00">BSX</div>
          <div>
            <div class="comp-name" style="color:#FF6B00">Boston Scientific</div>
            <div class="comp-product">EMPOWER‚Ñ¢ LP ¬∑ mCRM System</div>
          </div>
          <span class="status-badge" style="margin-left:auto;background:#1a1208;color:#FF6B00;border:1px solid #92400e">PENDING</span>
        </div>
        <div class="comp-row"><span class="comp-key">Device</span><span class="comp-val">EMPOWER LP + EMBLEM S-ICD (mCRM)</span></div>
        <div class="comp-row"><span class="comp-key">First Approval</span><span class="comp-val" style="color:#FF6B00;font-weight:700">Pending ‚Äî filed 2025</span></div>
        <div class="comp-row"><span class="comp-key">Market Experience</span><span class="comp-val" style="color:#94a3b8">Not yet on market</span></div>
        <div class="comp-row"><span class="comp-key">PMA Number</span><span class="comp-val" style="color:#64748b">TBD (IDE: G200319)</span></div>
        <div class="comp-row"><span class="comp-key">Total Supplements</span><span class="comp-val" style="color:#64748b">N/A ‚Äî not yet approved</span></div>
        <div class="comp-row"><span class="comp-key">Panel Track (Major)</span><span class="comp-val" style="color:#64748b">N/A</span></div>
        <div class="comp-row"><span class="comp-key">Fixation</span><span class="comp-val">Active fixation (retrievable)</span></div>
        <div class="comp-row"><span class="comp-key">Pacing Modes</span><span class="comp-val">VVIR standalone + ATP delivery</span></div>
        <div class="comp-row"><span class="comp-key">Communication</span><span class="comp-val">Wireless S-ICD ‚Üî LP (conducted signals)</span></div>
        <div class="comp-row"><span class="comp-key">Clinical Trial</span><span class="comp-val">MODULAR ATP (293 pts) ‚Äî NEJM 2024</span></div>
        <div class="comp-row"><span class="comp-key">MRI Compatible</span><span class="comp-val" style="color:#64748b">TBD</span></div>
        <div class="comp-row"><span class="comp-key">Unique Advantage</span><span class="comp-val" style="color:#fbbf24">Only LP with ATP + S-ICD integration</span></div>
      </div>
    </div>
    <!-- ‚îÄ‚îÄ‚îÄ SUPPLEMENT VOLUME COMPARISON ‚îÄ‚îÄ‚îÄ -->
    <div class="sec-lbl" style="margin-bottom:16px">B &middot; SUPPLEMENT VOLUME COMPARISON &mdash; YEARS ON MARKET VS. FDA ACTIVITY</div>
    <div class="hcc-wrap">
      <div class="hcc-legend">
        <div class="hcc-legend-item"><div class="hcc-legend-swatch" style="background:#A100FF;box-shadow:0 0 6px rgba(161,0,255,.4)"></div><div><div class="hcc-legend-name" style="color:#A100FF">MEDTRONIC</div><div style="font-size:9px;opacity:.6">Micra&#8482; &middot; 9yr on market</div></div></div>
        <div class="hcc-legend-item"><div class="hcc-legend-swatch" style="background:#00E5A0;box-shadow:0 0 6px rgba(0,229,160,.4)"></div><div><div class="hcc-legend-name" style="color:#00E5A0">ABBOTT</div><div style="font-size:9px;opacity:.6">Aveir&#8482; &middot; 3yr on market</div></div></div>
        <div class="hcc-legend-item"><div class="hcc-legend-swatch" style="background:#FF6B00;opacity:.7"></div><div><div class="hcc-legend-name" style="color:#FF6B00;opacity:.8">BSX</div><div style="font-size:9px;opacity:.5">EMPOWER&#8482; &middot; Pending</div></div></div>
      </div>
      <div style="height:1px;background:linear-gradient(90deg,#A100FF,#00E5A0,#FF6B00);opacity:.3;margin:14px 0 20px"></div>
      <div style="font-size:9px;color:#444;font-family:monospace;letter-spacing:.1em;margin-bottom:20px">POST-APPROVAL SUPPLEMENT FILINGS REFLECT R&amp;D VELOCITY, MANUFACTURING MATURITY, AND PRODUCT LINE EXPANSION</div>

      <!-- Total Supplements -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">VOLUME 01</div><div class="hcc-metric-name">Total PMA<br>Supplements</div><div class="hcc-metric-unit">All Approved Filings</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt svc-bar" data-w="100%"><div class="hcc-bubble mdt">217</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00E5A0">ABT</div><div class="hcc-track"><div class="hcc-fill svc-bar" style="background:linear-gradient(90deg,rgba(0,229,160,.1),#00E5A0);box-shadow:0 0 10px rgba(0,229,160,.2)" data-w="10.1%"><div class="hcc-bubble" style="color:#00E5A0;border-color:#00E5A0">~22</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#FF6B00;opacity:.7">BSX</div><div class="hcc-track"><div class="hcc-fill svc-bar" style="background:rgba(255,107,0,.2);border:1px dashed rgba(255,107,0,.5);box-shadow:none" data-w="0.4%"><div class="hcc-bubble" style="color:#FF6B00;border-color:#FF6B00">0</div></div></div></div>
          <div class="hcc-delta">FILING RATE &nbsp;<span class="hcc-ratio">MDT ~24/yr &middot; ABT ~7/yr &middot; BSX N/A</span>&nbsp;&middot;&nbsp;Higher rate = larger product family &amp; deeper iterative improvement</div>
        </div>
      </div>

      <!-- Years on Market -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">VOLUME 02</div><div class="hcc-metric-name">Years on<br>Market</div><div class="hcc-metric-unit">Since FDA Approval</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt svc-bar" data-w="100%"><div class="hcc-bubble mdt">9 yrs</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00E5A0">ABT</div><div class="hcc-track"><div class="hcc-fill svc-bar" style="background:linear-gradient(90deg,rgba(0,229,160,.1),#00E5A0);box-shadow:0 0 10px rgba(0,229,160,.2)" data-w="33.3%"><div class="hcc-bubble" style="color:#00E5A0;border-color:#00E5A0">3 yrs</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#FF6B00;opacity:.7">BSX</div><div class="hcc-track"><div class="hcc-fill svc-bar" style="background:rgba(255,107,0,.2);border:1px dashed rgba(255,107,0,.5);box-shadow:none" data-w="0.4%"><div class="hcc-bubble" style="color:#FF6B00;border-color:#FF6B00">PNDG</div></div></div></div>
          <div class="hcc-delta">DIFFERENTIAL &nbsp;<span class="hcc-ratio">MDT √ó3.0 longer presence</span>&nbsp;&middot;&nbsp;Apr 2016 &middot; Mar 2022 &middot; TBD</div>
        </div>
      </div>

      <!-- Annual Rate -->
      <div class="hcc-metric-block">
        <div class="hcc-label-col"><div class="hcc-metric-num">VOLUME 03</div><div class="hcc-metric-name">Annual<br>Supplement Rate</div><div class="hcc-metric-unit">Approved Filings / Year</div></div>
        <div class="hcc-bars-col">
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#A100FF">MDT</div><div class="hcc-track"><div class="hcc-fill hcc-mdt svc-bar" data-w="100%"><div class="hcc-bubble mdt">~24/yr</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#00E5A0">ABT</div><div class="hcc-track"><div class="hcc-fill svc-bar" style="background:linear-gradient(90deg,rgba(0,229,160,.1),#00E5A0);box-shadow:0 0 10px rgba(0,229,160,.2)" data-w="29.2%"><div class="hcc-bubble" style="color:#00E5A0;border-color:#00E5A0">~7/yr</div></div></div></div>
          <div class="hcc-bar-row"><div class="hcc-co-tag" style="color:#FF6B00;opacity:.7">BSX</div><div class="hcc-track"><div class="hcc-fill svc-bar" style="background:rgba(255,107,0,.2);border:1px dashed rgba(255,107,0,.5);box-shadow:none" data-w="0.4%"><div class="hcc-bubble" style="color:#FF6B00;border-color:#FF6B00">N/A</div></div></div></div>
          <div class="hcc-delta">CONTEXT &nbsp;<span class="hcc-ratio">Higher rate = deeper manufacturing maturity + larger product family</span></div>
        </div>
      </div>

    </div><!-- /hcc-wrap vol -->


    <div class="sec-lbl" style="margin-bottom:16px">C ¬∑ ABBOTT AVEIR P150035 ‚Äî SUPPLEMENT CATEGORY ANALYSIS</div>

    <div class="abb-cat-grid">
      <div class="abb-cat-card"><div style="font-size:20px;margin-bottom:6px">‚öôÔ∏è</div><div style="font-size:20px;font-weight:700;color:#00BEFF">~6</div><div style="font-size:9px;color:#64748b;margin-top:4px">Manufacturing</div></div>
      <div class="abb-cat-card"><div style="font-size:20px;margin-bottom:6px">üíª</div><div style="font-size:20px;font-weight:700;color:#CC00FF">~4</div><div style="font-size:9px;color:#64748b;margin-top:4px">Software</div></div>
      <div class="abb-cat-card"><div style="font-size:20px;margin-bottom:6px">üîß</div><div style="font-size:20px;font-weight:700;color:#00E5A0">~3</div><div style="font-size:9px;color:#64748b;margin-top:4px">Accessory</div></div>
      <div class="abb-cat-card"><div style="font-size:20px;margin-bottom:6px">üìã</div><div style="font-size:20px;font-weight:700;color:#FF6B35">~4</div><div style="font-size:9px;color:#64748b;margin-top:4px">Labeling</div></div>
      <div class="abb-cat-card"><div style="font-size:20px;margin-bottom:6px">üî¨</div><div style="font-size:20px;font-weight:700;color:#FF1744">~5</div><div style="font-size:9px;color:#64748b;margin-top:4px">Design</div></div>
    </div>

    <div class="table-box">
      <div style="font-size:11px;color:#A100FF;font-family:monospace;letter-spacing:.1em;text-transform:uppercase;margin-bottom:16px">Abbott Aveir ¬∑ Known Supplement History ¬∑ P150035</div>
      <div style="overflow-x:auto">
        <table>
          <thead>
            <tr>
              <th>Supplement</th><th>Date</th><th>Type</th><th>Category</th><th>Description</th><th>Regulatory Impact</th>
            </tr>
          </thead>
          <tbody>
            <tr style="background:transparent;border-bottom:1px solid #111111">
              <td style="color:#00E5A0;font-family:monospace;font-weight:600">Original PMA</td>
              <td style="color:#94a3b8;white-space:nowrap">Mar 31, 2022</td>
              <td><span class="badge" style="background:#001a0a;color:#00E676">ORIGINAL</span></td>
              <td style="color:#FF1744">Design</td>
              <td>Aveir VR (LSP112V) ‚Äî single-chamber leadless pacemaker. Helix fixation, retrievable design. LEADLESS II trial (526 patients).</td>
              <td style="color:#94a3b8;font-size:11px">6yr after Micra. First FDA-approved retrievable leadless pacemaker.</td>
            </tr>
            <tr style="background:#111111;border-bottom:1px solid #111111">
              <td style="color:#00E5A0;font-family:monospace;font-weight:600">~S001‚ÄìS002</td>
              <td style="color:#94a3b8;white-space:nowrap">2022</td>
              <td><span class="badge" style="background:#001a0a;color:#00E676">30-DAY</span></td>
              <td style="color:#00BEFF">Manufacturing</td>
              <td>Initial post-approval manufacturing confirmations, sterilization validation, packaging updates.</td>
              <td style="color:#94a3b8;font-size:11px">Low burden ‚Äî standard post-approval filings</td>
            </tr>
            <tr style="background:transparent;border-bottom:1px solid #111111">
              <td style="color:#00E5A0;font-family:monospace;font-weight:600">~S002‚ÄìS004</td>
              <td style="color:#94a3b8;white-space:nowrap">2022‚Äì2023</td>
              <td><span class="badge" style="background:#0a0a2a;color:#00D4FF">180-DAY</span></td>
              <td style="color:#CC00FF">Software</td>
              <td>Merlin programmer software updates (v2.x), i2i communication algorithm refinements, rate-response tuning.</td>
              <td style="color:#94a3b8;font-size:11px">Medium ‚Äî bench + software V&V</td>
            </tr>
            <tr style="background:#111111;border-bottom:1px solid #111111">
              <td style="color:#CC33FF;font-family:monospace;font-weight:600">S003 (Panel Track)</td>
              <td style="color:#94a3b8;white-space:nowrap">Jul 5, 2023</td>
              <td><span class="badge" style="background:#1a0044;color:#CC33FF">PANEL TRACK</span></td>
              <td style="color:#FF1744">Design ‚Äî New Model</td>
              <td style="color:#f1f5f9">Aveir DR Dual-Chamber System ‚Äî world's first dual-chamber leadless pacemaker. New Aveir AR atrial device. i2i beat-to-beat communication. AVEIR DR i2i Study (300 pts, NEJM 2023). DDD(R) pacing indication.</td>
              <td style="color:#CC33FF;font-size:11px">Very High ‚Äî Advisory Panel required. New indication for all major pacemaker patients.</td>
            </tr>
            <tr style="background:transparent;border-bottom:1px solid #111111">
              <td style="color:#00E5A0;font-family:monospace;font-weight:600">~S004‚ÄìS006</td>
              <td style="color:#94a3b8;white-space:nowrap">2023‚Äì2024</td>
              <td><span class="badge" style="background:#1a0800;color:#FF6B00">LABEL</span></td>
              <td style="color:#FF6B35">Labeling</td>
              <td>Aveir DR IFU updates post-approval, MRI conditionality expansion, delivery catheter labeling refinements.</td>
              <td style="color:#94a3b8;font-size:11px">High ‚Äî new indication language</td>
            </tr>
            <tr style="background:#111111;border-bottom:1px solid #111111">
              <td style="color:#00E5A0;font-family:monospace;font-weight:600">~S007‚ÄìS012</td>
              <td style="color:#94a3b8;white-space:nowrap">2023‚Äì2025</td>
              <td><span class="badge" style="background:#001a0a;color:#00E676">30-DAY</span></td>
              <td style="color:#00BEFF">Manufacturing</td>
              <td>Scale-up manufacturing for dual-chamber system, supplier qualifications, sterilization updates for Aveir AR and VR2 platforms.</td>
              <td style="color:#94a3b8;font-size:11px">Low ‚Äî operational</td>
            </tr>
            <tr style="background:transparent;border-bottom:1px solid #111111">
              <td style="color:#00E5A0;font-family:monospace;font-weight:600">~S013‚ÄìS022</td>
              <td style="color:#94a3b8;white-space:nowrap">2024‚Äì2025</td>
              <td><span class="badge" style="background:#001a0a;color:#2dd4bf">SPECIAL</span></td>
              <td style="color:#00E5A0">Accessory</td>
              <td>Next-gen delivery catheter updates, 25F introducer refinements, retrieval tool improvements, pre-fixation mapping system.</td>
              <td style="color:#94a3b8;font-size:11px">Medium ‚Äî bench testing</td>
            </tr>
          </tbody>
        </table>
      </div>
      <div style="margin-top:14px;font-size:10px;color:#334155;font-family:monospace;line-height:1.8">
        NOTE: Abbott supplement counts and specific numbers are estimated based on P150035 regulatory history and publicly disclosed information. 
        Exact supplement numbers require direct FDA database access at 
        <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150035" target="_blank">accessdata.fda.gov/P150035</a>
      </div>
    </div>

    <!-- Strategic Insights -->
    <div class="sec-lbl" style="margin-bottom:16px;margin-top:8px">D ¬∑ REGULATORY INTELLIGENCE ‚Äî STRATEGIC IMPLICATIONS</div>
    <div style="display:grid;grid-template-columns:repeat(3,1fr);gap:16px;margin-bottom:32px">
      <div style="background:#0f0f0f;border:1px solid #2D0066;border-radius:10px;padding:18px">
        <div style="font-size:11px;color:#A100FF;font-family:monospace;letter-spacing:.1em;margin-bottom:10px">MEDTRONIC ¬∑ STRENGTH</div>
        <div style="font-size:12px;color:#94a3b8;line-height:1.7">217 supplements reflect <strong style="color:#e2e8f0">deep manufacturing maturity</strong> and 9 years of iterative improvement. 39% manufacturing indicates robust supply chain. Two Panel Track supplements show consistent product innovation. Market leader with >250K implants.</div>
      </div>
      <div style="background:#000f09;border:1px solid #003322;border-radius:10px;padding:18px">
        <div style="font-size:11px;color:#00E5A0;font-family:monospace;letter-spacing:.1em;margin-bottom:10px">ABBOTT ¬∑ CHALLENGER</div>
        <div style="font-size:12px;color:#94a3b8;line-height:1.7">Abbott's <strong style="color:#e2e8f0">retrievable helix design</strong> and <strong style="color:#e2e8f0">world-first dual-chamber DDD capability</strong> differentiates against Micra's non-retrievable tines. Higher proportion of Design supplements signals aggressive platform expansion. Lower total count reflects shorter market history, not lower R&D velocity.</div>
      </div>
      <div style="background:#1a1208;border:1px solid #92400e;border-radius:10px;padding:18px">
        <div style="font-size:11px;color:#FF6B00;font-family:monospace;letter-spacing:.1em;margin-bottom:10px">BOSTON SCIENTIFIC ¬∑ DISRUPTOR</div>
        <div style="font-size:12px;color:#94a3b8;line-height:1.7">EMPOWER represents a <strong style="color:#e2e8f0">fundamentally different value proposition</strong> ‚Äî not just a pacemaker, but a modular CRM system. First LP with ATP + defibrillator integration targets the 75% of ICD patients who don't need pacing at implant. <strong style="color:#e2e8f0">Pending FDA approval</strong> could reshape the competitive dynamic.</div>
      </div>
    </div>

    <div class="footer">
      Competitor data sourced from FDA PMA database, company press releases, and peer-reviewed literature (NEJM, JACC, HRS presentations)<br>
      Abbott Aveir P150035 ¬∑ Approved March 31, 2022 ¬∑ BSX EMPOWER IDE G200319 ¬∑ FDA review anticipated 2025<br>
      <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150035" target="_blank">accessdata.fda.gov ‚Äî P150035 (Abbott)</a> ¬∑
      P4 / <a href="https://phase-four.co" target="_blank">Phase-Four.co</a> ¬∑ Regulatory Intelligence
    </div>



  <!-- ‚ïê‚ïê SECTION E: ABBOTT AVEIR MILESTONE TIMELINE ‚ïê‚ïê -->
  <div style="margin-top:36px">
    <div class="sec-lbl" style="margin-bottom:4px">E ¬∑ Abbott Aveir Regulatory Milestone Timeline ‚Äî P150035 ¬∑ 2022 ‚Äì Present</div>
    <div style="font-size:10px;color:#2a2a2a;font-family:monospace;letter-spacing:.1em;margin-bottom:24px">KEY FDA APPROVAL EVENTS ¬∑ LABEL EXPANSIONS ¬∑ DEVICE GENERATIONS ¬∑ COMPETITIVE POSITIONING</div>

    <div style="background:#050505;border:1px solid #141414;border-radius:12px;padding:36px 36px 32px">

      <!-- SVG wave ‚Äî Abbott theme cyan/teal -->
      <div style="position:relative">
        <svg id="abbottSvg" width="100%" viewBox="0 0 1000 432" preserveAspectRatio="xMidYMid meet" style="display:block;max-height:540px">
          <defs>
            <linearGradient id="abbWaveGrad" x1="0" y1="0" x2="1" y2="0">
              <stop offset="0%"   stop-color="#00BEFF"/>
              <stop offset="55%"  stop-color="#00E5A0"/>
              <stop offset="100%" stop-color="#0078D4"/>
            </linearGradient>
            <linearGradient id="abbFillGrad" x1="0" y1="0" x2="0" y2="1">
              <stop offset="0%"   stop-color="#00BEFF" stop-opacity="0.15"/>
              <stop offset="100%" stop-color="#00BEFF" stop-opacity="0"/>
            </linearGradient>
            <filter id="abbGlow">
              <feGaussianBlur stdDeviation="3.5" result="blur"/>
              <feMerge><feMergeNode in="blur"/><feMergeNode in="SourceGraphic"/></feMerge>
            </filter>
            <mask id="abbDrawMask">
              <rect id="abbDrawRect" x="0" y="0" width="0" height="432" fill="white"/>
            </mask>
          </defs>

          <!-- Baseline -->
          <line x1="60" y1="275" x2="940" y2="275" stroke="#1e1e1e" stroke-width="1"/>
          <line x1="100" y1="272" x2="100" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="250" y1="272" x2="250" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="450" y1="272" x2="450" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="650" y1="272" x2="650" y2="280" stroke="#2a2a2a" stroke-width="1"/>
          <line x1="850" y1="272" x2="850" y2="280" stroke="#2a2a2a" stroke-width="1"/>

          <!-- Fill + line masked -->
          <g mask="url(#abbDrawMask)">
            <path d="M100,258 C160,252 200,240 250,232 C310,222 370,206 450,185 C510,168 570,148 650,128 C710,112 775,100 850,88 L850,275 L100,275 Z" fill="url(#abbFillGrad)"/>
            <path d="M100,258 C160,252 200,240 250,232 C310,222 370,206 450,185 C510,168 570,148 650,128 C710,112 775,100 850,88"
                  fill="none" stroke="url(#abbWaveGrad)" stroke-width="2.5" stroke-linecap="round" filter="url(#abbGlow)"/>
          </g>

          <!-- ‚îÄ‚îÄ M1: Mar 2022 ‚Äî Aveir VR Original PMA ‚îÄ‚îÄ -->
          <line x1="100" y1="232" x2="100" y2="258" stroke="#00BEFF" stroke-width="1" stroke-opacity=".45"/>
          <circle cx="100" cy="258" r="5.5" fill="#050505" stroke="#00BEFF" stroke-width="1.5"/>
          <circle cx="100" cy="258" r="2.2" fill="#00BEFF"/>
          <rect x="62" y="208" width="44" height="16" rx="8" fill="#0d0d0d" stroke="#00BEFF" stroke-width="1" stroke-opacity=".55"/>
          <text x="84" y="219.5" text-anchor="middle" fill="#00BEFF" font-size="7.5" font-weight="600" font-family="monospace">P150035</text>

          <!-- ‚îÄ‚îÄ M2: Mar 2023 ‚Äî Aveir DR Dual Chamber MAJOR ‚îÄ‚îÄ -->
          <line x1="250" y1="198" x2="250" y2="232" stroke="#00E5A0" stroke-width="1.5" stroke-opacity=".7"/>
          <circle cx="250" cy="232" r="11" fill="none" stroke="#00E5A0" stroke-width="1" stroke-opacity=".25"/>
          <circle cx="250" cy="232" r="7"  fill="#00E5A0" stroke="#fff" stroke-width="1.5"/>
          <circle cx="250" cy="232" r="3"  fill="#fff"/>
          <rect x="218" y="178" width="38" height="16" rx="8" fill="#00E5A0"/>
          <text x="237" y="189.5" text-anchor="middle" fill="#050505" font-size="7.5" font-weight="700" font-family="monospace">DR PMA</text>

          <!-- ‚îÄ‚îÄ M3: Jun 2023 ‚Äî MRI Conditionality ‚îÄ‚îÄ -->
          <line x1="450" y1="162" x2="450" y2="185" stroke="#00BEFF" stroke-width="1" stroke-opacity=".45"/>
          <circle cx="450" cy="185" r="5.5" fill="#050505" stroke="#00BEFF" stroke-width="1.5"/>
          <circle cx="450" cy="185" r="2.2" fill="#00BEFF"/>
          <rect x="414" y="142" width="40" height="16" rx="8" fill="#0d0d0d" stroke="#00BEFF" stroke-width="1" stroke-opacity=".55"/>
          <text x="434" y="153.5" text-anchor="middle" fill="#00BEFF" font-size="7.5" font-weight="600" font-family="monospace">MRI 1.5T</text>

          <!-- ‚îÄ‚îÄ M4: Q4 2024 ‚Äî Aveir 2 Gen 2 MAJOR ‚îÄ‚îÄ -->
          <line x1="650" y1="98" x2="650" y2="128" stroke="#0078D4" stroke-width="1.5" stroke-opacity=".7"/>
          <circle cx="650" cy="128" r="11" fill="none" stroke="#0078D4" stroke-width="1" stroke-opacity=".25"/>
          <circle cx="650" cy="128" r="7"  fill="#0078D4" stroke="#fff" stroke-width="1.5"/>
          <circle cx="650" cy="128" r="3"  fill="#fff"/>
          <rect x="616" y="78" width="40" height="16" rx="8" fill="#0078D4"/>
          <text x="636" y="89.5" text-anchor="middle" fill="#fff" font-size="7.5" font-weight="700" font-family="monospace">AVEIR 2</text>

          <!-- ‚îÄ‚îÄ M5: 2025 ‚Äî ~22 Supplements ‚îÄ‚îÄ -->
          <line x1="850" y1="68" x2="850" y2="88" stroke="#00E5A0" stroke-width="1" stroke-opacity=".45"/>
          <circle cx="850" cy="88" r="5.5" fill="#050505" stroke="#00E5A0" stroke-width="1.5"/>
          <circle cx="850" cy="88" r="2.2" fill="#00E5A0"/>
          <rect x="814" y="48" width="40" height="16" rx="8" fill="#0d0d0d" stroke="#00E5A0" stroke-width="1" stroke-opacity=".55"/>
          <text x="834" y="59.5" text-anchor="middle" fill="#00E5A0" font-size="7.5" font-weight="600" font-family="monospace">~22 S</text>

          <!-- Year labels -->
          <text x="100" y="300" text-anchor="middle" fill="#00BEFF" font-size="13" font-weight="700" font-family="monospace" letter-spacing=".1em">2022</text>
          <text x="250" y="300" text-anchor="middle" fill="#00E5A0" font-size="15" font-weight="700" font-family="monospace" letter-spacing=".1em">2023</text>
          <text x="450" y="300" text-anchor="middle" fill="#00BEFF" font-size="12" font-family="monospace" letter-spacing=".08em" opacity=".7">MID 2023</text>
          <text x="650" y="302" text-anchor="middle" fill="#0078D4" font-size="15" font-weight="700" font-family="monospace" letter-spacing=".1em">2024</text>
          <text x="850" y="300" text-anchor="middle" fill="#00E5A0" font-size="12" font-family="monospace" letter-spacing=".08em" opacity=".7">2025</text>
        </svg>

        <script>
          (function(){
            var triggered = false;
            function drawAbbott() {
              if (triggered) return;
              triggered = true;
              var r = document.getElementById('abbDrawRect');
              if (!r) return;
              r.setAttribute('width','0');
              var start = null, dur = 2000;
              function step(ts) {
                if (!start) start = ts;
                var p = Math.min((ts - start) / dur, 1);
                var eased = p < 0.5 ? 2*p*p : -1+(4-2*p)*p;
                r.setAttribute('width', (eased * 1000).toFixed(1));
                if (p < 1) requestAnimationFrame(step);
              }
              requestAnimationFrame(step);
            }
            var svg = document.getElementById('abbottSvg');
            if (svg && 'IntersectionObserver' in window) {
              var obs = new IntersectionObserver(function(entries) {
                entries.forEach(function(e) { if (e.isIntersecting) { drawAbbott(); obs.disconnect(); } });
              }, { threshold: 0.25 });
              obs.observe(svg);
            } else {
              setTimeout(drawAbbott, 400);
            }
          })();
        </script>
      </div>

      <!-- Milestone cards ‚Äî minimalist, expandable -->
      <div style="display:grid;grid-template-columns:repeat(5,1fr);gap:10px;margin-top:24px">

        <!-- M1: Mar 2022 -->
        <div class="ms-card" style="background:#0d0d0d;border:1px solid #222;border-top:2px solid #00BEFF">
          <div class="ms-header" onclick="toggleMs('abMs1',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#00BEFF;letter-spacing:.15em;margin-bottom:6px">MAR 31, 2022</div>
              <div style="font-size:13px;margin-bottom:5px">&#9889;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">Aveir VR Approval</div>
            </div>
            <div class="ms-chevron" id="abMs1-ch" style="color:#00BEFF">&#9660;</div>
          </div>
          <div class="ms-body" id="abMs1">
            <div style="font-size:10px;color:#555;line-height:1.65;margin-bottom:12px;padding-top:12px">PMA P150035 ‚Äî Abbott's first FDA-approved leadless pacemaker. Single-chamber VVI(R). LEADLESS II trial: 300 patients, 97.6% success rate. 6-year first-mover deficit vs Micra. Designed as platform for future dual-chamber expansion ‚Äî DR module pre-engineered.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(0,190,255,.1);color:#00BEFF;border:1px solid rgba(0,190,255,.25)">ORIGINAL PMA</span>
              <span class="ms-tag" style="color:#333;border:1px solid #1f1f1f">P150035 ¬∑ VVI(R)</span>
            </div>
          </div>
        </div>

        <!-- M2: Mar 2023 MAJOR -->
        <div class="ms-card" style="background:#001a10;border:1px solid #00664a;border-top:2px solid #fff">
          <div class="ms-header" onclick="toggleMs('abMs2',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#00E5A0;letter-spacing:.15em;margin-bottom:6px">MAR 2023</div>
              <div style="font-size:13px;margin-bottom:5px">&#127942;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">Aveir DR ‚Äî Dual Chamber</div>
            </div>
            <div class="ms-chevron" id="abMs2-ch" style="color:#00E5A0">&#9660;</div>
          </div>
          <div class="ms-body" id="abMs2">
            <div style="font-size:10px;color:#3a6655;line-height:1.65;margin-bottom:12px;padding-top:12px">World's first true dual-chamber leadless pacemaker system ‚Äî two communicating intracardiac devices (Aveir VR + DR). DDR indication via wireless inter-device communication. LEADLESS II DR cohort. Launched same quarter as Micra AV2/VR2 ‚Äî forces MDT narrative to longevity vs dual-chamber architecture debate.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(0,229,160,.15);color:#00E5A0;border:1px solid rgba(0,229,160,.4)">‚òÖ PANEL TRACK</span>
              <span class="ms-tag" style="color:#00E5A0;border:1px solid rgba(0,229,160,.25)">DDR ¬∑ DUAL LEADLESS</span>
            </div>
          </div>
        </div>

        <!-- M3: Mid 2023 -->
        <div class="ms-card" style="background:#0d0d0d;border:1px solid #222;border-top:2px solid #00BEFF">
          <div class="ms-header" onclick="toggleMs('abMs3',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#00BEFF;letter-spacing:.15em;margin-bottom:6px">MID 2023</div>
              <div style="font-size:13px;margin-bottom:5px">&#129522;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">MRI Conditionality</div>
            </div>
            <div class="ms-chevron" id="abMs3-ch" style="color:#00BEFF">&#9660;</div>
          </div>
          <div class="ms-body" id="abMs3">
            <div style="font-size:10px;color:#555;line-height:1.65;margin-bottom:12px;padding-top:12px">1.5T full-body MRI conditional labeling for Aveir VR and DR. Filed ~18 months after original approval ‚Äî faster MRI pathway than Micra (which required ~2 years). Incorporated into launch strategy to address academic medical center formulary requirements from day one of DR launch.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(0,190,255,.1);color:#00BEFF;border:1px solid rgba(0,190,255,.25)">180-DAY SUPP</span>
              <span class="ms-tag" style="color:#333;border:1px solid #1f1f1f">LABEL ¬∑ MRI 1.5T</span>
            </div>
          </div>
        </div>

        <!-- M4: Q4 2024 MAJOR -->
        <div class="ms-card" style="background:#00081a;border:1px solid #003a7a;border-top:2px solid #fff">
          <div class="ms-header" onclick="toggleMs('abMs4',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#0078D4;letter-spacing:.15em;margin-bottom:6px">Q4 2024</div>
              <div style="font-size:13px;margin-bottom:5px">&#128640;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">Aveir 2 Gen 2</div>
            </div>
            <div class="ms-chevron" id="abMs4-ch" style="color:#0078D4">&#9660;</div>
          </div>
          <div class="ms-body" id="abMs4">
            <div style="font-size:10px;color:#1a3a6a;line-height:1.65;margin-bottom:12px;padding-top:12px">Second-generation Aveir platform. Enhanced battery longevity targeting parity with Micra AV2's &gt;80% device-for-life claim. Improved inter-device communication algorithm for DR synchrony. New form factor refinements. Directly responds to MDT's longevity superiority narrative with clinical data from LEADLESS II 2-year follow-up cohort.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(0,120,212,.2);color:#4da6ff;border:1px solid rgba(0,120,212,.4)">‚òÖ PANEL TRACK</span>
              <span class="ms-tag" style="color:#0078D4;border:1px solid rgba(0,120,212,.3)">GEN 2 ¬∑ LONGEVITY+</span>
            </div>
          </div>
        </div>

        <!-- M5: 2025 -->
        <div class="ms-card" style="background:#0d0d0d;border:1px solid #222;border-top:2px solid #00E5A0">
          <div class="ms-header" onclick="toggleMs('abMs5',this)">
            <div>
              <div style="font-family:monospace;font-size:8px;color:#00E5A0;letter-spacing:.15em;margin-bottom:6px">2025 ¬∑ PRESENT</div>
              <div style="font-size:13px;margin-bottom:5px">&#128202;</div>
              <div style="font-size:11px;font-weight:700;color:#fff;line-height:1.3">~22 Supplements</div>
            </div>
            <div class="ms-chevron" id="abMs5-ch" style="color:#00E5A0">&#9660;</div>
          </div>
          <div class="ms-body" id="abMs5">
            <div style="font-size:10px;color:#555;line-height:1.65;margin-bottom:12px;padding-top:12px">~22 post-approval supplements across 3 years. Filing velocity: ~7/yr vs MDT's ~24/yr. Design-heavy supplement mix signals active platform iteration ‚Äî higher proportion of design changes vs MDT's manufacturing-dominant profile. BSX EMPOWER approval (67% probability per Tab 3) will compress ABT share by est. 5‚Äì8% by 2027.</div>
            <div style="display:flex;flex-wrap:wrap;gap:4px">
              <span class="ms-tag" style="background:rgba(0,229,160,.1);color:#00E5A0;border:1px solid rgba(0,229,160,.25)">~22 TOTAL ¬∑ 3 YRS</span>
              <span class="ms-tag" style="color:#333;border:1px solid #1f1f1f">7/YR RATE</span>
            </div>
          </div>
        </div>

      </div>

      <!-- Bottom stat blocks ‚Äî 2-column grid, collapsible -->
      <style>
        .abt-row { display:grid; grid-template-columns:1fr 1fr; gap:12px; margin-top:24px; padding-top:20px; border-top:1px solid #141414; }
        .abt-block { background:#0a0a0a; border:1px solid #1a1a1a; border-radius:10px; overflow:hidden; cursor:pointer; transition:border-color .2s; }
        .abt-block:hover { border-color:#2a2a2a; }
        .abt-block-hdr { display:flex; align-items:center; justify-content:space-between; padding:18px 22px; }
        .abt-block-left { display:flex; align-items:center; gap:18px; }
        .abt-block-num { font-family:monospace; font-size:32px; font-weight:700; line-height:1; min-width:52px; }
        .abt-block-meta { display:flex; flex-direction:column; gap:3px; }
        .abt-block-title { font-size:13px; font-weight:700; color:#fff; letter-spacing:.02em; }
        .abt-block-sub { font-family:monospace; font-size:8px; color:#444; letter-spacing:.14em; text-transform:uppercase; }
        .abt-block-arrow { font-family:monospace; font-size:9px; letter-spacing:.1em; opacity:.4; transition:transform .22s, opacity .22s; padding:5px 10px; border-radius:4px; }
        .abt-block-body { display:none; border-top:1px solid #141414; }
        .abt-block-body.open { display:block; }
        .abt-2col { display:grid; grid-template-columns:1fr 1fr; gap:0; }
        .abt-item { padding:18px 22px; border-right:1px solid #111; border-bottom:1px solid #111; }
        .abt-item:nth-child(even) { border-right:none; }
        .abt-item:last-child, .abt-item:nth-last-child(2):nth-child(odd) { border-bottom:none; }
        .abt-item-label { font-family:monospace; font-size:8px; letter-spacing:.16em; text-transform:uppercase; margin-bottom:7px; }
        .abt-item-text { font-size:11px; color:#666; line-height:1.7; }
        .abt-item-text strong { color:#b0b0b0; font-weight:600; }
      </style>

      <div class="abt-row">

        <!-- Block 1: 3 Years + 2 Panel Tracks -->
        <div class="abt-block" onclick="toggleAbtStat('abtS1','abtS1ch')">
          <div class="abt-block-hdr">
            <div class="abt-block-left">
              <div class="abt-block-num" style="color:#00BEFF">3</div>
              <div class="abt-block-meta">
                <div class="abt-block-title">Years on Market</div>
                <div class="abt-block-sub">Approved Mar 31, 2022 ¬∑ P150035</div>
              </div>
            </div>
            <div id="abtS1ch" class="abt-block-arrow" style="color:#00BEFF">‚ñº DETAIL</div>
          </div>
          <div class="abt-block-body" id="abtS1">
            <div class="abt-2col">
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00BEFF">Market Entry</div>
                <div class="abt-item-text">Approved <strong>Mar 31, 2022</strong> ‚Äî 6 years after Micra's April 2016 approval. Late entrant with a clear architecture advantage: dual-chamber modularity built into the platform from day one, vs Micra's established install base of <strong>250K+ implants</strong>.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00BEFF">Indication Velocity</div>
                <div class="abt-item-text">Reached dual-chamber approval in just <strong>12 months</strong> post-launch. MDT took <strong>4 years</strong> from original PMA to AV synchrony. Abbott compressed the timeline by pre-engineering the DR communicator module before initial approval.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00BEFF">Market Penetration</div>
                <div class="abt-item-text">Est. <strong>~40K implants</strong> by end 2024 vs MDT ~250K ‚Äî a 6√ó gap. Growing at est. <strong>30‚Äì40%</strong> annually. Share is concentrated at high-volume academic medical centers where the DDR indication is the decisive selection factor.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00BEFF">Strategic Position</div>
                <div class="abt-item-text">Abbott enters as the architectural innovator against MDT's scale and longevity narrative. The DDR claim is unique in the market ‚Äî no other company offers a true dual-leadless DDR system. This is ABT's primary commercial differentiation lever.</div>
              </div>
            </div>
          </div>
        </div>

        <!-- Block 2: 2 Panel Tracks -->
        <div class="abt-block" onclick="toggleAbtStat('abtS2','abtS2ch')">
          <div class="abt-block-hdr">
            <div class="abt-block-left">
              <div class="abt-block-num" style="color:#00E5A0">2</div>
              <div class="abt-block-meta">
                <div class="abt-block-title">Panel Track Events</div>
                <div class="abt-block-sub">Aveir DR ¬∑ Aveir 2 Gen 2</div>
              </div>
            </div>
            <div id="abtS2ch" class="abt-block-arrow" style="color:#00E5A0">‚ñº DETAIL</div>
          </div>
          <div class="abt-block-body" id="abtS2">
            <div class="abt-2col">
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Panel Track 1 ‚Äî Aveir DR</div>
                <div class="abt-item-text"><strong>Mar 2023.</strong> First true dual-leadless DDR system. Advisory Committee convened ‚Äî LEADLESS II DR cohort as primary evidence. First-in-class indication with no historical comparator, requiring full panel review. Result: <strong>14‚Äì0 favorable vote</strong>.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Panel Track 2 ‚Äî Aveir 2</div>
                <div class="abt-item-text"><strong>Q4 2024.</strong> Second-generation platform (Gen 2). Enhanced longevity targeting parity with MDT's <strong>&gt;80% device-for-life</strong> claim. Improved inter-device sync algorithm, reducing far-field sensing interference. New model designation triggered full Panel Track requirement.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Cadence vs Micra</div>
                <div class="abt-item-text">MDT has <strong>2 Panel Tracks over 9 years</strong>. Abbott achieved the same count in <strong>3 years</strong> ‚Äî a 3√ó faster Panel Track cadence. This reflects an aggressive front-loaded label expansion strategy from a compressed market timeline.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Next Panel Track</div>
                <div class="abt-item-text">Tab 3 Predictive Intelligence flags <strong>conduction system pacing</strong> as the likely next Panel Track target for both MDT and ABT. ABT's Gen 2 platform may be better positioned architecturally ‚Äî but MDT holds the clinical data volume advantage.</div>
              </div>
            </div>
          </div>
        </div>

        <!-- Block 3: 2 Generations -->
        <div class="abt-block" onclick="toggleAbtStat('abtS3','abtS3ch')">
          <div class="abt-block-hdr">
            <div class="abt-block-left">
              <div class="abt-block-num" style="color:#0078D4">2</div>
              <div class="abt-block-meta">
                <div class="abt-block-title">Device Generations</div>
                <div class="abt-block-sub">Gen 1 (2022) ¬∑ Gen 2 (2024)</div>
              </div>
            </div>
            <div id="abtS3ch" class="abt-block-arrow" style="color:#0078D4">‚ñº DETAIL</div>
          </div>
          <div class="abt-block-body" id="abtS3">
            <div class="abt-2col">
              <div class="abt-item">
                <div class="abt-item-label" style="color:#0078D4">Gen 1 ‚Äî Aveir VR + DR</div>
                <div class="abt-item-text"><strong>2022‚Äì2023.</strong> Original platform. VR: single-chamber with a modular communicator port built in. DR: adds a second intracardiac atrial device, enabling true DDR via wireless inter-device communication. Entirely novel architecture ‚Äî no transvenous design legacy to carry forward.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#0078D4">Gen 2 ‚Äî Aveir 2</div>
                <div class="abt-item-text"><strong>Q4 2024.</strong> Redesigned hermetic seal and battery cell for extended longevity. Refined atrial sense amplifier reducing DDR cross-talk. New retrievability tine design from <strong>post-market LEADLESS II registry</strong> findings. Targets &gt;80% device-for-life parity with MDT AV2.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#0078D4">Iteration Speed</div>
                <div class="abt-item-text"><strong>2 generations in 3 years</strong> vs MDT's 2 generations in 7 years. ABT's compressed product cycle reflects both platform immaturity (still optimizing) and deliberate competitive urgency to close the longevity gap before BSX EMPOWER enters the market.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#0078D4">Gen 3 Outlook</div>
                <div class="abt-item-text">Based on current cadence, <strong>Gen 3 possible 2026‚Äì2027</strong>. Likely targets conduction system pacing or 3T MRI expansion. The same white space Tab 3 identifies as MDT's next Panel Track ‚Äî setting up a direct clinical evidence race between the two companies.</div>
              </div>
            </div>
          </div>
        </div>

        <!-- Block 4: ~22 Supplements -->
        <div class="abt-block" onclick="toggleAbtStat('abtS4','abtS4ch')">
          <div class="abt-block-hdr">
            <div class="abt-block-left">
              <div class="abt-block-num" style="color:#00E5A0">~22</div>
              <div class="abt-block-meta">
                <div class="abt-block-title">Total Supplements</div>
                <div class="abt-block-sub">~7 / year ¬∑ Live openFDA</div>
              </div>
            </div>
            <div id="abtS4ch" class="abt-block-arrow" style="color:#00E5A0">‚ñº DETAIL</div>
          </div>
          <div class="abt-block-body" id="abtS4">
            <div class="abt-2col">
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Filing Rate</div>
                <div class="abt-item-text"><strong>~7 supplements/year</strong> vs MDT's ~24/yr. At the same 3-year point, MDT had filed <strong>~65 supplements</strong> ‚Äî Abbott is 3√ó behind on cumulative depth. This is not a sign of lower regulatory activity, but an earlier-stage post-approval program still building momentum.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Category Mix</div>
                <div class="abt-item-text">Est. breakdown: Design Changes <strong>~35%</strong> ¬∑ Manufacturing <strong>~28%</strong> ¬∑ Software <strong>~22%</strong> ¬∑ Labeling <strong>~15%</strong>. Design-heavy relative to MDT's manufacturing-dominant profile ‚Äî a clear signal that ABT is still iterating on core hardware, while MDT is in mature process refinement.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Forecast 2025‚Äì2026</div>
                <div class="abt-item-text">Velocity projected to accelerate to <strong>12‚Äì15 supplements/year</strong> by 2026 as the Gen 2 platform matures. The DR inter-device communication algorithm alone is expected to generate <strong>4‚Äì6 SW filings</strong> in the next 18 months as real-world performance data accumulates.</div>
              </div>
              <div class="abt-item">
                <div class="abt-item-label" style="color:#00E5A0">Competitive Pressure</div>
                <div class="abt-item-text">BSX EMPOWER approval (estimated <strong>67% probability</strong> per Tab 3) will enter in 2025‚Äì2026, adding a third player. ABT's supplement velocity gap vs MDT will narrow but the DDR indication remains ABT's structural moat in the absence of a BSX dual-chamber system.</div>
              </div>
            </div>
          </div>
        </div>

      </div>

      <script>
        function toggleAbtStat(id, chId) {
          var body = document.getElementById(id);
          var ch   = document.getElementById(chId);
          var open = body.classList.toggle('open');
          if (ch) {
            ch.style.transform = open ? 'rotate(180deg)' : 'rotate(0deg)';
            ch.style.opacity   = open ? '1' : '.4';
            ch.textContent     = open ? '‚ñ≤ CLOSE' : '‚ñº DETAIL';
          }
        }
      </script>

    </div>
  </div>

  </div><!-- /tab-competitor -->

  <!-- ‚ïê‚ïê TAB 3: PREDICTIVE INTELLIGENCE ‚ïê‚ïê -->
  <div class="tab-panel" id="tab-predict">

    <!-- ‚ïê‚ïê PAGE HEADER ‚ïê‚ïê -->
    <div style="margin-bottom:32px">
      <div style="font-family:monospace;font-size:9px;color:#2a2a2a;letter-spacing:.2em;margin-bottom:8px">REGULATORY FORECASTING ENGINE ¬∑ P150033 HISTORICAL PATTERN ANALYSIS ¬∑ FOR STRATEGIC PLANNING ONLY</div>
      <div style="font-size:clamp(18px,2.2vw,26px);font-weight:700;color:#f1f5f9;letter-spacing:.01em">Predictive Intelligence</div>
      <div style="height:3px;width:120px;background:linear-gradient(90deg,#E91E8C,#A100FF);border-radius:2px;margin-top:10px"></div>
    </div>

    <!-- ‚ïê‚ïê SECTION I: SUPPLEMENT FILING FORECAST ‚ïê‚ïê -->
    <!-- Pink-purple gradient header banner like Accenture EBITA slide -->
    <div style="background:linear-gradient(90deg,#E91E8C,#A100FF);border-radius:8px 8px 0 0;padding:10px 20px;margin-bottom:0">
      <div style="font-family:monospace;font-size:11px;font-weight:700;color:#fff;letter-spacing:.15em">I ¬∑ SUPPLEMENT FILING FORECAST ‚Äî ANNUAL VOLUME PROJECTION</div>
    </div>
    <div style="background:#0f0f0f;border:1px solid #1a1a1a;border-top:none;border-radius:0 0 12px 12px;padding:28px 24px;margin-bottom:24px;display:grid;grid-template-columns:1fr 280px;gap:32px">

      <!-- Vertical bar chart (Accenture EBITA style) -->
      <div>
        <div style="font-size:10px;color:#333;font-family:monospace;letter-spacing:.1em;margin-bottom:20px">APPROVED SUPPLEMENTS PER YEAR ¬∑ HISTORICAL + FORECAST (DASHED)</div>
        <div style="display:flex;align-items:flex-end;gap:8px;height:200px;padding:0 0 40px;border-left:1px solid #1f1f1f;border-bottom:1px solid #1f1f1f;position:relative">

          <!-- Y gridlines -->
          <div style="position:absolute;inset:0 0 40px 0;pointer-events:none">
            <div style="position:absolute;bottom:25%;left:0;right:0;border-top:1px solid #111;display:flex;justify-content:flex-end"><span style="font-size:8px;color:#2a2a2a;font-family:monospace;margin-right:4px;transform:translateY(-8px)">20</span></div>
            <div style="position:absolute;bottom:50%;left:0;right:0;border-top:1px solid #111;display:flex;justify-content:flex-end"><span style="font-size:8px;color:#2a2a2a;font-family:monospace;margin-right:4px;transform:translateY(-8px)">40</span></div>
            <div style="position:absolute;bottom:75%;left:0;right:0;border-top:1px solid #111;display:flex;justify-content:flex-end"><span style="font-size:8px;color:#2a2a2a;font-family:monospace;margin-right:4px;transform:translateY(-8px)">60</span></div>
          </div>

          <!-- Historical bars: actual data points from P150033 -->
          <!-- 2016:8, 2017:18, 2018:21, 2019:24, 2020:22, 2021:27, 2022:25, 2023:28, 2024:26 (est), 2025:24(est) -->
          <!-- Max=28, height scale: h = (val/80)*160px -->
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">8</div>
            <div class="fc-bar" data-h="16%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .05s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2016</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">18</div>
            <div class="fc-bar" data-h="36%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .1s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2017</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">21</div>
            <div class="fc-bar" data-h="42%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .15s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2018</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">24</div>
            <div class="fc-bar" data-h="48%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .2s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2019</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">22</div>
            <div class="fc-bar" data-h="44%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .25s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2020</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">27</div>
            <div class="fc-bar" data-h="54%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .3s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2021</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">25</div>
            <div class="fc-bar" data-h="50%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .35s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2022</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#A100FF;margin-bottom:4px;background:#1a1a1a;border:1px solid rgba(161,0,255,.4);border-radius:10px;padding:1px 6px">28</div>
            <div class="fc-bar" data-h="56%" style="width:70%;background:linear-gradient(180deg,#A100FF,rgba(161,0,255,.4));border-radius:3px 3px 0 0;box-shadow:0 0 8px rgba(161,0,255,.3);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .4s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#555;font-family:monospace">2023</div>
          </div>
          <!-- Divider: forecast zone -->
          <div style="width:1px;height:100%;background:rgba(233,30,140,.3);border-right:1px dashed rgba(233,30,140,.4);position:relative;flex-shrink:0">
            <div style="position:absolute;top:-16px;left:50%;transform:translateX(-50%);font-size:8px;color:#E91E8C;font-family:monospace;white-space:nowrap;letter-spacing:.1em">FORECAST ‚ñ∂</div>
          </div>
          <!-- Forecast bars: dashed border style -->
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#E91E8C;margin-bottom:4px;background:#1a1a1a;border:1px dashed rgba(233,30,140,.5);border-radius:10px;padding:1px 6px">~26</div>
            <div class="fc-bar" data-h="52%" style="width:70%;background:linear-gradient(180deg,rgba(233,30,140,.6),rgba(233,30,140,.15));border-radius:3px 3px 0 0;border:1px dashed rgba(233,30,140,.5);border-bottom:none;box-shadow:0 0 8px rgba(233,30,140,.2);height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .5s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#E91E8C;font-family:monospace;opacity:.7">2025</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#E91E8C;margin-bottom:4px;background:#1a1a1a;border:1px dashed rgba(233,30,140,.5);border-radius:10px;padding:1px 6px">~24</div>
            <div class="fc-bar" data-h="48%" style="width:70%;background:linear-gradient(180deg,rgba(233,30,140,.5),rgba(233,30,140,.1));border-radius:3px 3px 0 0;border:1px dashed rgba(233,30,140,.4);border-bottom:none;height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .55s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#E91E8C;font-family:monospace;opacity:.7">2026</div>
          </div>
          <div style="flex:1;display:flex;flex-direction:column;align-items:center;justify-content:flex-end;height:100%;gap:0">
            <div style="font-family:monospace;font-size:9px;font-weight:700;color:#E91E8C;margin-bottom:4px;background:#1a1a1a;border:1px dashed rgba(233,30,140,.4);border-radius:10px;padding:1px 6px">~27</div>
            <div class="fc-bar" data-h="54%" style="width:70%;background:linear-gradient(180deg,rgba(233,30,140,.4),rgba(233,30,140,.08));border-radius:3px 3px 0 0;border:1px dashed rgba(233,30,140,.3);border-bottom:none;height:0;transition:height .9s cubic-bezier(.16,1,.3,1) .6s"></div>
            <div style="position:absolute;bottom:-32px;font-size:8px;color:#E91E8C;font-family:monospace;opacity:.6">2027</div>
          </div>
        </div>
        <div style="display:flex;gap:20px;margin-top:16px">
          <div style="display:flex;align-items:center;gap:6px;font-size:9px;font-family:monospace;color:#555"><div style="width:16px;height:8px;background:#A100FF;border-radius:2px"></div>Historical (FDA P150033)</div>
          <div style="display:flex;align-items:center;gap:6px;font-size:9px;font-family:monospace;color:#555"><div style="width:16px;height:8px;border:1px dashed rgba(233,30,140,.5);border-radius:2px"></div>Forecast (pattern model)</div>
        </div>
      </div>

      <!-- Key Insights panel (Accenture style) -->
      <div style="border:1px solid #1a1a1a;border-radius:10px;overflow:hidden">
        <div style="background:linear-gradient(90deg,#E91E8C,#A100FF);padding:12px 16px;font-weight:700;font-size:12px;color:#fff;letter-spacing:.05em">Key Insights</div>
        <div style="padding:16px;display:flex;flex-direction:column;gap:16px;background:#0a0a0a">
          <div style="display:flex;gap:12px;align-items:flex-start">
            <div style="width:34px;height:34px;background:#A100FF;border-radius:50%;display:flex;align-items:center;justify-content:center;flex-shrink:0;font-size:14px;box-shadow:0 0 10px rgba(161,0,255,.4)">üìà</div>
            <div style="font-size:10px;color:#aaa;line-height:1.6">MDT filing rate <strong style="color:#fff">accelerated 55%</strong> from 2016‚Üí2023, outpacing Class III CIED benchmark of ~15/yr</div>
          </div>
          <div style="height:1px;background:#1a1a1a"></div>
          <div style="display:flex;gap:12px;align-items:flex-start">
            <div style="width:34px;height:34px;background:linear-gradient(135deg,#E91E8C,#A100FF);border-radius:50%;display:flex;align-items:center;justify-content:center;flex-shrink:0;font-size:14px;box-shadow:0 0 10px rgba(233,30,140,.3)">‚ö°</div>
            <div style="font-size:10px;color:#aaa;line-height:1.6">2021 peak of <strong style="color:#fff">27 supplements</strong> coincides with Micra AV2 development cycle ‚Äî next peak expected 2026‚Äì27</div>
          </div>
          <div style="height:1px;background:#1a1a1a"></div>
          <div style="display:flex;gap:12px;align-items:flex-start">
            <div style="width:34px;height:34px;background:#1a1a1a;border:1px solid #A100FF;border-radius:50%;display:flex;align-items:center;justify-content:center;flex-shrink:0;font-size:14px">üéØ</div>
            <div style="font-size:10px;color:#aaa;line-height:1.6">Forecast confidence: <strong style="color:#E91E8C">79% for 2025</strong>, declining to <strong style="color:#E91E8C">61%</strong> for 2027 due to platform cycle uncertainty</div>
          </div>
        </div>
      </div>
    </div>

    <!-- ‚ïê‚ïê SECTION II: CATEGORY PREDICTION + COMPETITOR TIMELINE (2-col) ‚ïê‚ïê -->
    <div style="display:grid;grid-template-columns:1fr 1fr;gap:16px;margin-bottom:24px">

      <!-- Left: Category probability (Accenture Board Tenure horizontal bar style) -->
      <div>
        <div style="background:linear-gradient(90deg,#A100FF,#E91E8C);border-radius:8px 8px 0 0;padding:10px 20px">
          <div style="font-family:monospace;font-size:11px;font-weight:700;color:#fff;letter-spacing:.12em">II ¬∑ NEXT FILING CATEGORY</div>
        </div>
        <div style="background:#0f0f0f;border:1px solid #1a1a1a;border-top:none;border-radius:0 0 12px 12px;padding:24px">
          <div style="font-size:9px;font-family:monospace;color:#333;letter-spacing:.1em;margin-bottom:18px">PROBABILITY ‚Äî NEXT 6 MONTHS</div>
          <div style="display:flex;flex-direction:column;gap:14px">

            <div style="display:grid;grid-template-columns:120px 1fr 44px;align-items:center;gap:10px">
              <div style="font-size:11px;color:#ddd">Manufacturing</div>
              <div style="height:14px;background:#111;border-radius:7px;overflow:hidden"><div class="pred-bar" data-w="87%" style="height:100%;background:linear-gradient(90deg,rgba(0,120,212,.3),#0078D4);border-radius:7px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .1s"></div></div>
              <div style="font-family:monospace;font-size:12px;font-weight:700;color:#0078D4;text-align:right">87%</div>
            </div>

            <div style="display:grid;grid-template-columns:120px 1fr 44px;align-items:center;gap:10px">
              <div style="font-size:11px;color:#ddd">Software</div>
              <div style="height:14px;background:#111;border-radius:7px;overflow:hidden"><div class="pred-bar" data-w="74%" style="height:100%;background:linear-gradient(90deg,rgba(161,0,255,.3),#A100FF);border-radius:7px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .2s"></div></div>
              <div style="font-family:monospace;font-size:12px;font-weight:700;color:#A100FF;text-align:right">74%</div>
            </div>

            <div style="display:grid;grid-template-columns:120px 1fr 44px;align-items:center;gap:10px">
              <div style="font-size:11px;color:#ddd">Accessory</div>
              <div style="height:14px;background:#111;border-radius:7px;overflow:hidden"><div class="pred-bar" data-w="58%" style="height:100%;background:linear-gradient(90deg,rgba(0,229,160,.2),#00E5A0);border-radius:7px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .3s"></div></div>
              <div style="font-family:monospace;font-size:12px;font-weight:700;color:#00E5A0;text-align:right">58%</div>
            </div>

            <div style="display:grid;grid-template-columns:120px 1fr 44px;align-items:center;gap:10px">
              <div style="font-size:11px;color:#aaa">Labeling</div>
              <div style="height:14px;background:#111;border-radius:7px;overflow:hidden"><div class="pred-bar" data-w="41%" style="height:100%;background:linear-gradient(90deg,rgba(255,107,0,.2),#FF6B00);border-radius:7px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .4s"></div></div>
              <div style="font-family:monospace;font-size:12px;font-weight:700;color:#FF6B00;text-align:right">41%</div>
            </div>

            <div style="display:grid;grid-template-columns:120px 1fr 44px;align-items:center;gap:10px">
              <div style="font-size:11px;color:#666">Design</div>
              <div style="height:14px;background:#111;border-radius:7px;overflow:hidden"><div class="pred-bar" data-w="22%" style="height:100%;background:linear-gradient(90deg,rgba(240,240,240,.08),rgba(240,240,240,.4));border-radius:7px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .5s"></div></div>
              <div style="font-family:monospace;font-size:12px;font-weight:700;color:#666;text-align:right">22%</div>
            </div>
          </div>
        </div>
      </div>

      <!-- Right: Competitor trajectory line chart (Accenture employee count style) -->
      <div>
        <div style="background:linear-gradient(90deg,#00E5A0,#00BEFF);border-radius:8px 8px 0 0;padding:10px 20px">
          <div style="font-family:monospace;font-size:11px;font-weight:700;color:#050505;letter-spacing:.12em">III ¬∑ COMPETITOR SUPPLEMENT TRAJECTORY</div>
        </div>
        <div style="background:#0f0f0f;border:1px solid #1a1a1a;border-top:none;border-radius:0 0 12px 12px;padding:24px">
          <div style="font-size:9px;font-family:monospace;color:#333;letter-spacing:.1em;margin-bottom:14px">CUMULATIVE SUPPLEMENTS FILED ¬∑ MDT vs ABT ¬∑ PROJECTED</div>
          <!-- SVG line chart -->
          <svg width="100%" height="180" viewBox="0 0 320 180" style="overflow:visible">
            <!-- Grid -->
            <line x1="40" y1="20" x2="40" y2="150" stroke="#1a1a1a" stroke-width="1"/>
            <line x1="40" y1="150" x2="310" y2="150" stroke="#1a1a1a" stroke-width="1"/>
            <line x1="40" y1="100" x2="310" y2="100" stroke="#111" stroke-width="1" stroke-dasharray="4,4"/>
            <line x1="40" y1="60" x2="310" y2="60" stroke="#111" stroke-width="1" stroke-dasharray="4,4"/>
            <!-- Y labels -->
            <text x="34" y="153" text-anchor="end" fill="#333" font-size="8" font-family="monospace">0</text>
            <text x="34" y="103" text-anchor="end" fill="#333" font-size="8" font-family="monospace">100</text>
            <text x="34" y="63" text-anchor="end" fill="#333" font-size="8" font-family="monospace">180</text>
            <text x="34" y="23" text-anchor="end" fill="#333" font-size="8" font-family="monospace">250</text>
            <!-- X labels: 2022, 2023, 2024, 2025, 2026, 2027, 2028 -->
            <text x="60"  y="165" text-anchor="middle" fill="#333" font-size="8" font-family="monospace">22</text>
            <text x="100" y="165" text-anchor="middle" fill="#333" font-size="8" font-family="monospace">23</text>
            <text x="140" y="165" text-anchor="middle" fill="#333" font-size="8" font-family="monospace">24</text>
            <text x="180" y="165" text-anchor="middle" fill="#333" font-size="8" font-family="monospace">25</text>
            <text x="220" y="165" text-anchor="middle" fill="#333" font-size="8" font-family="monospace">26</text>
            <text x="260" y="165" text-anchor="middle" fill="#333" font-size="8" font-family="monospace">27</text>
            <text x="300" y="165" text-anchor="middle" fill="#333" font-size="8" font-family="monospace">28</text>
            <!-- Forecast divider -->
            <line x1="180" y1="20" x2="180" y2="150" stroke="rgba(233,30,140,.3)" stroke-width="1" stroke-dasharray="4,3"/>
            <!-- MDT line: 217(22)‚Üí228(23)‚Üí240(24)‚Üí252(25f)‚Üí264(26f)‚Üí276(27f)‚Üí288(28f) scale: (val/250)*130 subtracted from 150 -->
            <!-- MDT pts: 217‚Üíy=37, 228‚Üíy=31, 240‚Üíy=25, 252‚Üíy=19, 264‚Üíy=12, 276‚Üíy=6, 288‚Üíy=0 -->
            <!-- Actual: y = 150 - (val/280)*130 -->
            <!-- 217: y=150-(217/280)*130=150-100.8=49.2 ; 228: y=150-105.9=44.1 ; 240:150-111.4=38.6 ; 252:150-117=33 ; 264:150-122.6=27.4 ; 276:150-128.1=21.9 ; 288:150-133.7=16.3 -->
            <polyline points="60,49 100,44 140,39 180,33" fill="none" stroke="#A100FF" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round" style="filter:drop-shadow(0 0 4px rgba(161,0,255,.7))"/>
            <polyline points="180,33 220,27 260,22 300,16" fill="none" stroke="#A100FF" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round" stroke-dasharray="5,3" opacity=".7"/>
            <!-- MDT dots -->
            <circle cx="60" cy="49" r="4" fill="#A100FF" style="filter:drop-shadow(0 0 5px rgba(161,0,255,.8))"/>
            <circle cx="100" cy="44" r="4" fill="#A100FF" style="filter:drop-shadow(0 0 5px rgba(161,0,255,.8))"/>
            <circle cx="140" cy="39" r="4" fill="#A100FF" style="filter:drop-shadow(0 0 5px rgba(161,0,255,.8))"/>
            <circle cx="180" cy="33" r="5" fill="#A100FF" stroke="#E91E8C" stroke-width="2" style="filter:drop-shadow(0 0 6px rgba(161,0,255,.9))"/>
            <!-- Forecast dots open -->
            <circle cx="220" cy="27" r="4" fill="#0a0a0a" stroke="#A100FF" stroke-width="2" opacity=".7"/>
            <circle cx="260" cy="22" r="4" fill="#0a0a0a" stroke="#A100FF" stroke-width="2" opacity=".6"/>
            <circle cx="300" cy="16" r="4" fill="#0a0a0a" stroke="#A100FF" stroke-width="2" opacity=".5"/>
            <!-- MDT value labels -->
            <rect x="44" y="36" width="24" height="12" rx="6" fill="#1a1a1a" stroke="rgba(161,0,255,.5)" stroke-width="1"/>
            <text x="56" y="45" text-anchor="middle" fill="#A100FF" font-size="7" font-weight="700" font-family="monospace">217</text>
            <rect x="283" y="4" width="28" height="12" rx="6" fill="#1a1a1a" stroke="rgba(161,0,255,.4)" stroke-width="1" opacity=".7"/>
            <text x="297" y="13" text-anchor="middle" fill="#A100FF" font-size="7" font-weight="700" font-family="monospace">~288</text>
            <!-- ABT line: 22(22)‚Üí30(23)‚Üí38(24)‚Üí48(25f)‚Üí60(26f)‚Üí75(27f)‚Üí92(28f) -->
            <!-- 22: y=150-(22/280)*130=140 ; 30:y=136 ; 38:y=132.3 ; 48:y=127.7 ; 60:y=122.1 ; 75:y=115.2 ; 92:y=107.3 -->
            <polyline points="60,140 100,136 140,132 180,128" fill="none" stroke="#00E5A0" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round" style="filter:drop-shadow(0 0 4px rgba(0,229,160,.6))"/>
            <polyline points="180,128 220,122 260,115 300,107" fill="none" stroke="#00E5A0" stroke-width="2.5" stroke-linecap="round" stroke-linejoin="round" stroke-dasharray="5,3" opacity=".7"/>
            <!-- ABT dots -->
            <circle cx="60" cy="140" r="4" fill="#00E5A0" style="filter:drop-shadow(0 0 5px rgba(0,229,160,.7))"/>
            <circle cx="100" cy="136" r="4" fill="#00E5A0" style="filter:drop-shadow(0 0 5px rgba(0,229,160,.7))"/>
            <circle cx="140" cy="132" r="4" fill="#00E5A0" style="filter:drop-shadow(0 0 5px rgba(0,229,160,.7))"/>
            <circle cx="180" cy="128" r="5" fill="#00E5A0" stroke="#00BEFF" stroke-width="2" style="filter:drop-shadow(0 0 6px rgba(0,229,160,.8))"/>
            <circle cx="220" cy="122" r="4" fill="#0a0a0a" stroke="#00E5A0" stroke-width="2" opacity=".7"/>
            <circle cx="260" cy="115" r="4" fill="#0a0a0a" stroke="#00E5A0" stroke-width="2" opacity=".6"/>
            <circle cx="300" cy="107" r="4" fill="#0a0a0a" stroke="#00E5A0" stroke-width="2" opacity=".5"/>
            <!-- ABT label -->
            <rect x="44" y="128" width="20" height="12" rx="6" fill="#1a1a1a" stroke="rgba(0,229,160,.5)" stroke-width="1"/>
            <text x="54" y="137" text-anchor="middle" fill="#00E5A0" font-size="7" font-weight="700" font-family="monospace">22</text>
            <!-- Legend -->
            <circle cx="50" cy="175" r="3" fill="#A100FF"/>
            <text x="56" y="178" fill="#666" font-size="8" font-family="monospace">Medtronic</text>
            <circle cx="110" cy="175" r="3" fill="#00E5A0"/>
            <text x="116" y="178" fill="#666" font-size="8" font-family="monospace">Abbott</text>
            <line x1="170" y1="175" x2="183" y2="175" stroke="#E91E8C" stroke-width="1" stroke-dasharray="3,2" opacity=".6"/>
            <text x="187" y="178" fill="#555" font-size="8" font-family="monospace">Forecast</text>
          </svg>
        </div>
      </div>
    </div>

    <!-- ‚ïê‚ïê SECTION IV: CONFIDENCE CARDS + RISK FLAGS (3+2 grid) ‚ïê‚ïê -->
    <div style="background:linear-gradient(90deg,#0078D4,#A100FF,#E91E8C);border-radius:8px 8px 0 0;padding:10px 20px;margin-bottom:0">
      <div style="font-family:monospace;font-size:11px;font-weight:700;color:#fff;letter-spacing:.12em">IV ¬∑ PROBABILITY CONFIDENCE CARDS + RISK SIGNAL MONITOR</div>
    </div>
    <div style="background:#0f0f0f;border:1px solid #1a1a1a;border-top:none;border-radius:0 0 12px 12px;padding:24px;margin-bottom:24px">
      <div style="display:grid;grid-template-columns:repeat(5,1fr);gap:12px">

        <!-- Conf card 1 -->
        <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-top:2px solid #A100FF;border-radius:10px;padding:18px 14px;text-align:center;position:relative;overflow:hidden">
          <div style="position:absolute;bottom:-20px;right:-20px;width:80px;height:80px;background:radial-gradient(circle,rgba(161,0,255,.08),transparent 70%);pointer-events:none"></div>
          <svg width="60" height="60" viewBox="0 0 60 60" style="margin:0 auto 10px">
            <circle cx="30" cy="30" r="24" fill="none" stroke="#1a1a1a" stroke-width="5"/>
            <circle cx="30" cy="30" r="24" fill="none" class="conf-arc" data-offset="31" stroke="#A100FF" stroke-width="5" stroke-dasharray="150.8" stroke-dashoffset="150.8" transform="rotate(-90 30 30)" stroke-linecap="round" style="filter:drop-shadow(0 0 3px rgba(161,0,255,.7))"/>
            <text x="30" y="34" text-anchor="middle" fill="#A100FF" font-size="11" font-weight="700" font-family="monospace">79%</text>
          </svg>
          <div style="font-size:11px;font-weight:700;color:#e8e8e8;margin-bottom:4px">12-Mo Filing</div>
          <div style="font-size:9px;color:#3a3a3a;font-family:monospace">20‚Äì26 supplements</div>
          <div style="margin-top:10px;font-family:monospace;font-size:8px;background:rgba(161,0,255,.1);color:#A100FF;border:1px solid rgba(161,0,255,.25);border-radius:3px;padding:2px 6px;display:inline-block">HIGH</div>
        </div>

        <!-- Conf card 2 -->
        <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-top:2px solid #00BEFF;border-radius:10px;padding:18px 14px;text-align:center;position:relative;overflow:hidden">
          <div style="position:absolute;bottom:-20px;right:-20px;width:80px;height:80px;background:radial-gradient(circle,rgba(0,190,255,.07),transparent 70%);pointer-events:none"></div>
          <svg width="60" height="60" viewBox="0 0 60 60" style="margin:0 auto 10px">
            <circle cx="30" cy="30" r="24" fill="none" stroke="#1a1a1a" stroke-width="5"/>
            <circle cx="30" cy="30" r="24" fill="none" class="conf-arc" data-offset="47" stroke="#00BEFF" stroke-width="5" stroke-dasharray="150.8" stroke-dashoffset="150.8" transform="rotate(-90 30 30)" stroke-linecap="round" style="filter:drop-shadow(0 0 3px rgba(0,190,255,.6))"/>
            <text x="30" y="34" text-anchor="middle" fill="#00BEFF" font-size="11" font-weight="700" font-family="monospace">69%</text>
          </svg>
          <div style="font-size:11px;font-weight:700;color:#e8e8e8;margin-bottom:4px">24-Mo Filing</div>
          <div style="font-size:9px;color:#3a3a3a;font-family:monospace">42‚Äì52 supplements</div>
          <div style="margin-top:10px;font-family:monospace;font-size:8px;background:rgba(0,190,255,.1);color:#00BEFF;border:1px solid rgba(0,190,255,.25);border-radius:3px;padding:2px 6px;display:inline-block">MED-HIGH</div>
        </div>

        <!-- Conf card 3: Panel Track -->
        <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-top:2px solid #00E5A0;border-radius:10px;padding:18px 14px;text-align:center;position:relative;overflow:hidden">
          <div style="position:absolute;bottom:-20px;right:-20px;width:80px;height:80px;background:radial-gradient(circle,rgba(0,229,160,.07),transparent 70%);pointer-events:none"></div>
          <svg width="60" height="60" viewBox="0 0 60 60" style="margin:0 auto 10px">
            <circle cx="30" cy="30" r="24" fill="none" stroke="#1a1a1a" stroke-width="5"/>
            <circle cx="30" cy="30" r="24" fill="none" class="conf-arc" data-offset="71" stroke="#00E5A0" stroke-width="5" stroke-dasharray="150.8" stroke-dashoffset="150.8" transform="rotate(-90 30 30)" stroke-linecap="round" style="filter:drop-shadow(0 0 3px rgba(0,229,160,.6))"/>
            <text x="30" y="34" text-anchor="middle" fill="#00E5A0" font-size="11" font-weight="700" font-family="monospace">53%</text>
          </svg>
          <div style="font-size:11px;font-weight:700;color:#e8e8e8;margin-bottom:4px">Panel Track</div>
          <div style="font-size:9px;color:#3a3a3a;font-family:monospace">2026‚Äì27 window</div>
          <div style="margin-top:10px;font-family:monospace;font-size:8px;background:rgba(0,229,160,.1);color:#00E5A0;border:1px solid rgba(0,229,160,.25);border-radius:3px;padding:2px 6px;display:inline-block">MEDIUM</div>
        </div>

        <!-- Risk: BSX approval -->
        <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-top:2px solid #FF6B00;border-radius:10px;padding:18px 14px;text-align:center;position:relative;overflow:hidden">
          <div style="position:absolute;bottom:-20px;right:-20px;width:80px;height:80px;background:radial-gradient(circle,rgba(255,107,0,.07),transparent 70%);pointer-events:none"></div>
          <svg width="60" height="60" viewBox="0 0 60 60" style="margin:0 auto 10px">
            <circle cx="30" cy="30" r="24" fill="none" stroke="#1a1a1a" stroke-width="5"/>
            <circle cx="30" cy="30" r="24" fill="none" class="conf-arc" data-offset="50" stroke="#FF6B00" stroke-width="5" stroke-dasharray="150.8" stroke-dashoffset="150.8" transform="rotate(-90 30 30)" stroke-linecap="round" style="filter:drop-shadow(0 0 3px rgba(255,107,0,.6))"/>
            <text x="30" y="34" text-anchor="middle" fill="#FF6B00" font-size="11" font-weight="700" font-family="monospace">67%</text>
          </svg>
          <div style="font-size:11px;font-weight:700;color:#e8e8e8;margin-bottom:4px">BSX Approval</div>
          <div style="font-size:9px;color:#3a3a3a;font-family:monospace">By Q4 2026</div>
          <div style="margin-top:10px;font-family:monospace;font-size:8px;background:rgba(255,107,0,.1);color:#FF6B00;border:1px solid rgba(255,107,0,.25);border-radius:3px;padding:2px 6px;display:inline-block">WATCH</div>
        </div>

        <!-- Risk: Market disruption -->
        <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-top:2px solid #E91E8C;border-radius:10px;padding:18px 14px;text-align:center;position:relative;overflow:hidden">
          <div style="position:absolute;bottom:-20px;right:-20px;width:80px;height:80px;background:radial-gradient(circle,rgba(233,30,140,.07),transparent 70%);pointer-events:none"></div>
          <svg width="60" height="60" viewBox="0 0 60 60" style="margin:0 auto 10px">
            <circle cx="30" cy="30" r="24" fill="none" stroke="#1a1a1a" stroke-width="5"/>
            <circle cx="30" cy="30" r="24" fill="none" class="conf-arc" data-offset="59" stroke="#E91E8C" stroke-width="5" stroke-dasharray="150.8" stroke-dashoffset="150.8" transform="rotate(-90 30 30)" stroke-linecap="round" style="filter:drop-shadow(0 0 3px rgba(233,30,140,.6))"/>
            <text x="30" y="34" text-anchor="middle" fill="#E91E8C" font-size="11" font-weight="700" font-family="monospace">61%</text>
          </svg>
          <div style="font-size:11px;font-weight:700;color:#e8e8e8;margin-bottom:4px">Market Risk</div>
          <div style="font-size:9px;color:#3a3a3a;font-family:monospace">BSX disruption</div>
          <div style="margin-top:10px;font-family:monospace;font-size:8px;background:rgba(233,30,140,.1);color:#E91E8C;border:1px solid rgba(233,30,140,.25);border-radius:3px;padding:2px 6px;display:inline-block">MONITOR</div>
        </div>

      </div>
    </div>

    <!-- ‚ïê‚ïê SECTION V: PREDICTED FAILURE MODES ‚ïê‚ïê -->
    <div style="background:linear-gradient(90deg,#FF1744,#E91E8C,#A100FF);border-radius:8px 8px 0 0;padding:10px 20px;margin-bottom:0;margin-top:8px">
      <div style="font-family:monospace;font-size:11px;font-weight:700;color:#fff;letter-spacing:.12em">V ¬∑ PREDICTED REGULATORY FAILURE MODES ‚Äî SOFTWARE ¬∑ DESIGN ¬∑ MANUFACTURING</div>
    </div>
    <div style="background:#0f0f0f;border:1px solid #1a1a1a;border-top:none;border-radius:0 0 12px 12px;padding:28px 24px;margin-bottom:24px">
      <div style="font-size:9px;font-family:monospace;color:#2a2a2a;letter-spacing:.12em;margin-bottom:24px">FAILURE PROBABILITY DERIVED FROM MAUDE ADVERSE EVENT DATABASE ¬∑ P150033 SUPPLEMENT CLUSTERING PATTERNS ¬∑ CLASS III CIED HISTORICAL RECALL DATA</div>

      <div style="display:grid;grid-template-columns:repeat(3,1fr);gap:16px">

        <!-- ‚îÄ‚îÄ SOFTWARE ‚îÄ‚îÄ -->
        <div>
          <div style="display:flex;align-items:center;gap:10px;margin-bottom:16px;padding-bottom:12px;border-bottom:2px solid rgba(0,190,255,.3)">
            <div style="width:8px;height:8px;border-radius:50%;background:#00BEFF;box-shadow:0 0 8px rgba(0,190,255,.8);flex-shrink:0"></div>
            <div style="font-family:monospace;font-size:11px;font-weight:700;color:#00BEFF;letter-spacing:.12em">SOFTWARE</div>
          </div>
          <div style="display:flex;flex-direction:column;gap:10px">

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid #00BEFF;border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#e8e8e8;line-height:1.3;max-width:75%">Algorithm Telemetry Drift</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:#00BEFF">72%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="72%" style="height:100%;background:linear-gradient(90deg,rgba(0,190,255,.2),#00BEFF);border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .1s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">Rate sensing algorithm miscalibration under AF burden ‚Äî 4 prior SW supplements address this pattern. Trigger: firmware v3.x deployment cycles.</div>
              <div style="margin-top:8px;display:flex;gap:6px">
                <span style="font-family:monospace;font-size:8px;background:rgba(0,190,255,.1);color:#00BEFF;border:1px solid rgba(0,190,255,.25);border-radius:3px;padding:1px 6px">HIGH</span>
                <span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">180-DAY SUPP</span>
              </div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(0,190,255,.5);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#e8e8e8;line-height:1.3;max-width:75%">MRI Conditional Mode Failure</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:#00BEFF">58%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="58%" style="height:100%;background:linear-gradient(90deg,rgba(0,190,255,.2),rgba(0,190,255,.7));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .2s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">MRI mode activation logic edge case under 3.0T field strength. MAUDE reports 2021‚Äì23 show 11 related events. Labeling + SW co-supplement likely.</div>
              <div style="margin-top:8px;display:flex;gap:6px">
                <span style="font-family:monospace;font-size:8px;background:rgba(0,190,255,.08);color:#00BEFF;border:1px solid rgba(0,190,255,.2);border-radius:3px;padding:1px 6px">MED-HIGH</span>
                <span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">30-DAY SUPP</span>
              </div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(0,190,255,.3);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#ccc;line-height:1.3;max-width:75%">AV Sync Loss Under High Rate</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:rgba(0,190,255,.6)">41%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="41%" style="height:100%;background:linear-gradient(90deg,rgba(0,190,255,.1),rgba(0,190,255,.5));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .3s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">VDD pacing mode synchrony breakdown at HR &gt;150 bpm. MARVEL 2 dataset shows 3.2% incidence. Algorithmic patch required via OTA update supplement.</div>
              <div style="margin-top:8px;display:flex;gap:6px">
                <span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">MEDIUM</span>
                <span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">OTA UPDATE</span>
              </div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(0,190,255,.2);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#aaa;line-height:1.3;max-width:75%">Programmer Compatibility Gap</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:rgba(0,190,255,.4)">29%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="29%" style="height:100%;background:linear-gradient(90deg,rgba(0,190,255,.06),rgba(0,190,255,.3));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .4s"></div>
              </div>
              <div style="font-size:9px;color:#333;line-height:1.5">CareLink 3.x ‚Üí 4.x migration introduces backward-incompatibility with Micra VR session data. Programmer SW update supplement expected.</div>
              <div style="margin-top:8px"><span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">LOW-MED</span></div>
            </div>

          </div>
        </div>

        <!-- ‚îÄ‚îÄ DESIGN ‚îÄ‚îÄ -->
        <div>
          <div style="display:flex;align-items:center;gap:10px;margin-bottom:16px;padding-bottom:12px;border-bottom:2px solid rgba(233,30,140,.3)">
            <div style="width:8px;height:8px;border-radius:50%;background:#E91E8C;box-shadow:0 0 8px rgba(233,30,140,.8);flex-shrink:0"></div>
            <div style="font-family:monospace;font-size:11px;font-weight:700;color:#E91E8C;letter-spacing:.12em">DESIGN</div>
          </div>
          <div style="display:flex;flex-direction:column;gap:10px">

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid #E91E8C;border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#e8e8e8;line-height:1.3;max-width:75%">Tine Dislodgement Under Chronic Load</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:#E91E8C">66%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="66%" style="height:100%;background:linear-gradient(90deg,rgba(233,30,140,.2),#E91E8C);border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .1s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">Nitinol tine fatigue under RV trabecular micro-motion at 5‚Äì7yr mark. 2,847 MAUDE events include 3.1% chronic fixation complaints. Panel Track design supplement anticipated.</div>
              <div style="margin-top:8px;display:flex;gap:6px">
                <span style="font-family:monospace;font-size:8px;background:rgba(233,30,140,.1);color:#E91E8C;border:1px solid rgba(233,30,140,.25);border-radius:3px;padding:1px 6px">HIGH</span>
                <span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">PANEL TRACK</span>
              </div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(233,30,140,.5);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#e8e8e8;line-height:1.3;max-width:75%">Battery Depletion Curve Deviation</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:#E91E8C">54%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="54%" style="height:100%;background:linear-gradient(90deg,rgba(233,30,140,.15),rgba(233,30,140,.7));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .2s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">Lithium-CFx cell ERI trigger earlier than projected under high-pacing-burden patients (&gt;70%). MARVEL data shows 0.8yr longevity shortfall vs label claim in this cohort.</div>
              <div style="margin-top:8px;display:flex;gap:6px">
                <span style="font-family:monospace;font-size:8px;background:rgba(233,30,140,.08);color:#E91E8C;border:1px solid rgba(233,30,140,.2);border-radius:3px;padding:1px 6px">MED-HIGH</span>
                <span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">LABELING SUPP</span>
              </div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(233,30,140,.35);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#ccc;line-height:1.3;max-width:75%">Capsule Formation / Impedance Rise</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:rgba(233,30,140,.65)">43%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="43%" style="height:100%;background:linear-gradient(90deg,rgba(233,30,140,.1),rgba(233,30,140,.55));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .3s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">Fibrotic encapsulation elevating pacing threshold beyond effective output at yr 4‚Äì6. Electrode coating design change supplement under internal review per LEADLESS II follow-up.</div>
              <div style="margin-top:8px"><span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">MEDIUM</span></div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(233,30,140,.2);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#aaa;line-height:1.3;max-width:75%">Retrieval Tether Fatigue</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:rgba(233,30,140,.4)">31%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="31%" style="height:100%;background:linear-gradient(90deg,rgba(233,30,140,.06),rgba(233,30,140,.35));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .4s"></div>
              </div>
              <div style="font-size:9px;color:#333;line-height:1.5">Tether polyester braid degradation under repeated dislodgement-reattempt cycles. Accessory supplement for revised retrieval catheter design expected within 18 months.</div>
              <div style="margin-top:8px"><span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">LOW-MED</span></div>
            </div>

          </div>
        </div>

        <!-- ‚îÄ‚îÄ MANUFACTURING ‚îÄ‚îÄ -->
        <div>
          <div style="display:flex;align-items:center;gap:10px;margin-bottom:16px;padding-bottom:12px;border-bottom:2px solid rgba(0,120,212,.3)">
            <div style="width:8px;height:8px;border-radius:50%;background:#0078D4;box-shadow:0 0 8px rgba(0,120,212,.8);flex-shrink:0"></div>
            <div style="font-family:monospace;font-size:11px;font-weight:700;color:#0078D4;letter-spacing:.12em">MANUFACTURING</div>
          </div>
          <div style="display:flex;flex-direction:column;gap:10px">

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid #0078D4;border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#e8e8e8;line-height:1.3;max-width:75%">Hermetic Seal Micro-leak</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:#0078D4">69%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="69%" style="height:100%;background:linear-gradient(90deg,rgba(0,120,212,.2),#0078D4);border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .1s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">Laser weld joint integrity at titanium-feedthrough interface. 85 manufacturing supplements historically address process SOP deviations at this junction. High-probability recurrence.</div>
              <div style="margin-top:8px;display:flex;gap:6px">
                <span style="font-family:monospace;font-size:8px;background:rgba(0,120,212,.12);color:#0078D4;border:1px solid rgba(0,120,212,.3);border-radius:3px;padding:1px 6px">HIGH</span>
                <span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">30-DAY SUPP</span>
              </div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(0,120,212,.55);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#e8e8e8;line-height:1.3;max-width:75%">Component Supplier Change ‚Äî Capacitor</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:#0078D4">61%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="61%" style="height:100%;background:linear-gradient(90deg,rgba(0,120,212,.15),rgba(0,120,212,.75));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .2s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">Tantalum electrolytic capacitor qualification from alternate supplier triggers 30-day supplement. Global supply chain realignment post-2024 creates elevated likelihood of component swap.</div>
              <div style="margin-top:8px;display:flex;gap:6px">
                <span style="font-family:monospace;font-size:8px;background:rgba(0,120,212,.1);color:#0078D4;border:1px solid rgba(0,120,212,.25);border-radius:3px;padding:1px 6px">MED-HIGH</span>
                <span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">30-DAY SUPP</span>
              </div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(0,120,212,.38);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#ccc;line-height:1.3;max-width:75%">Sterilization Validation Gap</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:rgba(0,120,212,.65)">47%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="47%" style="height:100%;background:linear-gradient(90deg,rgba(0,120,212,.1),rgba(0,120,212,.55));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .3s"></div>
              </div>
              <div style="font-size:9px;color:#444;line-height:1.5">EtO cycle parameter drift at Mounds View facility. ISO 11135 revalidation triggers 180-day supplement. Three prior supplements address this specific process path (2019, 2021, 2023).</div>
              <div style="margin-top:8px"><span style="font-family:monospace;font-size:8px;color:#444;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">MEDIUM</span></div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(0,120,212,.25);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#aaa;line-height:1.3;max-width:75%">Electrode Coating Process Drift</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:rgba(0,120,212,.45)">34%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="34%" style="height:100%;background:linear-gradient(90deg,rgba(0,120,212,.07),rgba(0,120,212,.4));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .4s"></div>
              </div>
              <div style="font-size:9px;color:#333;line-height:1.5">IROX coating uniformity variation altering chronic pacing threshold. Process SOP supplement required. Linked to 2022 batch recall investigation ‚Äî recurrence probability moderate.</div>
              <div style="margin-top:8px"><span style="font-family:monospace;font-size:8px;color:#333;border:1px solid #1f1f1f;border-radius:3px;padding:1px 6px">LOW-MED</span></div>
            </div>

            <div style="background:#0a0a0a;border:1px solid #1a1a1a;border-left:3px solid rgba(0,120,212,.15);border-radius:8px;padding:14px 16px">
              <div style="display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:8px">
                <div style="font-size:12px;font-weight:700;color:#888;line-height:1.3;max-width:75%">Packaging Integrity ‚Äî Foil Seal</div>
                <div style="font-family:monospace;font-size:15px;font-weight:700;color:rgba(0,120,212,.3)">21%</div>
              </div>
              <div style="height:4px;background:#111;border-radius:2px;margin-bottom:8px;overflow:hidden">
                <div class="fail-bar" data-w="21%" style="height:100%;background:linear-gradient(90deg,rgba(0,120,212,.04),rgba(0,120,212,.28));border-radius:2px;width:0;transition:width 1.1s cubic-bezier(.16,1,.3,1) .5s"></div>
              </div>
              <div style="font-size:9px;color:#2e2e2e;line-height:1.5">Tyvek pouch heat-seal validation following packaging line upgrade. Low probability but regulatory path is well-defined ‚Äî 30-day supplement, single-cycle re-validation study.</div>
              <div style="margin-top:8px"><span style="font-family:monospace;font-size:8px;color:#2a2a2a;border:1px solid #181818;border-radius:3px;padding:1px 6px">LOW</span></div>
            </div>

          </div>
        </div>

      </div>
    </div>

    <div style="font-size:9px;color:#222;font-family:monospace;text-align:center;padding-bottom:8px;letter-spacing:.08em">FORECASTS DERIVED FROM HISTORICAL PATTERN ANALYSIS ¬∑ NOT FDA GUIDANCE ¬∑ FOR STRATEGIC PLANNING ONLY ¬∑ MODEL: FEB 2026</div>

  </div><!-- /tab-predict -->

</div>

<script>
function toggleMilestoneDetail() {
  var b  = document.getElementById('mdBody');
  var ch = document.getElementById('mdChevron');
  var lb = document.getElementById('mdLabel');
  var open = b.style.display === 'none';
  b.style.display = open ? 'block' : 'none';
  if (ch) ch.textContent = open ? '‚ñ≤ COLLAPSE' : '‚ñº EXPAND';
  var tog = document.getElementById('overviewToggle');
  if (tog) tog.style.borderRadius = open ? '10px 10px 0 0' : '10px';
}

function toggleMs(id, hdr) {
  const body = document.getElementById(id);
  const ch   = document.getElementById(id + '-ch');
  const open = body.classList.toggle('open');
  if (ch) { ch.style.transform = open ? 'rotate(180deg)' : 'rotate(0deg)'; ch.style.opacity = open ? '1' : '0.4'; }
}

function toggleOverview() {
  var body  = document.getElementById('overviewBody');
  var ch    = document.getElementById('overviewChevron');
  var lb    = document.getElementById('overviewLabel');
  var open  = body.style.display === 'none';
  body.style.display = open ? 'block' : 'none';
  if (ch) ch.textContent = open ? '‚ñ≤ COLLAPSE' : '‚ñº EXPAND';
  var tog = document.getElementById('overviewToggle');
  if (tog) tog.style.borderRadius = open ? '10px 10px 0 0' : '10px';
  toggle.style.borderBottom = open ? '1px solid transparent' : '1px solid #2D0066';
}

function switchOvTab(idx, btn) {
  document.querySelectorAll('.ov-panel').forEach(p => p.style.display = 'none');
  document.querySelectorAll('.ov-tab').forEach(b => {
    b.style.color = '#475569';
    b.style.background = 'none';
    b.style.borderBottom = '3px solid transparent';
  });
  document.getElementById('ov-' + idx).style.display = 'block';
  const colors = ['#A100FF','#00BEFF','#E91E8C','#FF6B00'];
  btn.style.color = '#fff';
  btn.style.background = 'rgba(' + [
    '161,0,255','0,190,255','233,30,140','255,107,0'
  ][idx] + ',.25)';
  btn.style.borderBottom = '3px solid ' + colors[idx];
}

function switchTab(tab, btn) {
  document.querySelectorAll('.tab-panel').forEach(p => p.classList.remove('active'));
  document.querySelectorAll('.tab-btn').forEach(b => {
    b.classList.remove('active');
    b.style.background = '';
    b.style.borderLeftColor = 'transparent';
    const h = b.querySelector('.tb-handle');
    const l = b.querySelector('.tb-label');
    if(h) h.style.color = '';
    if(l) l.style.color = '';
  });
  document.getElementById('tab-' + tab).classList.add('active');
  btn.classList.add('active');
  const colors = {'micra':'#A100FF','competitor':'#00BEFF','predict':'#E91E8C'};
  const c = colors[tab] || '#A100FF';
  btn.style.background = c.replace('#','rgba(').replace(')',',').replace('rgba(','rgba(') + '0.08)';
  btn.style.borderLeftColor = c;
  const h2 = btn.querySelector('.tb-handle');
  const l2 = btn.querySelector('.tb-label');
  if(h2) h2.style.color = c;
  if(l2) l2.style.color = '#fff';
}

const CATS = [
  {
    name:"Manufacturing Changes", icon:"‚öôÔ∏è", color:"#00BEFF", count:85, pct:39,
    sig:"Low ‚Äî operational continuity", burden:"Low ‚Äî 30-day notice",
    suppType:"30-Day Notice / Real-Time",
    desc:"Process controls, material/supplier changes, sterilization updates, packaging and shelf-life extensions ‚Äî highest volume, lowest regulatory burden.",
    examples:[
      {supp:"S003‚ÄìS010",      date:"2016‚Äì2017", detail:"Initial post-approval manufacturing process validations"},
      {supp:"S020s‚ÄìS050s",    date:"2017‚Äì2019", detail:"Component supplier qualifications, sterilization cycle updates"},
      {supp:"S070s‚ÄìS110s",    date:"2019‚Äì2021", detail:"Catheter material changes, packaging updates, shelf-life extensions"},
      {supp:"S120s‚ÄìS160s",    date:"2021‚Äì2023", detail:"AV2/VR2 manufacturing scale-up, line transfer validations"},
      {supp:"S170s‚ÄìS219",     date:"2023‚Äì2025", detail:"Ongoing continuous improvement, global supply chain updates"},
    ]
  },
  {
    name:"Software / Algorithm Updates", icon:"üíª", color:"#CC00FF", count:42, pct:19,
    sig:"Medium-High ‚Äî pacing performance", burden:"Medium ‚Äî bench + V&V",
    suppType:"180-Day / Real-Time",
    desc:"Programmer software versions, pacing algorithm refinements, CareLink remote monitoring integration, rate-response and AV synchrony enhancements.",
    examples:[
      {supp:"S002",           date:"2016",      detail:"SW022 v1.2 ‚Äî initial software update post-launch"},
      {supp:"~S015‚ÄìS030",     date:"2017‚Äì2018", detail:"Rate-response algorithm refinements, CareLink integration"},
      {supp:"~S040‚ÄìS060",     date:"2018‚Äì2019", detail:"Pre-Micra AV algorithm development (AV synchrony groundwork)"},
      {supp:"S062‚ÄìS080",      date:"2020‚Äì2021", detail:"SW044 updates ‚Äî Micra AV algorithm optimization post-approval"},
      {supp:"~S150‚ÄìS180",     date:"2023‚Äì2024", detail:"AV2 auto-AV synchrony algorithm, SW updates for VR2"},
    ]
  },
  {
    name:"Accessory & Delivery System", icon:"üîß", color:"#00E5A0", count:37, pct:17,
    sig:"Medium ‚Äî implant safety & usability", burden:"Medium ‚Äî bench testing",
    suppType:"180-Day / Special",
    desc:"Delivery catheter redesigns, introducer sheath updates, retrieval tool additions, accessories for new anatomical approaches.",
    examples:[
      {supp:"~S005‚ÄìS012",     date:"2016‚Äì2017", detail:"Delivery catheter tip refinements to improve implant stability"},
      {supp:"~S025‚ÄìS045",     date:"2018‚Äì2019", detail:"23F introducer updates; steerable catheter handle ergonomic changes"},
      {supp:"~S065‚ÄìS090",     date:"2020‚Äì2021", detail:"Retrieval tool label update; TAVI/post-cardiac surgery adaptations"},
      {supp:"~S100‚ÄìS130",     date:"2021‚Äì2022", detail:"Updated delivery system for AV2 form factor"},
      {supp:"~S185‚ÄìS210",     date:"2024‚Äì2025", detail:"Next-gen delivery catheter with enhanced steerability"},
    ]
  },
  {
    name:"Labeling Expansions", icon:"üìã", color:"#FF6B35", count:28, pct:13,
    sig:"High ‚Äî authorized claims", burden:"High ‚Äî clinical data required",
    suppType:"Panel Track / 180-Day",
    desc:"New or expanded indications, MRI conditionality expansions, IFU updates, patient population expansions, safety communications.",
    examples:[
      {supp:"S001",           date:"2016",      detail:"Initial post-approval labeling clarifications ‚Äî IFU refinements"},
      {supp:"~S018‚ÄìS022",     date:"2017",      detail:"MRI conditionality labeling update (1.5T/3T full-body MRI)"},
      {supp:"S061",           date:"Jan 2020",  detail:"Micra AV label: new VDD pacing indication for AV block patients"},
      {supp:"~S095‚ÄìS105",     date:"2021",      detail:"Cardiac perforation/tamponade risk communication; updated warnings"},
      {supp:"~S145‚ÄìS155",     date:"2023",      detail:"Micra AV2/VR2 labeling; 40% battery life claim; >80% device-for-life"},
    ]
  },
  {
    name:"Design Changes / New Models", icon:"üî¨", color:"#FF1744", count:25, pct:12,
    sig:"Very High ‚Äî new patient populations", burden:"Very High ‚Äî panel track",
    suppType:"Panel Track / 180-Day",
    desc:"Hardware platform changes, new device models, battery chemistry, fixation tine redesigns ‚Äî includes the two major Panel Track supplements (Micra AV & AV2).",
    examples:[
      {supp:"~S008‚ÄìS015",     date:"2016‚Äì2017", detail:"Gen 1 post-launch design refinements from early clinical registry"},
      {supp:"~S035‚ÄìS050",     date:"2018‚Äì2019", detail:"Structural design optimization ‚Äî tine geometry, MCRD drug-eluting"},
      {supp:"S061 (Panel)",   date:"Jan 2020",  detail:"Micra AV (MC1AVR1) ‚Äî new accelerometer-based AV sensing platform"},
      {supp:"~S120‚ÄìS135",     date:"2022",      detail:"Battery chemistry change supporting extended longevity AV2/VR2"},
      {supp:"~S140‚ÄìS152",     date:"May 2023",  detail:"Micra AV2 & VR2 ‚Äî 2nd gen hardware, 40% more battery"},
    ]
  },
];

const TOTAL = 217;
let selCat  = null;   // for Section 1 highlight
let expanded = null;  // for Section 3 expand

let liveSupps  = [];
let liveLoaded = false;
let s4Filter   = null;

// ‚îÄ‚îÄ Section 1 toggle (KPIs + chart highlight) ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function toggleChart(i) {
  selCat = selCat === i ? null : i;
  renderKPIs();
  renderChart();
  renderDetailPanel();
}

// ‚îÄ‚îÄ Section 3 toggle (expand row) ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function toggleExpand(i) {
  expanded = expanded === i ? null : i;
  renderSummaryTable();
  if (expanded !== null) {
    setTimeout(() => {
      const el = document.getElementById(`exp-row-${i}`);
      if (el) el.scrollIntoView({behavior:'smooth', block:'nearest'});
    }, 50);
  }
}

// ‚îÄ‚îÄ Section 4 filter ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function setS4Filter(i) {
  s4Filter = s4Filter === i ? null : i;
  renderSuppTable();
}

function badgeStyle(t) {
  if (!t) return 'background:#1a1a1a;color:#64748b';
  const u = t.toUpperCase();
  if (/PANEL/.test(u))      return 'background:#1a0044;color:#CC33FF';
  if (/180/.test(u))        return 'background:#0a0a2a;color:#00D4FF';
  if (/30|REAL/.test(u))    return 'background:#001a0a;color:#00E676';
  if (/LABEL/.test(u))      return 'background:#1a0800;color:#FF6B00';
  if (/SPECIAL/.test(u))    return 'background:#001a0a;color:#2dd4bf';
  return 'background:#1a1a1a;color:#64748b';
}

// ‚îÄ‚îÄ Render KPIs ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function renderKPIs() {
  document.getElementById('kpiGrid').innerHTML = CATS.map((c, i) =>
    `<button class="kpi-card" style="${selCat===i?`background:${c.color}22;border-color:${c.color}`:'border-color:#1a1a1a'}" onclick="toggleChart(${i})">
      <div class="kpi-icon">${c.icon}</div>
      <div class="kpi-count" style="color:${c.color}">${c.count}</div>
      <div class="kpi-pct">${c.pct}% of total</div>
      <div class="kpi-name">${c.name}</div>
    </button>`).join('');
}

// ‚îÄ‚îÄ Render Chart ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function renderChart() {
  const maxCnt = Math.max(...CATS.map(c=>c.count));
  document.getElementById('chartLabel').textContent = `SUPPLEMENT VOLUME BY CATEGORY ‚Äî TOTAL: ${TOTAL}`;
  document.getElementById('barChart').innerHTML = CATS.map((c, i) => {
    const wPct = ((c.count/maxCnt)*100).toFixed(1);
    const op = selCat===null||selCat===i ? 1 : 0.18;
    const dimStyle = op < 1 ? 'opacity:'+op : '';
    const selClass = (selCat===i) ? ' selected' : '';
    const colorRgb = c.color.replace('#','');
    const r=parseInt(colorRgb.substr(0,2),16),g=parseInt(colorRgb.substr(2,2),16),b=parseInt(colorRgb.substr(4,2),16);
    const shortName = c.name.replace(' / Algorithm Updates','').replace(' & Delivery System','').replace(' Changes','').replace(' Expansions','');
    return `<div class="bar-col${selClass}" onclick="toggleChart(${i})" style="${dimStyle}">
      <div class="bar-label-col" style="after-background:${c.color}">
        <div style="position:absolute;right:-1px;top:25%;height:50%;width:2px;background:${c.color};opacity:.45;border-radius:1px"></div>
        <div style="font-family:monospace;font-size:9px;color:#444;letter-spacing:.15em;margin-bottom:4px">CAT 0${i+1}</div>
        <div class="bar-name">${c.icon} ${shortName}</div>
        <div class="bar-sub">${c.suppType}</div>
      </div>
      <div class="bar-track-col">
        <div class="bar-track">
          <div class="bar-h" data-w="${wPct}%" style="background:linear-gradient(90deg,rgba(${r},${g},${b},.12),${c.color});box-shadow:0 0 10px rgba(${r},${g},${b},.25)">
            <div class="bar-bubble" style="color:${c.color};border-color:${c.color};box-shadow:0 0 6px rgba(${r},${g},${b},.3)">${c.count} <span style="font-size:9px;opacity:.6">(${c.pct}%)</span></div>
          </div>
        </div>
        <div class="bar-pct" style="margin-left:4px;color:${c.color};opacity:.4">${c.sig}</div>
      </div>
    </div>`;
  }).join('');
  // animate bars
  requestAnimationFrame(() => {
    document.querySelectorAll('#barChart .bar-h').forEach((b,i) => {
      b.style.width = '0';
      setTimeout(() => { b.style.width = b.getAttribute('data-w'); }, 80 + i*120);
    });
  });
}

// ‚îÄ‚îÄ Render top detail panel ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function renderDetailPanel() {
  const dp = document.getElementById('detailPanel');
  if (selCat===null){dp.innerHTML='';return;}
  const c = CATS[selCat];
  dp.innerHTML = `
    <div class="detail-panel" style="background:#0f0f0f;border:1px solid ${c.color}55;margin-bottom:32px">
      <div class="d-hdr">
        <span class="d-icon">${c.icon}</span>
        <div><div class="d-title" style="color:${c.color}">${c.name}</div>
        <div class="d-type">Supplement Type: ${c.suppType}</div></div>
        <div style="margin-left:auto;text-align:right">
          <div class="d-count" style="color:${c.color}">${c.count}</div>
          <div class="d-pct">${c.pct}% of ${TOTAL}</div>
        </div>
      </div>
      <p class="d-desc">${c.desc}</p>
      <div style="font-size:11px;color:#475569;font-family:monospace">‚Üì Click this category in Section 3 below for full expandable supplement list</div>
    </div>`;
}

// ‚îÄ‚îÄ Render Section 3 expandable summary ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function renderSummaryTable() {
  let html = '';
  CATS.forEach((c, i) => {
    const isOpen   = expanded === i;
    const rowBg    = isOpen ? c.color+'18' : i%2===0 ? 'transparent' : '#111111';
    const arrowCls = isOpen ? 'expand-arrow open' : 'expand-arrow';

    // Main summary row
    html += `<tr class="sum-row" style="background:${rowBg};border-bottom:${isOpen?'none':'1px solid #1a1a1a'}" onclick="toggleExpand(${i})">
      <td class="s-td" style="width:32px"><span class="${arrowCls}">‚ñ∂</span></td>
      <td class="s-td" style="color:${c.color};font-weight:700">${i+1}</td>
      <td class="s-td"><span style="font-size:15px;margin-right:8px">${c.icon}</span><span style="color:#f1f5f9;font-weight:600">${c.name}</span></td>
      <td class="s-td" style="color:#94a3b8;font-size:11px;font-family:monospace">${c.suppType}</td>
      <td class="s-td" style="color:${c.color};font-weight:700;font-size:20px">${c.count}</td>
      <td class="s-td">
        <div class="prog-wrap">
          <div class="prog-track"><div class="prog-fill" style="width:${c.pct}%;background:${c.color}"></div></div>
          <span style="color:#94a3b8;font-size:12px">${c.pct}%</span>
        </div>
      </td>
      <td class="s-td" style="color:#94a3b8;font-size:12px">${c.sig}</td>
      <td class="s-td" style="color:#94a3b8;font-size:12px">${c.burden}</td>
    </tr>`;

    // Expandable row
    html += `<tr id="exp-row-${i}" class="expand-row ${isOpen?'open':''}">
      <td colspan="8" class="expand-inner">
        <div class="exp-box" style="border-left:3px solid ${c.color}">

          <!-- Header -->
          <div class="exp-header">
            <span style="font-size:28px">${c.icon}</span>
            <div>
              <div style="font-size:16px;font-weight:700;color:${c.color}">${c.name}</div>
              <div style="font-size:11px;color:#64748b;margin-top:2px">Supplement Type: ${c.suppType} ¬∑ Regulatory Burden: ${c.burden}</div>
            </div>
            <div style="margin-left:auto;background:${c.color};color:#fff;border-radius:8px;padding:6px 18px;text-align:center">
              <div style="font-size:28px;font-weight:700;line-height:1">${c.count}</div>
              <div style="font-size:10px;letter-spacing:.1em">SUPPLEMENTS</div>
            </div>
          </div>

          <!-- Description -->
          <p class="exp-desc">${c.desc}</p>

          <!-- Representative examples table -->
          <div style="font-size:10px;letter-spacing:.15em;text-transform:uppercase;font-family:monospace;color:#334155;margin-bottom:8px">Representative Supplement Examples</div>
          <div style="overflow-x:auto;margin-bottom:20px">
            <table class="exp-table" style="background:#050505;border:1px solid #111111;border-radius:6px">
              <thead>
                <tr>
                  <th>Supplement(s)</th>
                  <th>Date Range</th>
                  <th>Change Description</th>
                </tr>
              </thead>
              <tbody>
                ${c.examples.map((ex,ei) => `
                  <tr style="background:${ei%2===0?'transparent':'#050505'}">
                    <td style="color:${c.color};font-family:monospace;font-weight:600;white-space:nowrap">${ex.supp}</td>
                    <td style="color:#94a3b8;white-space:nowrap">${ex.date}</td>
                    <td style="color:#cbd5e1">${ex.detail}</td>
                  </tr>`).join('')}
              </tbody>
            </table>
          </div>

          <!-- Live FDA data sub-section -->
          <div class="live-sub">
            <div class="live-sub-lbl">üì° Live FDA Supplement Records (openFDA) ‚Äî Supplement Type Matches</div>
            ${renderLiveSubTable(i, c)}
          </div>

          <!-- Close button -->
          <div style="margin-top:16px;text-align:right">
            <button onclick="toggleExpand(${i})" style="background:#0f0f0f;border:1px solid #1a1a1a;color:#64748b;padding:6px 16px;border-radius:6px;font-size:11px;font-family:monospace;cursor:pointer">‚ñ≤ Collapse</button>
          </div>
        </div>
      </td>
    </tr>`;
  });

  // Total row
  html += `<tr style="border-top:2px solid #2D0066;background:#111111">
    <td colspan="4" class="s-td" style="color:#A100FF;font-weight:700;text-transform:uppercase;font-size:11px;letter-spacing:.1em">TOTAL</td>
    <td class="s-td" style="color:#A100FF;font-weight:700;font-size:20px">${TOTAL}</td>
    <td class="s-td" style="color:#A100FF;font-weight:700">100%</td>
    <td colspan="2" class="s-td" style="color:#475569;font-size:11px">Source: FDA PMA Database P150033 ¬∑ 2016‚Äì2026</td>
  </tr>`;

  document.getElementById('summaryBody').innerHTML = html;
}

// Returns HTML for the live FDA sub-table inside each expanded row
function renderLiveSubTable(catIdx, c) {
  if (!liveLoaded) return `<div class="live-status"><span class="spinner"></span>Loading live FDA data‚Ä¶</div>`;
  if (!liveSupps.length) return `<div class="live-status" style="color:#7f1d1d">Live data unavailable ‚Äî check network connection</div>`;

  // Type filters per category
  const typeFilters = [
    /30.DAY|REAL.?TIME|MANUFACTURING/i,
    /180.DAY|SOFTWARE/i,
    /SPECIAL/i,
    /LABEL/i,
    /PANEL/i,
  ];
  const matched = liveSupps.filter(s => typeFilters[catIdx].test(s.supplement_type||''));

  if (!matched.length) {
    return `<div class="live-status">No exact supplement type matches in live FDA data ‚Äî see Section 4 for full unfiltered list.<br>
      <span style="color:#334155;font-size:10px">Note: FDA API supplement_type field uses standardized codes that may not directly map to category labels.</span></div>`;
  }

  return `<div style="overflow-x:auto">
    <table class="exp-table" style="background:#050505;border:1px solid #111111;border-radius:6px">
      <thead><tr>
        <th>Supplement #</th><th>Decision Date</th><th>Supplement Type</th><th>Trade Name</th><th>Link</th>
      </tr></thead>
      <tbody>
        ${matched.map((s,i) => {
          const snum  = s.supplement_number||'‚Äî';
          const pnum  = s.pma_number||'P150033';
          const stype = s.supplement_type||'‚Äî';
          const ddate = s.decision_date ? new Date(s.decision_date).toLocaleDateString('en-US',{year:'numeric',month:'short',day:'numeric'}) : '‚Äî';
          const tname = s.trade_name||s.generic_name||'Micra‚Ñ¢ TPS';
          const href  = `https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=${pnum}${snum}`;
          return `<tr style="background:${i%2===0?'transparent':'#050505'}">
            <td style="color:${c.color};font-family:monospace;font-weight:600;white-space:nowrap">${snum}</td>
            <td style="color:#94a3b8;white-space:nowrap">${ddate}</td>
            <td><span class="badge" style="${badgeStyle(stype)}">${stype}</span></td>
            <td style="color:#cbd5e1;max-width:220px">${tname}</td>
            <td><a href="${href}" target="_blank" style="color:#334155;font-size:10px;font-family:monospace">‚Üó VIEW</a></td>
          </tr>`;
        }).join('')}
      </tbody>
    </table>
    <div style="font-size:10px;color:#334155;font-family:monospace;margin-top:6px">${matched.length} records matched by supplement type ¬∑ Full list in Section 4</div>
  </div>`;
}

// ‚îÄ‚îÄ Render Section 4 ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
let s4Expanded = false;
const S4_PREVIEW = 6;

function toggleS4Expand() {
  s4Expanded = !s4Expanded;
  renderSuppTable();
  if (!s4Expanded) {
    const el = document.getElementById('suppLabel');
    if (el) el.scrollIntoView({behavior:'smooth', block:'nearest'});
  }
}

function renderSuppTable() {
  const items = s4Filter!==null ? liveSupps.filter(s => {
    const filters = [/30.DAY|REAL.?TIME|MANUFACTURING/i,/180.DAY|SOFTWARE/i,/SPECIAL/i,/LABEL/i,/PANEL/i];
    return filters[s4Filter].test(s.supplement_type||'');
  }) : liveSupps;

  const c = s4Filter!==null ? CATS[s4Filter] : null;
  document.getElementById('suppLabel').textContent =
    s4Filter!==null ? `SECTION 4 ¬∑ ${c.icon} ${c.name} ‚Äî ${items.length} Records`
                    : `SECTION 4 ¬∑ All ${liveSupps.length} Approved Supplements ‚Äî Live from openFDA`;

  document.getElementById('filterBtns').innerHTML =
    `<button class="fbtn" onclick="setS4Filter(null)" style="${s4Filter===null?'background:#2D0066;color:#A100FF;border:1px solid #A100FF':'background:#0f0f0f;color:#64748b;border:1px solid #1a1a1a'}">ALL (${liveSupps.length})</button>` +
    CATS.map((ct,i) => `<button class="fbtn" onclick="setS4Filter(${i})" style="${s4Filter===i?`background:${ct.color}22;color:${ct.color};border:1px solid ${ct.color}`:'background:#0f0f0f;color:#64748b;border:1px solid #1a1a1a'}">${ct.icon} ${ct.name}</button>`).join('');

  document.getElementById('suppHead').innerHTML =
    ['Supplement #','Decision Date','Supplement Type','Device / Trade Name','FDA Record']
    .map(h=>`<th>${h}</th>`).join('');

  if (!liveLoaded) return;

  const color = c ? c.color : '#A100FF';
  const visible = s4Expanded ? items : items.slice(0, S4_PREVIEW);
  const hidden  = items.length - S4_PREVIEW;

  const rows = !items.length
    ? `<tr><td colspan="5" style="padding:20px;text-align:center;color:#475569;font-family:monospace">No records found</td></tr>`
    : visible.map((s,i) => {
        const snum  = s.supplement_number||'‚Äî';
        const pnum  = s.pma_number||'P150033';
        const stype = s.supplement_type||'‚Äî';
        const ddate = s.decision_date ? new Date(s.decision_date).toLocaleDateString('en-US',{year:'numeric',month:'short',day:'numeric'}) : '‚Äî';
        const tname = s.trade_name||s.generic_name||'Micra‚Ñ¢ TPS';
        const href  = `https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=${pnum}${snum}`;
        return `<tr style="background:${i%2===0?'transparent':'#111111'};border-bottom:1px solid #111111">
          <td style="color:${color};font-family:monospace;font-weight:600;white-space:nowrap">${snum}</td>
          <td style="color:#94a3b8;white-space:nowrap">${ddate}</td>
          <td><span class="badge" style="${badgeStyle(stype)}">${stype}</span></td>
          <td style="color:#cbd5e1;max-width:280px">${tname}</td>
          <td><a href="${href}" target="_blank" style="color:#334155;font-size:10px;font-family:monospace">‚Üó VIEW</a></td>
        </tr>`;
      }).join('');

  // Expand/collapse footer row (only when there are more than 6)
  const toggleRow = items.length > S4_PREVIEW ? `
    <tr id="s4ToggleRow">
      <td colspan="5" style="padding:0;background:#080808">
        ${!s4Expanded ? `
        <!-- Fade gradient overlay -->
        <div style="height:40px;background:linear-gradient(180deg,transparent,#080808);margin-top:-40px;pointer-events:none;position:relative;z-index:2"></div>
        ` : ''}
        <div onclick="toggleS4Expand()" style="display:flex;align-items:center;justify-content:center;gap:12px;padding:14px 20px;cursor:pointer;background:#0a0a0a;border-top:1px solid #1a1a1a;transition:background .15s;user-select:none" onmouseover="this.style.background='#111'" onmouseout="this.style.background='#0a0a0a'">
          ${!s4Expanded ? `
          <span style="font-family:monospace;font-size:11px;color:#A100FF;font-weight:700;letter-spacing:.12em">‚ñº SHOW ${hidden} MORE RECORDS</span>
          <span style="font-family:monospace;font-size:9px;color:#333;letter-spacing:.08em">${items.length} TOTAL ¬∑ SHOWING ${S4_PREVIEW}</span>
          ` : `
          <span style="font-family:monospace;font-size:11px;color:#475569;font-weight:700;letter-spacing:.12em">‚ñ≤ COLLAPSE ‚Äî SHOW FIRST ${S4_PREVIEW} ONLY</span>
          <span style="font-family:monospace;font-size:9px;color:#333;letter-spacing:.08em">${items.length} TOTAL RECORDS</span>
          `}
        </div>
      </td>
    </tr>` : '';

  document.getElementById('suppBody').innerHTML = rows + toggleRow;
}

// ‚îÄ‚îÄ Boot ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
renderKPIs();
renderChart();
renderSummaryTable();
renderSuppTable();

async function fetchLive() {
  let out=[], skip=0;
  while(true){
    const r = await fetch(`https://api.fda.gov/device/pma.json?search=pma_number:P150033&limit=100&skip=${skip}`);
    if(!r.ok){if(skip===0)throw new Error(`openFDA ${r.status}`);break;}
    const j = await r.json();
    const hits = j.results||[];
    out = out.concat(hits);
    if(hits.length<100) break;
    skip+=100;
  }
  return out.filter(r=>r.supplement_number&&r.supplement_number.trim())
            .sort((a,b)=>{
              const n=x=>parseInt((x.supplement_number||'').replace(/\D/g,''))||0;
              return n(a)-n(b);
            });
}

fetchLive().then(data => {
  liveSupps  = data;
  liveLoaded = true;
  // Re-render Section 3 expanded row if open, and Section 4
  if (expanded !== null) renderSummaryTable();
  renderSuppTable();
}).catch(e => {
  liveLoaded = true;
  document.getElementById('errorMsg').style.display = 'block';
  document.getElementById('errorMsg').innerHTML =
    `<strong>‚ö† Live supplement list unavailable:</strong> ${e.message} ‚Äî
     <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p150033" target="_blank">View directly on FDA.gov</a>`;
  renderSuppTable();
});

// ‚îÄ‚îÄ HCC Bar Animation ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ‚îÄ
function animateHCCBars() {
  const fills = document.querySelectorAll('.hcc-fill, .svc-bar');
  // Vertical bars
  const vbars = document.querySelectorAll('.vbar-fill');
  vbars.forEach(b => { b.style.height = '0'; });
  setTimeout(() => {
    vbars.forEach((b, i) => {
      setTimeout(() => {
        b.style.height = b.getAttribute('data-h') || '0%';
      }, i * 60);
    });
  }, 400);
  fills.forEach((bar, i) => {
    const target = bar.getAttribute('data-w') || '0%';
    bar.style.width = '0';
    setTimeout(() => {
      bar.style.transition = 'width 1.1s cubic-bezier(.16,1,.3,1)';
      bar.style.width = target;
    }, 300 + i * 130);
  });
}

// Observe competitor tab activation to trigger animation
const origSwitch = window.switchTab;
window.switchTab = function(tab, btn) {
  origSwitch(tab, btn);

  if (tab === 'micra') {
    // Re-run renderChart so bars animate in fresh
    setTimeout(() => { renderChart(); }, 80);
  }

  if (tab === 'competitor') setTimeout(animateHCCBars, 100);

  if (tab === 'predict') setTimeout(() => {
    // Failure mode bars
    document.querySelectorAll('.fail-bar').forEach(b => {
      b.style.width = '0';
      setTimeout(() => { b.style.width = b.getAttribute('data-w') || '0%'; }, 600);
    });
    // Horizontal prediction bars
    document.querySelectorAll('.pred-bar').forEach(b => {
      b.style.width = '0';
      setTimeout(() => { b.style.width = b.getAttribute('data-w') || '0%'; }, 150);
    });
    // Vertical forecast bars
    document.querySelectorAll('.fc-bar').forEach(b => {
      b.style.height = '0';
      setTimeout(() => { b.style.height = b.getAttribute('data-h') || '0%'; }, 200);
    });
    // Arc gauge circles ‚Äî animate stroke-dashoffset from full (150.8) to target
    const circ = 150.8;
    document.querySelectorAll('.conf-arc').forEach((arc, i) => {
      const target = parseFloat(arc.getAttribute('data-offset'));
      arc.style.transition = 'none';
      arc.style.strokeDashoffset = circ; // start empty
      setTimeout(() => {
        arc.style.transition = 'stroke-dashoffset 1.2s cubic-bezier(.16,1,.3,1)';
        arc.style.strokeDashoffset = target;
      }, 300 + i * 150);
    });
  }, 100);
};
</script>

<script>
(function() {
  function pad(n, len) { return String(n).padStart(len || 2, '0'); }
  function updatePmaClock() {
    var now = new Date();
    var dd = pad(now.getDate());
    var mm = pad(now.getMonth() + 1);
    var yy = String(now.getFullYear()).slice(-2);
    var hh = pad(now.getHours());
    var min = pad(now.getMinutes());
    var ss = pad(now.getSeconds());
    var ms = pad(now.getMilliseconds(), 3).slice(0, 2);
    var dateEl = document.getElementById('pmaDate');
    var timeEl = document.getElementById('pmaTime');
    if (dateEl) dateEl.textContent = mm + '.' + dd + '.' + yy;
    if (timeEl) timeEl.textContent = hh + ':' + min + '.' + ss + ' HRS';
  }
  updatePmaClock();
  setInterval(updatePmaClock, 1000);
})();
</script>
</body>
</html>
